Join Clinical Trials in Texas for Cancer

All Categories Most Often Searched » Cancer » Texas

Preventing Sexual Dysfunction With Aromatase Inhibitors

Condition: Breast Cancer
Interventions: Behavioral: Questionnaires; Other: Education Materials; Other: Luvena; Other: Hyalo-Gyn; Other: Vaginal Lubricant; Behavioral: Interactive Internet-Based Website; Behavioral: Telephone Counseling.
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Duncan Family Institute Seed Money Grant; Fidia Farmaceutici s.p.a.; Laclede Inc. Healthcare Products
Not yet recruiting - verified May 2012
Exact CRC Screening Test: Stool Sample Collection Study to Support Assay Validation Testing

Conditions: Colorectal Neoplasms; Digestive System Diseases; Colonic Diseases; Colorectal Cancer
Intervention:
Sponsors: Exact Sciences Corporation; Exact Sciences Corporation
Recruiting - verified May 2012
An Observational Pilot Study Evaluating The Feasibility of Conducting Genomewide Association Studies Utilizing Subject-Provided Information in Subjects With Metastatic Breast Cancer Treated With Avastin (Bevacizumab)

Condition: Breast Cancer
Intervention:
Sponsors: Genentech; Genentech; 23andMe, Inc.
Recruiting - verified May 2012
Intrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous System

Conditions: Leukemia; Lymphoid Malignancies; Metastatic Malignant Neoplasm to the Leptomeninges
Intervention: Drug: Intrathecal Rituximab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Not yet recruiting - verified May 2012
Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer

Conditions: Advanced Cancer; Solid Tumor
Interventions: Drug: Vemurafenib; Drug: Everolimus; Drug: Temsirolimus
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Not yet recruiting - verified May 2012
A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer

Conditions: HER2 + Breast Cancer; HER2 + Gastric Cancer; Squamous Cell Carcinoma of Head and Neck
Intervention: Drug: LJM716
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012
Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2

Condition: Breast Cancer
Interventions: Drug: Paclitaxel; Drug: Eribulin; Drug: 5-Fluorouracil; Drug: Epirubicin; Drug: Cyclophosphamide; Drug: Doxorubicin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Eisai Inc.
Not yet recruiting - verified May 2012
A Prospective Phase III Trial to Compare Stereotactic Radiosurgery Versus Whole Brain Radiation Therapy

Condition: Brain Neoplasms
Interventions: Radiation: Stereotactic Radiosurgery (SRS); Radiation: Whole Brain Radiation Therapy (WBRT); Behavioral: Questionnaires; Behavioral: Cognitive Function Tests
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Not yet recruiting - verified May 2012
A Study of LY2784544 in Participants With Myeloproliferative Neoplasms

Condition: Neoplasms, Hematologic
Interventions: Drug: 200 mg LY2784544; Drug: 400 mg LY2784544; Drug: 600 mg LY2784544
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Not yet recruiting - verified May 2012
EphA2 Gene Targeting Using Neutral Liposomal Small Interfering RNA Delivery

Condition: Advanced Cancers
Intervention: Drug: siRNA-EphA2-DOPC
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Ovarian Cancer Research Fund
Not yet recruiting - verified May 2012
Aerosol IL-2 for Pulmonary Metastases

Conditions: Sarcoma; Solid Tumors; Pulmonary Metastases; Lung Metastases; Osteosarcomas; Ewing Sarcoma
Interventions: Drug: Aerosol IL-2; Procedure: Symptom Assessment
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Shannon Wilkes Foundation
Not yet recruiting - verified May 2012
A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas

Conditions: Advanced Solid Tumor; Lymphoma
Intervention: Drug: DS-3078a
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.
Recruiting - verified April 2012
Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Locally Advanced Head and Neck Squamous Cell Carcinoma

Conditions: Squamous Cell Carcinoma; Head and Neck Cancer
Intervention: Biological: EGFR Antisense DNA
Sponsors: The University of Texas Health Science Center at San Antonio; The University of Texas Health Science Center at San Antonio; University of Pittsburgh
Not yet recruiting - verified May 2012
ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma

Condition: Neuroblastoma
Interventions: Biological: ch14.18 -NCI; Biological: ch14.18-UTC; Biological: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF); Biological: Aldesleukin (IL-2); Drug: Isotretinoin
Sponsors: United Therapeutics; United Therapeutics
Not yet recruiting - verified May 2012
Ipilimumab for Uveal Melanoma

Condition: Melanoma
Intervention: Drug: Ipilimumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Bristol-Myers Squibb
Not yet recruiting - verified April 2012
Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma

Conditions: Brain Neoplasms; Central Nervous System Neoplasms
Interventions: Drug: TPI287; Drug: Bevacizumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Archer Biosciences, Inc.
Not yet recruiting - verified April 2012
Vandetanib With Everolimus

Condition: Advanced Cancers
Interventions: Drug: Vandetanib; Drug: Everolimus
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
Neuroblastoma Biology Study

Condition: Neuroblastoma
Intervention:
Sponsors: New Approaches to Neuroblastoma Therapy Consortium; New Approaches to Neuroblastoma Therapy Consortium
Recruiting - verified April 2012
Surgery and Oxaliplatin or Mitomycin C in Treating Patients With Tumors of the Appendix

Conditions: Carcinoma of the Appendix; Primary Peritoneal Cavity Cancer
Interventions: Drug: mitomycin C; Drug: oxaliplatin; Procedure: therapeutic conventional surgery; Other: quality-of-life assessment; Drug: hyperthermic intraperitoneal chemotherapy
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified October 2009
Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)

Conditions: Advanced Renal Cell Carcinoma; Renal Cell Carcinoma; Metastatic Renal Cell Carcinoma
Interventions: Drug: Standard Treatment; Biological: AGS-003
Sponsors: Argos Therapeutics; Argos Therapeutics
Not yet recruiting - verified April 2012
Abiraterone Acetate With or Without Veliparib in Treating Patients With Metastatic Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: abiraterone acetate; Drug: prednisone; Drug: veliparib
Sponsors: National Cancer Institute (NCI); University of Chicago; National Cancer Institute (NCI)
Recruiting - verified April 2012
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

Conditions: Dose Escalation; Safety; Preliminary Efficacy; Advanced Solid Tumors; Metastatic Breast Cancer; Advanced Pancreatic Adenocarcinoma; Metastatic Colorectal Cancer; Recurrent Glioblastoma Multiforme
Intervention: Drug: LDE225 and BKM120
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012
A Study in Recurrent Glioblastoma (GB)

Condition: Glioblastoma
Interventions: Drug: LY2157299 monohydrate; Drug: Lomustine; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours

Conditions: Carcinoid Tumor of the Small Bowel; Neuroendocrine Tumour
Interventions: Drug: Octreotide; Drug: Octreotide; Drug: 177Lu-DOTA0-Tyr3-Octreotate
Sponsors: Advanced Accelerator Applications; Advanced Accelerator Applications; Pierrel Research Europe GmbH
Not yet recruiting - verified April 2012
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0639 in Advanced Solid Tumors

Condition: Solid Tumors
Intervention: Biological: MEDI0639
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified April 2012
Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer

Condition: Gastric Carcinoma
Interventions: Drug: Tesetaxel; Drug: Placebo; Drug: Capecitabine
Sponsors: Genta Incorporated; Genta Incorporated
Recruiting - verified April 2012
Imetelstat for Children With Refractory or Recurrent Solid Tumors and Lymphoma

Conditions: Solid Tumors; Lymphoma
Intervention: Drug: Imetelstat
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified February 2012
Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning

Conditions: Leukemia; Acute Myeloid Leukemia; Acute Lymphocytic Leukemia; Chronic Myeloid Leukemia; Chronic Lymphocytic Leukemia; Myeloproliferative Diseases; Non-Hodgkins Lymphoma; Hodgkins Lymphoma; Multiple Myeloma; Myelodysplastic Syndrome
Interventions: Drug: Fludarabine monophosphate; Drug: Busulfan; Procedure: Stem Cell Infusion; Drug: Tacrolimus; Drug: Methotrexate; Drug: G-CSF
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
A Comparison of Recall Rates Between Conventional 2d Mammography and 2d Plus 3d (Tomosynthesis) Mammography in a Screening Population

Condition: Breast Cancer
Intervention:
Sponsors: Rose Imaging Specialists, P.A.; Rose Imaging Specialists, P.A.; Hologic, Inc.
Recruiting - verified March 2012
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer

Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: trastuzumab [Herceptin]; Drug: pertuzumab; Drug: trastuzumab [Herceptin]; Drug: vinorelbine
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax

Condition: Breast Cancer
Interventions: Drug: Herceptin; Drug: NeuVax vaccine; Drug: GM-CSF
Sponsors: San Antonio Military Medical Center; COL George Peoples, MD, FACS; Genentech; Galena Biopharma, Inc.
Not yet recruiting - verified April 2012
Phase I/II Study of APS001F With Flucytosine and Maltose in Solid Tumors

Conditions: Tumors; Neoplasms; Cancer
Interventions: Drug: APS001F; Drug: Flucytosine (5-FC); Drug: 10% maltose
Sponsors: Anaeropharma Science, Inc.; Anaeropharma Science, Inc.
Not yet recruiting - verified April 2012
Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas

Condition: Pancreatic Cancer
Interventions: Drug: Oxaliplatin; Drug: Irinotecan; Drug: 5-FU; Drug: Gemcitabine; Radiation: Radiation Therapy
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Not yet recruiting - verified March 2012
Study of Metformin With Simvastatin for Men With Prostate Carcinoma

Condition: Prostate Carcinoma
Interventions: Drug: Metformin; Drug: Simvastatin
Sponsors: Baylor College of Medicine; Nicholas Mitsiades
Recruiting - verified March 2012
Phase 1 Study of ONT-10 in Patients With Solid Tumors

Condition: Solid Tumors
Intervention: Biological: ONT-10
Sponsors: Oncothyreon Inc.; Oncothyreon Inc.
Recruiting - verified March 2012
T-Lymphocytes in Treating Patients With Active or Relapsed Hodgkin Lymphoma or Non-Hodgkin Lymphoma

Conditions: Lymphoma; Precancerous Condition
Intervention: Biological: lymphoma TAA-specific cytotoxic T lymphocytes
Sponsors: National Cancer Institute (NCI); Baylor College of Medicine; National Cancer Institute (NCI)
Recruiting - verified March 2012
Phase I Trial of IV Fenretinide (4-HPR) Plus IV Safingol for Patients With Relapsed Malignancies

Condition: Solid Tumor
Intervention: Drug: Fenretinide (4-HPR) plus Intravenous Safingol
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center
Not yet recruiting - verified August 2011
Bevacizumab, Temsirolimus, Valproic Acid, Cetuximab

Condition: Advanced Cancers
Interventions: Drug: Temsirolimus; Drug: Bevacizumab; Drug: Valproic Acid; Drug: Cetuximab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer

Condition: Advanced Cancers
Interventions: Drug: Crizotinib (Xalkori); Drug: Pazopanib; Drug: Pemetrexed
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer

Conditions: Carcinoma, Non-Small-Cell Lung; Non-Small Cell Lung Cancer
Interventions: Drug: CC-223; Drug: Erlotinib; Drug: Oral azacitidine
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified April 2012
Salvage Ovarian FANG Vaccine + Bevacizumab

Condition: Stage IIIC Ovarian Cancer
Interventions: Biological: FANG™ Vaccine; Drug: Bevacizumab
Sponsors: Gradalis, Inc.; Gradalis, Inc.
Recruiting - verified May 2012
Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer

Condition: Carcinoma, Squamous Cell of Head and Neck
Intervention: Drug: Docetaxel, Cisplatin, Cetuximab and Bevacizumab (TPE-A) Followed by Concurrent Radiation, Cisplatin, Cetuximab and Bevacizumab (XPE-A), surgery
Sponsors: The University of Texas Health Science Center at San Antonio; The University of Texas Health Science Center at San Antonio
Recruiting - verified April 2012
Trial of Fenretinide/LXS Plus Ketoconazole in Recurrent Ovarian Cancer and Primary Peritoneal Carcinoma

Condition: Recurrent Ovarian Cancer
Intervention: Drug: Ketoconazole and HPR/LXS
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center; South Plains Oncology Consortium
Not yet recruiting - verified February 2012
Natural History of Lung Nodules Seen on CT Scans From Participants at High-Risk of Developing Lung Cancer

Conditions: Lung Cancer; Precancerous Condition
Interventions: Other: medical chart review; Procedure: computed tomography; Procedure: computer-aided detection/diagnosis
Sponsors: National Cancer Institute (NCI); M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2012
Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy

Condition: Colorectal Neoplasms
Intervention: Drug: Regorafenib (BAY73-4506)
Sponsors: Bayer; Bayer
Available - verified May 2012
Impact of Body Weight on Pharmacokinetic Analysis of Doxorubicin + Cyclophosphamide in Breast Cancer

Condition: Breast Cancer
Intervention:
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center; Texas Tech University Health Sciences Center
Not yet recruiting - verified January 2012
Oral Versus Transdermal Ondansetron for Women With Cervical Cancer Receiving Chemoradiation

Condition: Cancer of the Cervix
Interventions: Drug: Granisetron; Drug: Ondansetron; Behavioral: Questionnaires; Behavioral: Study Drug Diary
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Sancuso
Recruiting - verified March 2012
A Five-Year Quality of Life Study for Cancer Patients

Condition: Cancer
Intervention:
Sponsors: The Kotsanis Institute; Constantine A. Kotsanis; The Best Answer for Cancer Foundation
Recruiting - verified February 2012
Effect of Weight on the Population Pharmacokinetic Analysis of Doxorubicin and Cyclophosphamide

Conditions: Breast Cancer; Obesity
Interventions: Drug: Doxorubicin; Drug: Cyclophosphamide
Sponsors: Texas Tech University Health Sciences Center; Texas Tech University Health Sciences Center; University of Texas
Recruiting - verified April 2012
Phase I, Open-label, Dose-escalation Study of ISIS-STAT3Rx, Administered to Patients With Advanced Cancers

Condition: Advanced Cancers
Intervention: Drug: ISIS-STAT3Rx
Sponsors: Isis Pharmaceuticals; Isis Pharmaceuticals
Recruiting - verified April 2012
Erlotinib in Combination With Pralatrexate in Advanced Malignancies

Conditions: Advanced Cancers; Solid Tumors
Interventions: Drug: Erlotinib; Drug: Pralatrexate
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
Vemurafenib and Sorafenib in Advanced Cancer

Condition: Advanced Cancers
Interventions: Drug: Vemurafenib; Drug: Sorafenib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified February 2012
Temsirolimus in Combination With Metformin in Patients With Advanced Cancers

Condition: Advanced Cancers
Interventions: Drug: Temsirolimus; Drug: Metformin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer

Conditions: Ovarian Cancer; Cancer of Ovary; Cancer of the Ovary; Ovary Neoplasms; Primary Peritoneal Carcinoma
Intervention: Drug: Fenretinide/LXS + Ketoconazole
Sponsors: South Plains Oncology Consortium; South Plains Oncology Consortium
Recruiting - verified February 2012
Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)

Condition: Myeloma
Interventions: Drug: Lenalidomide; Drug: Bortezomib; Drug: Siltuximab; Drug: Dexamethasone; Behavioral: Questionnaires
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Janssen Services, LLC
Recruiting - verified May 2012
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: Dovitinib; Drug: Fulvestrant
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
First in Human Trial of TAS266 in Patients With Advanced Solid Tumors

Condition: Advanced Solid Tumors
Intervention: Drug: TAS266
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012
A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors

Condition: Solid Tumors Harboring a BRAF V600 Mutation
Interventions: Drug: LGX818; Drug: MEK162
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified April 2012
Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer

Condition: Locally Advanced HER2-Negative Breast Cancer
Interventions: Drug: Eribulin Mesylate; Drug: Cyclophosphamide; Drug: Docetaxel
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; Eisai Inc.
Not yet recruiting - verified March 2012
A Dose-Escalation Study in Participants With Advanced Cancer

Condition: Advanced Cancer
Intervention: Drug: LY2495655
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified January 2012
A Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Cancers

Condition: Multiple Myeloma, Neoplasms
Intervention: Drug: Vemurafenib
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: erlotinib; Drug: afatinib
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012
BOTOX in Men With Prostate Cancer With Lower Urinary Tract Symptoms(LUTS)/Benign Prostatic Hyperplasia (BPH)

Conditions: Prostate Cancer; Benign Prostatic Hyperplasia; Enlarged Prostate With Lower Urinary Tract Symptoms (LUTS)
Intervention: Drug: BOTOX
Sponsors: Baylor College of Medicine; Baylor College of Medicine
Recruiting - verified January 2012
Optimal Tube Feeding Method in Head and Neck Cancer Patients

Condition: Head and Neck Cancer
Interventions: Procedure: Bolus; Procedure: Gravity; Device: Pump
Sponsors: Baylor Research Institute; Baylor Research Institute
Not yet recruiting - verified February 2012
BiPAP-Vapotherm RCT

Condition: Advanced Cancers
Interventions: Device: Oxygen Delivery Devices; Behavioral: Questionnaires
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Not yet recruiting - verified January 2012
Radium-223 Chloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases

Condition: Prostatic Neoplasms
Intervention: Drug: Radium-223 chloride (BAY88-8223)
Sponsors: Bayer; Bayer
Available - verified April 2012
Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)

Conditions: Leukemia; Lymphoma; Myeloma; Myeloproliferative Diseases
Interventions: Drug: Fludarabine; Drug: Melphalan; Drug: Alemtuzumab; Procedure: Stem Cell Infusion; Drug: Tacrolimus; Drug: Methotrexate; Drug: G-CSF; Procedure: Low Dose Donor T-Cells; Procedure: High Dose Donor T-Cells
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
A Phase I Study of Systemic Gene Therapy With SGT-94 in Patients With Solid Tumors

Condition: Neoplasm
Intervention: Genetic: SGT-94
Sponsors: SynerGene Therapeutics, Inc.; SynerGene Therapeutics, Inc.
Recruiting - verified January 2012
Trial of Dasatinib in Subjects With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation

Condition: Carcinoma, Non-small Cell Lung
Intervention: Drug: Dasatinib
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Not yet recruiting - verified May 2012
Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: temozolomide; Drug: veliparib; Genetic: gene expression analysis; Genetic: protein analysis; Other: laboratory biomarker analysis; Other: pharmacological study; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Pediatric Brain Tumor Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012
Proton Beam Therapy (PBT) Versus Intensity-Modulated Radiation Therapy (IMRT) Trial

Condition: Esophageal Cancer
Interventions: Radiation: Proton Beam Therapy (PBT); Radiation: Intensity Modulated Radiation Therapy (IMRT); Behavioral: Questionnaires
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment

Condition: Advanced Solid Tumors
Intervention: Drug: MM-151
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals
Recruiting - verified May 2012
Study of VGX-100 Administered Alone and Co-administered With Bevacizumab in Adult Subjects With Advanced Solid Tumors

Conditions: Neoplasms; Cancer
Interventions: Drug: VGX-100; Drug: Bevacizumab
Sponsors: Circadian Technologies Ltd.; Circadian Technologies Ltd.
Recruiting - verified March 2012
Stereotactic Body Radiotherapy (SBRT) Versus Stereotactic Body Proton Therapy (SBPT)

Condition: Non-small-cell Lung Cancer
Interventions: Radiation: SBRT (stereotactic body radiotherapy); Radiation: SBPT (stereotactic body proton therapy)
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Institutes of Health (NIH)
Not yet recruiting - verified January 2012
Breakthrough Dyspnea Fentanyl Study

Conditions: Advanced Cancers; Dyspnea
Interventions: Drug: Fentanyl; Other: Placebo; Other: Walking Tests; Behavioral: Questionnaires
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
Lifestyle Intervention for High Risk Cancer Survivors

Condition: Breast Cancer
Interventions: Behavioral: Exercise Program; Behavioral: Telephone Counseling Calls; Behavioral: Standard Care; Behavioral: Health Behavior Survey
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments

Condition: Non-Small Cell Lung Cancer
Intervention: Drug: Lenvatinib (E7080)
Sponsors: Eisai Inc.; Eisai Inc.; PharmaBio Development Inc.
Recruiting - verified May 2012
Validation of Colon Biomarkers for the Early Detection of Colorectal Adenocarcinoma

Conditions: Colon Cancer; Rectal Cancer
Intervention:
Sponsors: University of Michigan; University of Michigan; Early Detection Research Network
Recruiting - verified January 2012
The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer.

Condition: Metastatic Breast Cancer
Interventions: Drug: Veliparib; Drug: Temozolomide; Drug: Carboplatin; Drug: Paclitaxel; Drug: Placebo
Sponsors: Abbott; Abbott
Recruiting - verified May 2012
A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.

Conditions: Metastatic Pancreatic Adenocarcinoma; Pancreatic Cancer; Metastatic Pancreatic Cancer
Intervention: Drug: 90Y-hPAM4
Sponsors: Immunomedics, Inc.; Immunomedics, Inc.
Recruiting - verified May 2012
A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma

Condition: Liver Cancer
Interventions: Drug: RO5137382; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012
Phase I Intratumoral Pbi-shRNA STMN1 LP in Advanced and/or Metastatic Cancer

Conditions: Advanced Cancer; Metastatic Cancer; Solid Tumors
Intervention: Biological: pbi-shRNA STMN1 LP
Sponsors: Gradalis, Inc.; Gradalis, Inc.
Recruiting - verified May 2012
Randomized Phase II Adjuvant Chemotherapy ± FANG™ in Colorectal Carcinoma With Liver Metastases

Condition: Colon Cancer
Interventions: Biological: FANG Vaccine; Drug: Placebo
Sponsors: Gradalis, Inc.; Gradalis, Inc.
Recruiting - verified May 2012
Beta-Blocker / Ovarian

Conditions: Ovarian Cancer; Primary Peritoneal Carcinoma; Fallopian Tube Cancer
Interventions: Drug: Propranolol; Drug: Chemotherapy; Procedure: Surgery; Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffein, Midazolam, and Digoxin in Cancer Subjects

Condition: Solid Tumors
Interventions: Drug: tivantinib; Drug: omeprazole; Drug: s-warfarin; Drug: caffeine; Dietary Supplement: vitamin K; Drug: digoxin; Drug: midazolam
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.; Medpace, Inc.
Recruiting - verified January 2012
Cabazitaxel With or Without Carboplatin in Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Therapy

Condition: Prostate Cancer
Interventions: Drug: Cabazitaxel; Drug: Prednisone; Drug: Carboplatin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Sanofi-Aventis
Not yet recruiting - verified January 2012
Community Network Program

Condition: Psychosocial Problem
Interventions: Behavioral: Health Education; Behavioral: Questionnaires; Behavioral: Telephone Counseling Sessions; Drug: Nicotine Patches
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Institutes of Health (NIH)
Recruiting - verified January 2012
Part II: Exercise in Hispanic Breast Cancer Survivors

Condition: Breast Cancer
Interventions: Behavioral: Baseline Fitness Test; Behavioral: Questionnaires; Behavioral: Individualized Exercise Program; Behavioral: Written Materials
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2012
Epigenetic Testing for Breast Cancer Risk Stratification

Condition: Breast Cancer
Intervention:
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center; Department of Defense
Not yet recruiting - verified September 2011
Everolimus Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (Gastro Intestinal or Lung Origin)

Conditions: Advanced NET of GI Origin; Advanced NET of Lung Origin; Neuroendocrine Tumors
Interventions: Drug: Everolimus; Drug: Everolimus Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I

Condition: Breast Cancer
Interventions: Drug: TAC chemotherapy; Drug: TC chemotherapy; Drug: Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy; Drug: TCH chemotherapy
Sponsors: Agendia; Agendia; University of South Florida; University of Miami
Recruiting - verified January 2012
Respiratory Syncytial Virus - RSV Protocol

Conditions: Bone Marrow Transplant Infection; Infection in Marrow Transplant Recipients; Respiratory Syncytial Virus Infections; Respiratory Syncytial Virus Pneumonia; Cancer; Acute Leukemia
Interventions: Drug: Ribavirin; Drug: Ribavirin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
Immune Response and Safety of HS110 Vaccine in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer
Interventions: Biological: HS110 vaccine; Biological: Placebo; Biological: HS110 vaccine
Sponsors: Heat Biologics; Heat Biologics; Ground Zero Pharmaceuticals
Recruiting - verified January 2012
Data Collection of Normal Tissue Toxicity for Proton Therapy for Pediatrics

Condition: Pediatric Cancer
Interventions: Other: Data Collection; Other: Dose Distribution Data Collection
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified December 2011
Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood

Conditions: Leukemia; Lymphoma
Interventions: Procedure: Hematopoietic stem-cell transplant; Genetic: CD19-specific T cell Infusion
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified February 2012
A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma

Conditions: Glioblastoma; Small Cell Glioblastoma; Giant Cell Glioblastoma; Gliosarcoma; Glioblastoma With Oligodendroglial Component; Recurrent Glioblastoma; Relapsed Glioblastoma
Interventions: Drug: Bevacizumab; Drug: Rindopepimut (CDX-110) with GM-CSF; Drug: KLH
Sponsors: Celldex Therapeutics; Celldex Therapeutics
Recruiting - verified May 2012
Study to Learn if Two Doses of a Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer

Condition: Diffuse Large B-Cell Lymphoma
Interventions: Drug: Fostamatinib; Drug: Fostamatinib
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified May 2012
Caris Biorepository Research Protocol

Condition: Cancer
Intervention:
Sponsors: Caris Science, Inc.; Caris Science, Inc.
Recruiting - verified February 2012
The BEACON Study (Breast Cancer Outcomes With NKTR-102)

Conditions: Locally Recurrent Breast Cancer; Metastatic Breast Cancer
Interventions: Drug: NKTR-102; Drug: Treatment of Physician's Choice (TPC)
Sponsors: Nektar Therapeutics; Nektar Therapeutics
Recruiting - verified April 2012
R-21 Colorectal Cancer Screening (CRCS) Pilot Trial

Condition: Colorectal Neoplasms
Interventions: Behavioral: CRCS patient decision aid (PtDA) video; Behavioral: Questionnaires
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Not yet recruiting - verified December 2011
Long-Term Follow-Up of Recipient of Gene Transfer Research

Conditions: Retroviridae Infections; Cancer
Interventions: Other: Blood Tests; Behavioral: Questionnaires
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Center for Research Resources (NCRR); National Cancer Institute (NCI)
Recruiting - verified December 2011
The Role of Ghrelin in Cancer Cachexia

Condition: Cancer Cachexia
Interventions: Drug: Anamorelin HCl; Drug: Placebo
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs; Helsinn Therapeutics (U.S.), Inc
Not yet recruiting - verified March 2012
Administration of Donor T Cells With the Caspase-9 Suicide Gene

Conditions: Acute Lymphoblastic Leukemia; Myelodysplastic Syndrome; Acute Myeloid Leukemia; Chronic Myelogenous Leukemia; Non Hodgkin Lymphoma; Hemophagocytic Lymphohistiocytosis; Familial Hemophagocytic Lymphohistiocytosis; Hemophagocytic Syndrome; Epstein Barr Virus Infection; X-linked Lymphoproliferative Disease
Intervention: Genetic: Allodepleted T Cells Transduced with Inducible Caspase 9 Suicide Gene and AP1903
Sponsors: Baylor College of Medicine; Baylor College of Medicine; Texas Children's Hospital; The Methodist Hospital System
Recruiting - verified April 2012
A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer

Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: trastuzumab; Drug: Aromatase Inhibitor; Drug: Induction Chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012
Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)

Conditions: Leukemia; Lymphoma
Interventions: Drug: Rituximab; Drug: 111In Ibritumumab; Procedure: Planar Scintigraphy Imaging; Drug: 90Y IbritumumabTiuxetan; Drug: Fludarabine; Drug: Bendamustine; Drug: Thymoglobulin; Drug: Tacrolimus; Drug: Methotrexate; Drug: Mycophenolate; Drug: G-CSF; Procedure: Stem Cell Transplantation
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Spectrum Pharmaceuticals, Inc
Not yet recruiting - verified May 2012
Fosaprepitant in Patients Receiving Ifosfamide-based Regimen

Conditions: Sarcoma; Chemotherapy-induced Nausea and Vomiting; Effects of Chemotherapy; Adverse Effects of Medical Drugs
Interventions: Drug: Fosaprepitant; Drug: Dexamethasone; Drug: 5HT3 receptor antagonist; Drug: Ifosfamide-based chemotherapy (AI); Drug: Doxorubicin; Drug: Mesna; Drug: Ifosfamide; Drug: Vincristine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Merck
Recruiting - verified May 2012
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

Condition: Smoldering Multiple Myeloma
Interventions: Drug: Siltuximab; Drug: Placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified February 2012
Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: Degarelix
Sponsors: Ferring Pharmaceuticals; Ferring Pharmaceuticals
Recruiting - verified April 2012
Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab

Condition: Breast Cancer
Interventions: Drug: AMG 479; Drug: Trastuzumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Amgen
Not yet recruiting - verified November 2011
Determinants of Multiple Health Risk Behaviors Among Latinos

Conditions: Cancer; Risk Factors in Latinos
Interventions: Behavioral: Questionnaires; Device: Accelerometer; Device: Smart Phone
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified January 2012
Efficacy and Safety Study of NeuVax(TM) Vaccine to Prevent Breast Cancer Recurrence

Condition: HER2 Negative Breast Cancer
Interventions: Biological: NeuVax vaccine; Biological: Leukine (sargramostim, GM-CSF) and water for injection
Sponsors: Galena Biopharma, Inc.; Galena Biopharma, Inc.
Recruiting - verified May 2012
Oral Azacitidine as a Single Agent and in Combination With Carboplatin or Abraxane® in Subjects With Relapsed or Refractory Solid Tumors

Condition: Relapsed or Refractory Solid Tumors
Interventions: Drug: Oral azacitidine plus Abraxane; Drug: Carboplatin; Drug: Abraxane
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified April 2012
NBRST: Prospective Neo-adjuvant REGISTRY Trial

Condition: Breast Cancer
Interventions: Device: MammaPrint; Device: BluePrint; Device: TargetPrint; Device: TheraPrint
Sponsors: Agendia; Agendia
Recruiting - verified April 2012
Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)

Conditions: Familial Adenomatous Polyposis; Attenuated Familial Adenomatous Polyposis
Interventions: Drug: Eflornithine plus Sulindac; Drug: Eflornithine and Placebo; Drug: Sulindac and Placebo
Sponsors: Cancer Prevention Pharmaceuticals, Inc.; Cancer Prevention Pharmaceuticals, Inc.
Not yet recruiting - verified March 2012
Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match

Conditions: Acute Myelogenous Leukemia; Acute Lymphocytic Leukemia; Chronic Lymphocytic Leukemia; Chronic Myelogenous Leukemia; Hodgkins Disease; Non-Hodgkins Lymphoma; Aplastic Anemia; Multiple Myeloma; Myelodysplastic Syndrome
Interventions: Drug: Busulfan; Drug: Clofarabine; Drug: Fludarabine; Drug: Melphalan; Drug: Carmustine; Drug: Etoposide; Drug: Cytarabine
Sponsors: Texas Oncology Cancer Center; Texas Oncology Cancer Center
Recruiting - verified December 2011
GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases

Conditions: Breast Cancer; Brain Metastases
Interventions: Drug: GRN1005; Drug: Trastuzumab
Sponsors: Geron Corporation; Geron Corporation
Recruiting - verified May 2012
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma

Conditions: Glioblastoma; Small Cell Glioblastoma; Giant Cell Glioblastoma; Gliosarcoma; Glioblastoma With Oligodendroglial Component
Interventions: Drug: Rindopepimut (CDX-110) with GM-CSF; Drug: Temozolomide; Drug: KLH
Sponsors: Celldex Therapeutics; Celldex Therapeutics
Recruiting - verified May 2012
Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer

Condition: Lung Cancer - Non Small Cell
Interventions: Biological: Ipilimumab; Biological: Pemetrexed
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Not yet recruiting - verified February 2012
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Condition: Pancreatic Cancer
Interventions: Drug: GS-6624; Drug: GS-6624; Drug: Placebo; Drug: Gemcitabine; Drug: Gemcitabine; Drug: Gemcitabine; Drug: Gemcitabine; Drug: GS-6624
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012
Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors

Condition: Solid Tumor
Intervention: Drug: ARQ 092
Sponsors: ArQule; ArQule
Recruiting - verified November 2011
Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Metformin; Other: Placebo
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Susan G. Komen Breast Cancer Foundation
Not yet recruiting - verified February 2012
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Condition: Colorectal Cancer
Interventions: Drug: GS-6624; Drug: FOLFIRI; Drug: GS-6624; Drug: FOLFIRI; Drug: GS-6624; Drug: FOLFIRI; Drug: Placebo; Drug: FOLFIRI
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012
Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: paclitaxel; Drug: pazopanib hydrochloride; Other: placebo
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Cord Blood Fucosylation

Conditions: Blood And Marrow Transplantation; Leukemia; Lymphoma; Transplantation Infection; Transplantation, Bone Marrow
Interventions: Drug: Melphalan; Drug: Thiotepa; Drug: Fludarabine; Drug: Mycophenolate mofetil; Drug: Tacrolimus; Procedure: Cord Blood Infusion; Drug: Rituximab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Not yet recruiting - verified April 2012
Diffuse Intrinsic Pontine Glioma (DIPG) Reirradiation (ReRT)

Condition: Brain Cancer
Intervention: Radiation: Radiation Therapy
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified December 2011
An A/B Dose Escalation Study of AbGn-7 Alone and With FOLFOX7 Treatment in Patients With Advanced Solid Tumors

Conditions: Solid Tumor of Epithelial Origin; Gastric Cancer
Interventions: Drug: AbGn-7; Drug: AbGn-7
Sponsors: AbGenomics B.V Taiwan Branch; AbGenomics B.V Taiwan Branch
Recruiting - verified December 2011
A Study of LY3007113 in Patients With Advanced Cancer

Condition: Metastatic Cancer
Intervention: Drug: LY3007113
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012
Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Biological: Elotuzumab; Drug: Bortezomib; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified February 2012
Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: sunitinib malate; Genetic: gene expression analysis; Genetic: protein expression analysis; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) With Concomitant Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM)

Conditions: Glioblastoma; GBM; Glioma; High Grade Glioma
Intervention: Drug: Trans Sodium Crocetinate (TSC)
Sponsors: Diffusion Pharmaceuticals LLC; Diffusion Pharmaceuticals LLC
Recruiting - verified April 2012
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Conditions: Acute Lymphoid Leukemia; Acute Myeloid Leukemia; Chronic Lymphocytic Leukemia; Multiple Myeloma; Solid Tumors
Intervention: Drug: brentuximab vedotin
Sponsors: Seattle Genetics, Inc.; Seattle Genetics, Inc.
Recruiting - verified April 2012
Safety and Efficacy of Cryoablation for the Palliation of Painful Bone Metastases

Conditions: Pain; Neoplasm Metastasis
Intervention: Procedure: Cryoablation
Sponsors: Galil Medical; Galil Medical
Recruiting - verified April 2012
Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

Condition: Acute Lymphoblastic Leukemia
Intervention: Drug: blinatumomab
Sponsors: Micromet GmbH; Micromet GmbH
Recruiting - verified February 2012
Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients With Stage II-III Non-Small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer
Interventions: Radiation: Radiation Therapy; Radiation: Conventional radiation
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center
Not yet recruiting - verified June 2011
A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: onartuzumab [MetMAb]; Drug: erlotinib [Tarceva]; Drug: Placebo
Sponsors: Genentech; Genentech; Hoffmann-La Roche
Recruiting - verified January 2012
Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)

Condition: Leukemia
Interventions: Drug: Azacitidine (AZA); Drug: Tyrosine kinase inhibitor (TKI); Drug: Azacitidine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Celgene Corporation
Not yet recruiting - verified April 2012
A Study of LY2812176 in Multiple Myeloma or Advanced Solid Tumors

Conditions: Multiple Myeloma; Solid Tumors
Intervention: Drug: LY2812176
Sponsors: Dekkun Corporation; Dekkun Corporation
Recruiting - verified October 2011
FUS1-nanoparticles and Erlotinib in Stage IV Lung Cancer

Condition: Lung Cancer
Interventions: Drug: DOTAP:Chol-fus1; Drug: Erlotinib; Drug: Dexamethasone; Drug: Diphenhydramine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Convergen LifeSciences, Inc.
Not yet recruiting - verified March 2012
Clinical Trial of ARQ 761 in Advanced Solid Tumors

Condition: Solid Tumors
Intervention: Drug: ARQ 761
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center; ArQule
Recruiting - verified December 2011
Efficacy & Safety of ODSH (2-0, 3-0 Desulfated Heparin) in Patients With Metastatic Pancreatic Cancer Treated With Gemcitabine & Abraxane

Condition: Metastatic Pancreatic Cancer
Interventions: Drug: Abraxane ( Nab-paclitaxel); Drug: Abraxane ( Nab-paclitaxel); Drug: Gemcitabine; Drug: Gemcitabine; Drug: ODSH ( 2-O, 3-O Desulfated Heparin); Drug: ODSH ( 2-O, 3-O Desulfated Heparin); Drug: Abraxane ( nab-paclitaxel); Drug: Gemcitabine
Sponsors: ParinGenix; ParinGenix; TGen Drug Development Services
Recruiting - verified April 2012
A Safety Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib; Drug: Pomalidomide; Drug: Dexamethasone
Sponsors: Academic Myeloma Consortium; Academic Myeloma Consortium; CORE Science Solutions; Onyx Pharmaceuticals; Celgene Corporation
Recruiting - verified February 2012
A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers

Condition: Cancer
Interventions: Drug: GSK1120212; Drug: GSK2110183
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified November 2011
Phase 1 Study of Oral MLN9708 in Patients With Advanced Nonhematologic Malignancies or Lymphoma

Conditions: Lymphoma; Waldenstrom's Macroglobulinemia; Nonhematologic Malignancies
Interventions: Drug: MLN9708 Capsule B formulation; Drug: MLN9708 Capsule A or B formulation; Drug: MLN9708 Capsule B formulation
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2012
A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers

Conditions: CD27 Expressing B-cell Malignancies; CD27 Expressing Solid Tumors; Chronic Lymphocytic Leukemia; Burkett's Lymphoma; Mantle Cell Lymphoma; Primary Lymphoma of the Central Nervous System; Marginal Zone B Cell Lymphoma; Solid Tumor; Metastatic Melanoma; Renal (Clear) Cell Carcinoma; Hormone-refractory Prostate Adenocarcinoma; Ovarian Cancer; Colorectal Adenocarcinoma; Non-small Cell Lung Cancer
Intervention: Drug: CDX-1127
Sponsors: Celldex Therapeutics; Celldex Therapeutics
Recruiting - verified May 2012
Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors

Condition: Advanced Cancers
Interventions: Drug: Pazopanib; Drug: Lapatinib; Drug: Trastuzumab (Herceptin®); Drug: Pazopanib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab

Conditions: Locally Advance Breast Cancer (LABC); Metastatic Breast Cancer (MBC)
Interventions: Drug: BEZ235 + Trastuzumab Phase l/Phase ll); Drug: Lapatinib + Capecitabine (Phase II)
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone

Condition: Small Cell Lung Carcinoma
Interventions: Biological: Ipilimumab; Biological: Placebo matching Ipilimumab; Drug: Etoposide; Drug: Cisplatin; Drug: Carboplatin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified October 2011
A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors

Condition: Neoplasm Malignant
Interventions: Drug: Iniparib (SAR240550-BSI-201); Drug: Gemcitabine; Drug: Carboplatin; Drug: Placlitaxel; Drug: Pegylated liposomal doxorubicin
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified April 2012
A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Drug: LGH447
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer

Conditions: Urologic Neoplasms; Metastatic Bladder Cancer; Urinary Tract Neoplasms
Interventions: Drug: OGX-427 600 mg; Drug: OGX-427 1000 mg; Drug: Placebo
Sponsors: OncoGenex Technologies; OncoGenex Technologies; OncoGenex Pharmaceuticals; PRA International
Recruiting - verified May 2012
The Molecular Predisposition to Hereditary Nonpolyposis Colon Cancer (HNPCC)

Conditions: Bladder Cancer; Colorectal Cancer; Endometrial Cancer; Kidney Cancer; Skin Cancer; Uterus Cancer
Intervention: Behavioral: Health and Diet Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified April 2012
Adaptation of the American Cancer Society (ACS) Early Detection of Prostate Cancer Patient Decision Aid for Spanish Speaking Men

Conditions: Prostate Cancer; Cancer
Interventions: Behavioral: Post-Test Questionnaire; Behavioral: Interviews; Behavioral: Focus Groups
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Department of Defense
Not yet recruiting - verified April 2012
c-Met Inhibitor ARQ 197 (Tivantinib) in Treating Patients With Relapsed Multiple Myeloma

Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: tivantinib; Genetic: gene expression analysis; Genetic: protein expression analysis; Genetic: proteomic profiling; Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified December 2011
Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile

Condition: Multiple Myeloma
Intervention:
Sponsors: Multiple Myeloma Research Foundation; Multiple Myeloma Research Foundation; Translational Genomics Research Institute, Phoenix, Arizona.; Spectrum Health Hospitals; Van Andel Research Institute; Quintiles
Recruiting - verified May 2012
Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer

Conditions: Inoperable Locally Advanced Breast Cancer; Metastatic Breast Cancer (MBC)
Intervention: Drug: BEZ235 + Paclitaxel
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
Phase 1 Study of CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors

Conditions: Solid Tumour; Adenocarcinoma of the Colon; Adenocarcinoma of the Pancreas
Intervention: Drug: CEP-37250/KHK2804
Sponsors: Kyowa Hakko Kirin Pharma, Inc.; Kyowa Hakko Kirin Pharma, Inc.; Cephalon
Recruiting - verified February 2012
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cancer
Interventions: Drug: AMG 386; Drug: Paclitaxel; Drug: AMG 386 Placebo; Drug: Carboplatin
Sponsors: Amgen; Amgen
Recruiting - verified May 2012
Efficacy and Safety of Chloroquine in Combination With Taxane or Taxane-like Chemotherapy in the Treatment of Advanced or Metastatic Breast Cancer Patients Who Have Failed an Anthracycline

Conditions: Breast Neoplasms; Breast Cancer
Interventions: Drug: Taxane; Drug: Taxotere; Drug: Abraxane; Drug: Ixabepilone
Sponsors: The Methodist Hospital System; The Methodist Hospital System
Recruiting - verified September 2011
Phase II Study of Ofatumumab in Elderly Patients With Chronic Lymphocytic Leukemia (CLL)

Conditions: Advanced Cancers; Leukemia
Intervention: Drug: Ofatumumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Comprehensive Cancer Network; GlaxoSmithKline
Recruiting - verified January 2012
Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases

Conditions: Breast Neoplasms; Neoplasm Metastasis
Interventions: Drug: afatinib; Drug: afatinib; Drug: Vinorelbine; Drug: Investigator's choice of treatment
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012
Postoperative Thoracic Epidural Analgesia Versus Intravenous Patient-Controlled Analgesia For Liver and/or Pancreas

Conditions: Liver Cancer; Pancreatic Cancer
Interventions: Procedure: Intravenous Patient-Controlled Analgesia (IVPCA); Procedure: Thoracic Epidural Analgesia (TEA); Behavioral: Questionnaires; Behavioral: Pain Assessment
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer

Conditions: Estrogen Receptor Positive Tumor; Breast Cancer
Intervention: Drug: E7389 (eribulin mesylate) and capecitabine
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified April 2012
A Study of LY2510924 in Patients With Extensive-Stage Small Cell Lung Carcinoma

Condition: Extensive Stage Small Cell Lung Carcinoma
Interventions: Drug: LY2510924; Drug: Carboplatin; Drug: Etoposide
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified February 2012
Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients

Condition: Myeloma
Interventions: Drug: Panobinostat; Drug: Bortezomib; Drug: Lenalidomide; Drug: Dexamethasone; Behavioral: Symptom Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Novartis
Not yet recruiting - verified March 2012
Multi-arm Study of BMS-936558 in Combination With 3 Platinum-based Doublet Chemotherapy Regimens in Subjects With Treatment-Naive Stage IIIB/IV Non-small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer
Interventions: Drug: BMS-936558 (Anti-PD1); Drug: BMS-936558 (Anti-PD1); Drug: BMS-936558 (Anti-PD1); Drug: Gemcitabine; Drug: Cisplatin; Drug: Pemetrexed; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Ono Pharma
Recruiting - verified February 2012
GOAT; Phase I Open Label Study of CGTG-102, a GM-CSF Encoding Oncolytic Adenovirus, for Advanced Cancers

Conditions: Tumors; Solid Tumors
Intervention: Biological: CGTG-102
Sponsors: Baylor College of Medicine; Baylor College of Medicine; The Methodist Hospital System; Harris County Hospital District
Not yet recruiting - verified April 2012
Entinostat and Lapatinib Ditosylate in Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab

Condition: Breast Cancer
Interventions: Drug: entinostat; Drug: lapatinib ditosylate; Genetic: protein expression analysis; Other: circulating tumor cell analysis; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified January 2012
Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas

Conditions: Brain Neoplasms; Central Nervous System Neoplasms
Interventions: Drug: Everolimus; Drug: Sorafenib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Bayer; Novartis
Not yet recruiting - verified February 2012
Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer

Condition: Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer
Interventions: Drug: MEDI-573; Drug: Aromatase Inhibitor
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified May 2012
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy

Condition: Breast Cancer
Interventions: Drug: fulvestrant; Drug: GDC-0941; Drug: GDC-0980; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified April 2012
Inflammatory Response and Tissue Fibrosis/ Lymphatico-venous Bypass

Conditions: Breast Cancer; Genitourinary Cancer; Malignant Female Reproductive System Neoplasm; Melanoma; Sarcoma
Intervention: Procedure: Punch Biopsy
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Department of Defense
Recruiting - verified March 2012
A Multimodality Image-guided System for Peripheral Lung Cancer Diagnosis and Therapy

Condition: Lung Cancer
Interventions: Procedure: Biopsy With Fiber-Optical Imaging; Procedure: Biopsy Without Fiber-Optical Imaging; Other: ICG
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; The Methodist Hospital System
Not yet recruiting - verified May 2012
Mirror Grant - Understanding of Body Image Adaptation

Condition: Head and Neck Cancer
Interventions: Behavioral: Interview; Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
Lacosamide for Seizure Prophylaxis in High-Grade Gliomas

Condition: Brain Cancer
Interventions: Drug: Lacosamide; Other: Placebo
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; BRAIN TUMOR TRIALS COLLABORATIVE (BTTC); UCB, Inc.
Not yet recruiting - verified March 2012
Phase 1 Trial With SIR-Spheres and Cetuximab +/- Erlotinib

Condition: Advanced Cancers
Interventions: Device: SIR-Spheres; Drug: Cetuximab; Drug: Erlotinib; Procedure: Break-Through Scan
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Not yet recruiting - verified May 2012
Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients

Conditions: Advanced Cancers; Solid Tumors
Interventions: Drug: Pazopanib; Drug: Everolimus
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; GlaxoSmithKline; National Comprehensive Cancer Network
Recruiting - verified April 2012
Phase I Factorial Trial of Temozolomide, Memantine, Mefloquine, and Metformin for Post-Radiation Therapy (RT) Glioblastoma Multiforme (GBM)

Condition: Brain Cancer
Interventions: Drug: Temozolomide; Drug: Memantine; Drug: Mefloquine; Drug: Metformin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified January 2012
A Study of AMG 820 in Subjects With Advanced Solid Tumors

Conditions: Advanced Malignancy; Advanced Solid Tumors; Cancer; Oncology; Oncology Patients; Tumors
Intervention: Drug: AMG 820
Sponsors: Amgen; Amgen
Not yet recruiting - verified September 2011
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer

Condition: Breast Cancer
Interventions: Biological: Ramucirumab (IMC-1121B); Drug: Eribulin
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified May 2012
Phase II Study of Cetuximab With or Without OSI-906 in Head and Neck Squamous Cell Carcinoma (HNSCC)

Condition: Head and Neck Cancer
Interventions: Drug: Cetuximab; Drug: OSI-906; Other: Placebo
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; OSI Pharmaceuticals
Not yet recruiting - verified February 2012
Safety and Efficacy Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids

Conditions: Uterine Fibroids; Heavy Uterine Bleeding
Interventions: Drug: placebo; Drug: elagolix, elagolix sodium; Drug: Placebo; Drug: elagolix, elagolix sodium; Other: Elagolix Dose 1 plus estradiol/norethindrone acetate; Drug: Placebo Cohort 4; Drug: Elagolix, elagolix sodium; Drug: Elagolix, elagolix sodium
Sponsors: Abbott; Abbott; Neurocrine Biosciences
Recruiting - verified April 2012
Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors.

Condition: Oncology
Intervention: Drug: BAY94-9343
Sponsors: Bayer; Bayer
Recruiting - verified May 2012
MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery

Conditions: Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Liver Cancer
Interventions: Drug: Akt inhibitor MK2206; Genetic: mutation analysis; Genetic: proteomic profiling; Other: laboratory biomarker analysis; Other: pharmacogenomic studies; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Arthur G. James Cancer Hospital & Richard J. Solove Research Institute; National Cancer Institute (NCI)
Recruiting - verified August 2011
Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Patients With Metastatic Melanoma

Conditions: Melanoma; Metastatic Melanoma; Solid Tumor
Intervention: Drug: MLN2480
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2012
Clinical Study of BYM338 for the Treatment of Unintentional Weight Loss in Patients With Cancer of the Lung or the Pancreas

Condition: Cachexia
Interventions: Drug: BYM338 active drug; Drug: Placebo
Sponsors: Novartis; Novartis
Recruiting - verified April 2012
Study Determining the Safety and Tolerability of Combination Therapy With Pazopanib and GSK1120212 in Advanced Solid Tumors Enriched With Patients With Advanced Differentiated Thyroid Cancer

Conditions: Solid Tumors; Advanced Thyroid Cancer
Intervention: Drug: Combination of pazopanib and GSK1120212
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; National Comprehensive Cancer Network; GlaxoSmithKline
Recruiting - verified May 2012
Study of Ruxolitinib in Pancreatic Cancer Patients

Condition: Metastatic Pancreatic Adenocarcinoma
Interventions: Drug: Number 1 - Capecitabine and ruxolitinib; Drug: Number 2 - Capecitabine and placebo
Sponsors: Incyte Corporation; Incyte Corporation
Recruiting - verified May 2012
PF-04856884 (CVX-060) In Combination With Axitinib In Patients With Previously Treated Metastatic Renal Cell Carcinoma

Condition: Metastatic Renal Cell Carcinoma
Interventions: Biological: PF-04856884; Drug: AG-013736
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer

Conditions: ER Positive, Her2 Negative Breast Cancer Patients; Triple Negative Breast Cancer Patients
Interventions: Drug: MM-121 (SAR256212) plus paclitaxel; Drug: Paclitaxel
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals; Sanofi-Aventis
Recruiting - verified April 2012
Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma

Conditions: Solid Tumors; Non-Hodgkin's Lymphoma; Multiple Myeloma
Intervention: Drug: CC-122 HCL
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified September 2011
Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies

Condition: Lymphoma
Interventions: Drug: Vorinostat; Drug: Gemcitabine; Drug: Busulfan; Drug: Melphalan; Procedure: Stem Cell Infusion; Drug: Rituximab; Drug: G-CSF; Drug: Palifermin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Patients With HER2-Positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-Directed Therapy (TH3RESA)

Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine; Drug: anti-cancer therapy
Sponsors: Genentech; Genentech
Recruiting - verified March 2012
FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Drug: onartuzumab [MetMAb]; Drug: Placebo; Drug: bevacizumab [Avastin]; Drug: FOLFOX regimen; Drug: leucovorin; Drug: 5-FU
Sponsors: Genentech; Genentech; Sarah Cannon Research Institute
Recruiting - verified January 2012
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors

Conditions: Advanced Solid Tumors; Excluding Breast Cancer
Intervention: Drug: TKI258
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: Leuprolide acetate 22.5 mg depot, GP-Pharm SA
Sponsors: GP-Pharm; GP-Pharm
Recruiting - verified March 2012
A Study of LY2523355 in Patients With Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: LY2523355; Drug: Ixabepilone; Drug: pegfilgrastim; Drug: filgrastim
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
Temsirolimus In Phase 0

Condition: Advanced Cancer
Intervention: Drug: Temsirolimus
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer

Conditions: Cervical Cancer; Chemotherapeutic Agent Toxicity; Cognitive/Functional Effects; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity; Sexuality and Reproductive Issues
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Hashimotos Thyroiditis and Thyroid Cancer

Conditions: Thyroid Cancer; Hashimotos Thyroiditis
Intervention:
Sponsors: The University of Texas, Galveston; The University of Texas, Galveston
Recruiting - verified September 2011
Using Rapid Cine-MRI for Monitoring Moving and Deforming Tumors

Condition: Lung Cancer
Intervention: Other: cine MRI
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center
Recruiting - verified September 2011
Phase 1-2 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer

Conditions: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer
Interventions: Biological: DPX-Survivac; Drug: low dose cyclophosphamide (oral)
Sponsors: ImmunoVaccine Technologies, Inc.; ImmunoVaccine Technologies, Inc.
Recruiting - verified December 2011
A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma

Condition: Glioblastoma
Interventions: Drug: BKM120 + temozolomide; Drug: BKM120 +temozolomide with/without radiotherapy
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
HLA-Matched Allogeneic Cytotoxic T Lymphocytes (CTLs) for Treatment of Patients With Relapsed Epstein Barr Virus (EBV)-Associated Diseases

Conditions: Hodgkin Lymphoma; Non-Hodgkin Lymphoma; Lymphoproliferative Disorder; Nasopharyngeal Carcinoma; Leiomyosarcoma
Intervention: Drug: LMP specific T cells
Sponsors: Baylor College of Medicine; Baylor College of Medicine; Texas Children's Hospital; The Methodist Hospital System
Recruiting - verified April 2012
TEST: Registry for Endoscopic Head and Neck Surgery

Condition: Head and Neck Cancer
Intervention:
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified February 2012
Hippocampal-Avoiding Whole Brain Irradiation With Simultaneous Integrated Boost for Treatment of Brain Metastases

Condition: Brain Metastasis.
Intervention: Radiation: Radiotherapy
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center
Recruiting - verified October 2011
Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer

Conditions: Prostatic Neoplasm; Prostate Cancer; Prostatic Adenocarcinoma
Interventions: Biological: sipuleucel-T; Drug: leuprolide acetate
Sponsors: Dendreon; Dendreon
Recruiting - verified May 2012
Phase II FANG in Advanced Melanoma

Condition: Advanced Melanoma
Intervention: Biological: FANG™ Autologous Tumor Cell Vaccine in Advanced Melanoma
Sponsors: Gradalis, Inc.; Gradalis, Inc.
Recruiting - verified May 2012
Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer

Condition: Neoplasms
Intervention: Drug: BAY80-6946
Sponsors: Bayer; Bayer
Recruiting - verified May 2012
Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye

Condition: Intraocular Melanoma
Interventions: Biological: cixutumumab; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified August 2011
Multimodal Therapy for Treatment of Fatigue

Condition: Prostate Cancer
Interventions: Other: Placebo; Drug: Methylphenidate; Behavioral: Counseling Sessions; Other: Sham Exercise; Other: Standardized Exercise Intervention Program; Other: Cognitive Behavioral Therapy (CBT)
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; American Cancer Society
Recruiting - verified April 2012
Busulfan Plus Melphalan Versus Melphalan

Condition: Myeloma
Interventions: Drug: Busulfan; Drug: Melphalan; Other: Questionnaire; Drug: G-CSF; Drug: High Dose Melphalan; Procedure: Stem cell transplant
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified March 2012
Neoadjuvant Axitinib in Prostate Cancer

Condition: Prostate Cancer
Interventions: Other: ADT Therapy; Drug: Axitinib; Procedure: Prostatectomy
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Pfizer
Recruiting - verified April 2012
Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic Adenocarcinoma

Condition: Pancreas, Adenocarcinoma
Intervention: Biological: Biological/Vaccine: BC-819
Sponsors: BioCancell Therapeutics Israel Ltd.; BioCancell Therapeutics Israel Ltd.
Recruiting - verified May 2012
Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder Cancer

Condition: Bladder Cancer
Interventions: Drug: Apaziquone; Drug: Placebo
Sponsors: Spectrum Pharmaceuticals, Inc; Spectrum Pharmaceuticals, Inc; Allergan
Recruiting - verified April 2012
An Open-Label Study to Assess the Pharmacokinetics and Safety of HALAVEN™ in Subjects With Cancer Who Also Have Impaired Renal Function

Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: E7389; Drug: E7389; Drug: E7389
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified May 2012
Allogeneic Transplant in HIV Patients (BMT CTN 0903)

Conditions: Leukemia; Lymphoma; HIV
Interventions: Drug: Fludarabine and Busulfan (Flu/Bu); Drug: Fludarabine and Melphalan (Flu/Mel); Drug: Busulfan and Fludarabine (Bu/Flu); Drug: Cyclophosphamide and Total Body Irradiation (Cy/TBI); Drug: Fludarabine; Drug: Busulfan, Fludarabine, Cyclophosphamide
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI); National Cancer Institute (NCI); Blood and Marrow Transplant Clinical Trials Network
Recruiting - verified March 2012
Dose Escalation Trial of Nitroglycerin, 5-flourouracil and Rad Therapy for Rectal Cancer

Condition: Rectal Cancer
Intervention: Drug: nitroglycerin
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center; Department of Veterans Affairs
Recruiting - verified May 2012
Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects

Condition: Oral Mucositis
Interventions: Biological: ALD518; Drug: 0.9% saline
Sponsors: Alder Biopharmaceuticals, Inc.; Alder Biopharmaceuticals, Inc.
Recruiting - verified April 2012
Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients

Condition: Advanced Gastric Cancer
Intervention: Drug: AUY922 + Trastuzumab
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy

Condition: Metastatic Breast Cancer
Interventions: Drug: eribulin mesylate; Drug: eribulin mesylate; Drug: eribulin mesylate, trastuzumab
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; Eisai Inc.
Recruiting - verified March 2012
Multi-Target Colorectal Cancer Screening Test for the Detection of Colorectal Advanced Adenomatous Polyps and Cancer

Conditions: Colorectal Neoplasms; Digestive System Diseases; Colonic Diseases; Colorectal Cancer
Intervention:
Sponsors: Exact Sciences Corporation; Exact Sciences Corporation
Recruiting - verified August 2011
A Study of LY2228820 in Patients With Advanced Cancer

Condition: Advanced Cancer
Intervention: Drug: LY2228820
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified July 2011
A Phase 1 Study of LY2835219 In Subjects With Advanced Cancer

Condition: Advanced Cancer
Intervention: Drug: LY2835219
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer

Condition: Pancreatic Cancer
Intervention: Drug: dasatinib
Sponsors: Otsuka Pharmaceutical Development & Commercialization, Inc.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified February 2012
Phase II Evaluation of Exhaled Nitric Oxide (NO)

Condition: Lung Cancer
Interventions: Procedure: Nitric oxide breath test; Behavioral: Questionnaires
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Institutes of Health (NIH)
Recruiting - verified January 2012
Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)

Condition: Kidney Cancer
Interventions: Drug: Pazopanib; Drug: Temsirolimus; Behavioral: Quality of Life Assessment; Drug: Benadryl
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; GlaxoSmithKline
Not yet recruiting - verified March 2012
Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function

Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Biological: Elotuzumab (BMS-901608; HuLuc63); Drug: Lenalidomide; Drug: Lenalidomide
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified October 2011
End of Life Treatment Preferences

Condition: Advanced Cancers
Intervention: Behavioral: Telephone Survey
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified December 2011
Cryoablation for Invasive Breast Carcinoma Following Neoadjuvant Therapy

Condition: Breast Cancer
Interventions: Device: Visica 2™ Treatment System; Procedure: Cryoablation; Procedure: Surgical Resection
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified January 2012
Pegasys in Patients With Chronic Myeloid Leukemia (CML)

Condition: Leukemia
Intervention: Drug: PEG-IFNá-2a
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified February 2012
A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma

Condition: Metastatic Clear Cell Renal Cell Carcinoma
Interventions: Drug: LY2510924; Drug: Sunitinib
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012
Erlotinib Plus ARQ 197 Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Condition: Metastatic Non-Small Cell Lung Cancer
Interventions: Drug: ARQ 197 plus erlotinib; Drug: Pemetrexed, docetaxel or gemcitabine
Sponsors: ArQule; ArQule
Recruiting - verified January 2012
Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With MEK (Mitogen-activated Protein Kinase) Inhibitor BAY86-9766 in Patients With Advanced Cancer

Condition: Neoplasms
Interventions: Drug: BAY80-6946 + BAY86-9766; Drug: BAY80-6946 + BAY86-9766
Sponsors: Bayer; Bayer
Recruiting - verified April 2012
A Phase 2b Study of Modified Vaccinia Virus to Treat Advanced Liver Cancer

Conditions: Hepatocellular Carinoma; Liver Cancer; HCC
Interventions: Biological: JX-594 recombinant vaccina GM-CSF; Other: Best Supportive Care
Sponsors: Jennerex Biotherapeutics; Jennerex Biotherapeutics
Recruiting - verified November 2011
Modafinil in Treating Children With Memory and Attention Problems Caused by Cancer Treatment for a Brain Tumor

Conditions: Brain and Central Nervous System Tumors; Cognitive/Functional Effects; Fatigue; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment
Interventions: Drug: modafinil; Other: placebo
Sponsors: National Cancer Institute (NCI); University of South Florida; National Cancer Institute (NCI)
Recruiting - verified September 2011
A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy

Conditions: Metastatic ER+ Her2- Breast Cancer; Postmenopausal
Interventions: Drug: Exemestane; Drug: Abiraterone acetate + Prednisone/ Prednisolone + Exemestane; Drug: Abiraterone acetate + Prednisone or Prednisolone
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2012
MRD Testing Before and After Hematopoietic Cell Transplantation Transplantation for Pediatric Acute Myeloid Leukemia

Condition: Acute Myeloid Leukemia
Intervention:
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; Resource for Clinical Investigations in Blood and Marrow Transplantation (RCI-BMT); Pediatric Blood and Marrow Transplant Consortium
Recruiting - verified May 2012
An Extension Study of Linifanib (ABT-869) in Subjects With Advanced or Metastatic Solid Tumors

Condition: Advanced Solid Tumors
Intervention: Drug: linifanib
Sponsors: Abbott; Abbott
Recruiting - verified May 2012
Study of Oral MLN9708 in Combination With Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Drug: MLN9708 + Lenalidomide + Dexamethasone
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified May 2012
Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

Conditions: Recurrent Ovarian Cancer; Fallopian Tube Carcinoma; Primary Peritoneal Carcinoma
Intervention: Biological: Chimeric monoclonal antibody (TRC105) to CD105
Sponsors: Tracon Pharmaceuticals Inc.; Tracon Pharmaceuticals Inc.
Recruiting - verified March 2012
Combination Trial MSC1936369B With Temsirolimus

Condition: Advanced Solid Tumor
Intervention: Drug: MEK inhibitor MSC1936369B and Temsirolimus
Sponsors: EMD Serono; EMD Serono
Recruiting - verified April 2012
Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma

Condition: Relapsed Multiple Myeloma
Interventions: Drug: Lenalidomide 15mg; Drug: Lenalidomide 25mg
Sponsors: Boston VA Research Institute, Inc.; Boston VA Research Institute, Inc.; Celgene Corporation; Kansas City Veteran Affairs Medical Center; VA Pittsburgh Healthcare System; VA Greater Los Angeles Healthcare System; Michael Debakey Veterans Affairs Medical Center; Edward Hines Jr. VA Hospital
Recruiting - verified September 2011
Low Dose Arsenic Trioxide as a Potential Chemotherapy Protector

Condition: Cancer Other Than Leukemia
Intervention: Drug: Arsenic Trioxide
Sponsors: The University of Texas Health Science Center at San Antonio; The University of Texas Health Science Center at San Antonio
Recruiting - verified February 2012
Ginseng on Cancer-Related Fatigue

Conditions: Advanced Cancers; Solid Tumors
Interventions: Drug: Panax Ginseng; Dietary Supplement: Placebo; Behavioral: Questionnaires
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Indena
Recruiting - verified May 2012
Study of Bevacizumab/mFOLFOX6 Versus Bevacizumab/Folfiri With Biomarker Stratification in Patients With Previously Untreated Metastatic Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Drug: bevacizumab; Drug: FOLFIRI regimen; Drug: mFOLFOX6
Sponsors: Genentech; Genentech
Recruiting - verified December 2011
Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET

Condition: Islet Cell Tumor
Interventions: Drug: Everolimus; Drug: Pasireotide + Everolimus
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Conditions: Anxiety Disorder; Fallopian Tube Cancer; Fatigue; Nausea and Vomiting; Neurotoxicity; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Other: medical chart review; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: assessment of therapy complications; Procedure: cognitive assessment; Procedure: fatigue assessment and management; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Leukemias and Related Disorders

Conditions: Cancer; Hematologic Malignancies; Leukemia; Myeloid Leukemia
Interventions: Drug: Arm 1- Dose Escalation; Drug: Arm 2- Dose Expansion
Sponsors: Amgen; Amgen
Recruiting - verified January 2012
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

Condition: Prostate Cancer
Interventions: Radiation: radiation therapy; Radiation: selective external radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Clearance Of Mucus In Stents

Conditions: Lung Neoplasms; Respiratory Failure; Pneumonia; Acute Coronary Syndromes; Unstable Angina; Myocardial Infarction; Cardiac Arrhythmia; Thromboembolic Disease
Interventions: Other: Normal Saline; Other: Sodium Bicarbonate
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
Arry-520 + Carfilzomib for Multiple Myeloma (MM)

Condition: Myeloma
Interventions: Drug: Arry-520; Drug: Carfilzomib; Drug: Dexamethasone; Drug: Filgrastim
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Array BioPharma; Onyx Therapeutics, Inc.
Recruiting - verified February 2012
Bortezomib and Sorafenib Tosylate in Patients With Newly Diagnosed Acute Myeloid Leukemia With or Without Mutations

Condition: Leukemia
Interventions: Drug: asparaginase; Drug: bortezomib; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: etoposide; Drug: mitoxantrone hydrochloride; Drug: sorafenib tosylate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF

Conditions: Colorectal Cancer; Colorectal Adenocarcinoma
Interventions: Drug: Brivanib; Drug: Irinotecan
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Bristol-Myers Squibb
Recruiting - verified May 2012
Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: paclitaxel; Other: pharmacological study; Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group
Recruiting - verified May 2012
Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE)

Condition: Non-Small Cell Lung Cancer
Interventions: Drug: bevacizumab; Drug: carboplatin; Drug: MEGF0444A; Drug: paclitaxel; Drug: placebo
Sponsors: Genentech; Genentech
Recruiting - verified March 2012
CYCORE Feasibility

Conditions: Advanced Cancers; Colorectal Cancer; Head And Neck Cancer; Cancer Survivors
Interventions: Device: Smart phone; Device: Accelerometers (Arms 1 and 2); Device: Blood Pressure Monitor (Arms 1 and 2); Other: Telephone Surveys; Other: Home Visit; Device: Home Health Hub and Modem (All study groups); Device: Carbon Monoxide (CO) Monitor (Arm 4); Device: Heat Rate Monitor (Arm 1); Device: Global Positioning System (GPS) Device (Arm 1); Other: Surveys
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2012
Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix

Conditions: Cervical Squamous Cell Carcinoma; Adenosquamous Carcinoma; Adenocarcinoma; Locally Advanced Malignant Neoplasm; Cervical Cancer
Interventions: Procedure: Extraperitoneal laparoscopic lymphadenectomy (EPLND); Radiation: Chemoradiation
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified February 2012
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Conditions: Crohn's Disease; IBD; Colitis; Inflammatory Bowel Disease
Interventions: Drug: Group 2 ustekinumab 130 mg; Drug: Group 3: ustekinumab approximately 6 mg/kg; Drug: Group 1: Placebo
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified April 2012
Levofloxacin in Preventing Infection in Young Patients Receiving Chemotherapy For Acute Leukemia or Undergoing Stem Cell Transplantation

Conditions: Bacterial Infection; Leukemia; Musculoskeletal Complications; Neutropenia
Interventions: Drug: levofloxacin; Procedure: standard follow-up care
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer

Condition: Non Small Cell Lung Cancer
Interventions: Drug: IPI 504 plus Docetaxel; Drug: Placebo plus Docetaxel
Sponsors: Infinity Pharmaceuticals, Inc.; Infinity Pharmaceuticals, Inc.
Recruiting - verified February 2012
Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Patients With Non-Small Cell Lung Cancer and Platinum Resistant Ovarian Cancer

Condition: Non-Small Cell Lung Cancer, Ovarian Cancer
Intervention: Drug: DNIB0600A
Sponsors: Genentech; Genentech
Recruiting - verified October 2011
National Marrow Donor Program Long-Term Donor Follow-Up

Condition: Hematologic Neoplasms
Intervention:
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program
Recruiting - verified June 2011
Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments

Condition: Multiple Myeloma
Interventions: Drug: Group A: Carfilzomib & Non-IMiD Regimen; Drug: Group B: Carfilzomib & IMiD containing regimen.
Sponsors: Oncotherapeutics; Oncotherapeutics; Onyx Pharmaceuticals
Recruiting - verified February 2012
Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer

Conditions: Pain; Advanced Cancer
Interventions: Drug: Sativex®; Drug: Placebo (GA-0034)
Sponsors: GW Pharmaceuticals Ltd.; GW Pharmaceuticals Ltd.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified August 2011
AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer

Conditions: Breast Cancer; Metastatic Breast Cancer; HER-2 Positive Breast Cancer; ER Positive Breast Cancer
Intervention: Drug: AUY922
Sponsors: Texas Tech University Health Sciences Center; Texas Tech University Health Sciences Center
Recruiting - verified May 2012
Infusion of Allogeneic Umbilical Cord Blood-Derived CD19-Specific T Cells

Conditions: Leukemia; Lymphoma
Interventions: Procedure: T-Cell Infusion; Drug: Rituxan; Drug: Melphalan; Drug: Thiotepa; Drug: Fludarabine; Drug: ATG; Drug: Cyclophosphamide; Radiation: Total Body Irradiation (TBI)
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Not yet recruiting - verified May 2012
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer

Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: placebo; Drug: trastuzumab [Herceptin]; Drug: Chemotherapy
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; Breast International Group; Genentech
Recruiting - verified February 2012
An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer

Condition: Lung Cancer, Non-Small Cell
Interventions: Drug: GSK1120212; Drug: docetaxel
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)

Condition: Neuroendocrine Tumors
Intervention: Drug: Pasireotide LAR
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
A Study of RO5429083 in Patients With Metastatic and/or Locally Advanced, CD44-Expressing, Malignant Solid Tumors

Condition: Neoplasms
Interventions: Drug: RO5429083; Drug: RO5429083
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012
A Phase 2, Open-Label Study of Amuvatinib in Combination With Platinum-Etoposide Chemotherapy in Small Cell Lung Cancer

Condition: Small Cell Lung Carcinoma
Intervention: Drug: Amuvatinib
Sponsors: Astex Pharmaceuticals; Astex Pharmaceuticals
Recruiting - verified May 2012
Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Multiple Myeloma

Conditions: Multiple Myeloma; Non-Hodgkin's Lymphoma; Glioblastoma Multiforme; Head and Neck Squamous Cell Cancer; Triple Negative Breast Cancer; Hormone Receptor-Positive Breast Cancer; Castration-Resistant Prostate Cancer; Ewing's Family of Sarcomas
Intervention: Drug: CC-115
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2012
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)

Conditions: Muscle Wasting; Non Small Cell Lung Cancer
Interventions: Drug: GTx-024; Drug: placebo
Sponsors: GTx; GTx; Harrison Clinical Research
Recruiting - verified May 2012
Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum

Conditions: Muscle Wasting; Non-Small Cell Lung Cancer
Interventions: Drug: GTx-024; Drug: placebo
Sponsors: GTx; GTx; Harrison Clinical Research
Recruiting - verified May 2012
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Conditions: Hematological Malignancies; Certain Lysosomal Storage and Peroxisomal Enzyme Deficiency Disorders; Hurler Syndrome (MPS I); Krabbe Disease (Globoid Leukodystrophy); X-linked Adrenoleukodystrophy; Primary Immunodeficiency Diseases; Bone Marrow Failure; Beta-thalassemia
Intervention: Drug: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Sponsors: Center for International Blood and Marrow Transplant Research; Center for International Blood and Marrow Transplant Research; National Marrow Donor Program
Recruiting - verified April 2012
Higher-Dose Radiation Therapy or Standard Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery

Condition: Breast Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: accelerated radiation therapy; Radiation: hypofractionated radiation therapy; Radiation: intensity-modulated radiation therapy; Radiation: whole breast irradiation
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study of Oral LGK974 in Patients With Melanoma and Lobular Breast Cancer

Conditions: Melanoma; Breast Neoplasms; Lobular Carcinoma
Intervention: Drug: LGK974
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia

Conditions: B Cell Non-Hodgkin's Lymphoma; Chronic Lymphocytic Leukemia; Waldenstrom Macroglobulinemia
Intervention: Drug: AVL-292
Sponsors: Avila Therapeutics; Avila Therapeutics; The Leukemia and Lymphoma Society
Recruiting - verified May 2011
SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)

Conditions: CD-30 Positive Anaplastic Large T-cell Cutaneous Lymphoma; Lymphoma, Primary Cutaneous Anaplastic Large Cell; Lymphomatoid Papulosis; Mycosis Fungoides; Skin Lymphoma; Cutaneous Lymphomas; Lymphoma; Hematologic Disorder
Intervention: Drug: SGN-35
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Seattle Genetics, Inc.
Recruiting - verified March 2012
A Phase 2 Study of PLX3397 in Patients With Recurrent Glioblastoma

Condition: Recurrent Glioblastoma
Intervention: Drug: PLX3397
Sponsors: Plexxikon; Plexxikon
Recruiting - verified May 2012
A Dose Escalation Study of OMP-18R5 in Subjects With Solid Tumors

Condition: Solid Tumors
Intervention: Biological: OMP-18R5
Sponsors: OncoMed Pharmaceuticals, Inc.; OncoMed Pharmaceuticals, Inc.
Recruiting - verified December 2011
MaxAn Post Market Surveillance Validation

Conditions: DDD; Deformity; Tumor; Fracture
Intervention:
Sponsors: Biomet, Inc.; Biomet, Inc.
Recruiting - verified February 2012
A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma

Condition: Advanced Liposarcoma or Leiomyosarcoma
Interventions: Drug: Trabectedin; Drug: Dacarbazine
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC; Pharma Mar, S.A.U.
Recruiting - verified May 2012
EMD525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer

Condition: Prostate Cancer Metastatic
Interventions: Drug: EMD 525797; Drug: EMD 525797; Other: Placebo
Sponsors: EMD Serono; EMD Serono
Recruiting - verified May 2012
Surgery With or Without Internal Radiation Therapy Compared With Stereotactic Body Radiation Therapy in Treating Patients With High-Risk Stage I Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Procedure: therapeutic conventional surgery; Radiation: iodine I 125; Radiation: stereotactic body radiation therapy
Sponsors: National Cancer Institute (NCI); American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified May 2012
Open-Label Study of TPI 287 for Patients With Metastatic Melanoma

Condition: Metastatic Melanoma
Intervention: Drug: TPI 287
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Archer Biosciences, Inc.
Not yet recruiting - verified March 2012
Long Term Safety of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain

Conditions: Pain; Advanced Cancer
Intervention: Drug: Sativex®
Sponsors: GW Pharmaceuticals Ltd.; GW Pharmaceuticals Ltd.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified April 2011
Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma

Condition: Glioblastoma
Interventions: Drug: BKM120; Procedure: Surgery
Sponsors: Dana-Farber Cancer Institute; Patrick Y. Wen, MD; Brigham and Women's Hospital; Massachusetts General Hospital; Novartis Pharmaceuticals; M.D. Anderson Cancer Center; Memorial Sloan-Kettering Cancer Center; University of California, San Francisco; University of California, Los Angeles
Recruiting - verified February 2012
An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting

Condition: Chemotherapy-Induced Nausea and Vomiting
Interventions: Drug: Netupitant and Palonosetron; Drug: Palonosetron
Sponsors: Helsinn Healthcare SA; Helsinn Healthcare SA; Parexel
Recruiting - verified December 2011
Genomic Testing for Primary Breast Cancer

Condition: Breast Cancer
Interventions: Procedure: Tumor Biopsy; Other: Breast Cancer Registry
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Susan G. Komen Breast Cancer Foundation; Kellogg Company
Recruiting - verified March 2012
Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)

Condition: Breast Cancer
Interventions: Drug: Liposomal Doxorubicin; Drug: Seliciclib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Institutes of Health (NIH)
Not yet recruiting - verified March 2012
HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular Cancer

Condition: Hepatocellular Carcinoma
Interventions: Device: HepaSphere/QuadraSphere Microspheres; Procedure: PVA, lipiodol, doxorubicin
Sponsors: Merit Medical Systems, Inc.; Merit Medical Systems, Inc.
Recruiting - verified January 2012
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Drug: Dexamethasone; Biological: Elotuzumab (BMS-901608; HuLuc63); Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified October 2011
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency

Conditions: Multiple Myeloma; Renal Insufficiency
Interventions: Drug: BHQ880; Drug: BHQ990
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
Single Agent Armodafinil for Patient-Reported Fatigue

Conditions: Head And Neck Cancer; Fatigue
Interventions: Drug: Armodafinil; Other: Placebo; Behavioral: Questionnaires
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified January 2012
Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma

Condition: Neuroblastoma
Interventions: Biological: hu14.18-IL2 fusion protein; Biological: sargramostim; Drug: isotretinoin; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients

Conditions: Unspecified Adult Solid Tumor, Protocol Specific; Solid Tumor
Intervention: Drug: BEZ235 + MEK162
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Administration of TAA-Specific Cytotoxic T-Lymphocytes (CTLS) to Patients With Hodgkin or Non-Hodgkin Lymphoma

Conditions: Hodgkin Lymphoma; Non-Hodgkin Lymphoma; Hodgkin Disease
Intervention: Drug: TAA CTL Administration
Sponsors: Baylor College of Medicine; Baylor College of Medicine; Texas Children's Hospital; The Methodist Hospital System
Recruiting - verified April 2012
Afatinib (BIBW2992) in HER2-overexpressing Inflammatory Breast Cancer

Condition: Breast Neoplasms
Interventions: Drug: Vinorelbine Weekly; Drug: Afatinib once daily (OD)
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012
A Phase 3 Efficacy Study of a Recombinant Vaccinia Virus Vaccine to Treat Metastatic Prostate Cancer

Condition: Prostate Cancer Metastatic
Interventions: Biological: PROSTVAC-V/F-TRICOM + GM-CSF; Biological: PROSTVAC-V/F-TRICOM + GM-CSF placebo; Biological: Placebo
Sponsors: BN ImmunoTherapeutics; BN ImmunoTherapeutics
Recruiting - verified January 2012
Study of Cholecalciferol and Daily Genistein (G-2535) Versus Placebo in Men With Early Stage Prostate Cancer

Condition: Prostate Cancer
Interventions: Dietary Supplement: Vitamin D and Genistein; Other: Placebo
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison; University of Alabama at Birmingham; University of Rochester; University of Minnesota - Clinical and Translational Science Institute; Lahey Clinic; Urology San Antonio
Recruiting - verified January 2012
A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma

Condition: Basal Cell Carcinoma
Intervention: Drug: LDE225
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
18-F-Fluoroacetate as PET Imaging Agent

Conditions: Brain Cancer; Breast Cancer; Prostate Cancer
Intervention: Drug: 18F-fluoroacetate
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Not yet recruiting - verified December 2011
Study of 18F-Fluoro-PEG6-IPQA

Condition: Lung Cancer
Interventions: Drug: 18F-PEG6-IPQA; Procedure: Positron emission tomography (PET)
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
A Study for Reducing Symptom Burden Produced by Chemoradiation Treatment for Non Small Cell Lung Cancer by Minocycline and Armodafinil

Condition: Lung Cancer
Interventions: Drug: Armodafinil; Other: Placebo; Drug: Minocycline; Behavioral: Questionnaires
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2012
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer

Condition: Thyroid Cancer
Interventions: Drug: lenvatinib 24 mg administered orally, once a day; Drug: Placebo 24mg administered orally, once a day
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified April 2012
Effectiveness of Using Biomarkers to Detect and Identify Cardiotoxicity and Describe Treatment (PREDICT)

Conditions: Breast Cancer; Gastrointestinal Cancer; Genitourinary Cancer; Leukemia; Lung Cancer
Intervention: Other: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Biosite
Recruiting - verified December 2011
Virtual Reality Intervention in Cancer Genetics

Conditions: Cancer; Prevention Harmful Effects
Interventions: Behavioral: Questionnaires; Behavioral: Physiological Measurements; Behavioral: Virtual Reality Scene Viewing
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy

Condition: Prostate Cancer
Interventions: Drug: abiraterone acetate; Drug: degarelix; Drug: goserelin acetate; Drug: leuprolide acetate; Procedure: orchiectomy
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

Conditions: Prostate Cancer; Prostatic Neoplasm
Intervention: Drug: abiraterone acetate in combination with prednisone
Sponsors: Janssen Biotech, Inc.; Janssen Biotech, Inc.
Recruiting - verified May 2012
Telephone Counseling-Mailed Materials Versus Internet Interventions in Overweight Cancer Survivors

Conditions: Breast Cancer; Colorectal Cancer; Prostate Cancer
Interventions: Behavioral: Standard Arm (mail/telephone); Behavioral: Internet Arm; Behavioral: Surveys and Questionnaires; Behavioral: Exercise and Diet
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
Evaluation of Safety, Tolerability, PK & PD of Intravenous VX15/2503 in Patients With Advanced Solid Tumors

Condition: Solid Tumors
Intervention: Drug: VX15/2503
Sponsors: Vaccinex Inc.; Vaccinex Inc.; PPD
Recruiting - verified May 2012
Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Cabazitaxel (XRP6258); Drug: Prednisone
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012
Bioprosthetic Mesh to Expand the Lower Pole in Tissue Expander Reconstruction

Condition: Breast Cancer
Interventions: Device: Alloderm; Device: Surgimend
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Drug: Akt inhibitor MK2206; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Dana-Farber Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified October 2011
A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer

Conditions: Advanced Prostate Cancer; Prostatic Neoplasms
Intervention: Biological: sipuleucel-T
Sponsors: Dendreon; Dendreon
Recruiting - verified March 2012
In Vivo Dosimetry During Prostate Cancer Radiotherapy

Condition: Prostate Disease
Intervention: Device: Plastic Scintillation Detectors
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified February 2012
ABT-888 With Cyclophosphamide in Refractory BRCA-Positive Ovarian, Primary Peritoneal or Ovarian High-Grade Serous Carcinoma, Fallopian Tube Cancer, Triple-Negative Breast Cancer, and Low-Grade Non-Hodgkin's Lymphoma

Conditions: Ovarian; Primary Peritoneal; Serous Carcinoma; Triple-Negative Breast; Fallopian Tube
Interventions: Drug: ABT-888 with Cyclophospharmide; Drug: Cyclophosphamide
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified November 2011
Trial of Adjuvant FANG™ Vaccine for High Risk Stage IIIc Ovarian Cancer

Condition: Ovarian Cancer
Interventions: Biological: FANG; Drug: standard of care observational follow-up
Sponsors: Gradalis, Inc.; Gradalis, Inc.
Recruiting - verified May 2012
A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma

Condition: Conventional Chondrosarcoma
Interventions: Drug: IPI-926; Drug: Placebo Arm
Sponsors: Infinity Pharmaceuticals, Inc.; Infinity Pharmaceuticals, Inc.
Recruiting - verified May 2012
Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer

Conditions: Head and Neck Cancer; Precancerous Condition
Interventions: Biological: cetuximab; Drug: cisplatin
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy

Conditions: Fungal Infection; Leukemia; Neutropenia
Interventions: Drug: caspofungin acetate; Drug: fluconazole
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Drug: ACY-1215
Sponsors: Acetylon Pharmaceuticals Incorporated; Acetylon Pharmaceuticals Incorporated; The Leukemia and Lymphoma Society
Recruiting - verified April 2012
Ganitumab and Gemcitabine Hydrochloride Followed by Radiation Therapy, Ganitumab, Capecitabine, and Maintenance Therapy in Treating Patients With Locally Advanced Cancer of the Pancreas

Condition: Pancreatic Cancer
Interventions: Biological: ganitumab; Drug: capecitabine; Drug: gemcitabine hydrochloride; Radiation: 3-dimensional conformal radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Carfilzomib Plus Panobinostat in Relapsed/Refractory Multiple Myeloma (MM)

Condition: Myeloma
Interventions: Drug: Carfilzomib; Drug: Panobinostat
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Novartis; Onyx Therapeutics, Inc.
Recruiting - verified February 2012
A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer

Condition: HER-2 Gene Amplification
Interventions: Drug: Cisplatin, Capecitabine, Trastuzumab and MM-111; Drug: Lapatinib, Trastuzumab and MM-111; Drug: Paclitaxel, Trastuzumab and MM-111
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals
Recruiting - verified March 2012
Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer
Interventions: Drug: BKM120 or Docetaxel; Drug: BKM120 or Docetaxel or Pemetrexed
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
Carboplatin and Bevacizumab for Recurrent Ependymoma

Conditions: Brain Tumor; Spinal Tumor; Glial Tumour of Brain; Ependymal Tumour of Brain; Spinal Cord Ependymoma; Anaplastic Ependymoma
Interventions: Drug: Bevacizumab; Drug: Carboplatin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; CERN Foundation - Collaborative Ependymoma Research Network
Recruiting - verified February 2012
Study of MK-3475 in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001 AM4)

Condition: Cancer, Solid Tumor
Interventions: Drug: MK-3475 1 mg/kg; Drug: MK-3475 3 mg/kg; Drug: MK-3475 10 mg/kg; Drug: MK-3475 MEL; Drug: MK-3475 NSCLC
Sponsors: Schering-Plough; Schering-Plough
Recruiting - verified April 2012
Obesity: Cancer Risk Among African Americans

Conditions: Cancer; Obesity
Interventions: Behavioral: Health Education; Behavioral: MAPS
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1)

Conditions: Recurrence of Solid Tumor; Glioblastoma Multiforme; Melanoma
Interventions: Drug: MK-4827; Drug: Temozolomide
Sponsors: Merck; Merck
Recruiting - verified May 2012
A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST

Condition: Gastrointestinal Stromal Tumor (GIST)
Intervention: Drug: AT13387 and Imatinib
Sponsors: Astex Pharmaceuticals; Astex Pharmaceuticals
Recruiting - verified March 2012
Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049 AM1)

Condition: Advanced Cancer
Interventions: Drug: ridaforolimus; Drug: MK-0752; Drug: MK-2206
Sponsors: Merck; Merck
Recruiting - verified May 2012
Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors

Conditions: Solid Tumors; Relapsed/Refractory Sarcomas
Intervention: Drug: Vorinostat and Etoposide
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Merck; Phoenix Children's Hospital; Penn State Children's Hospital; Johns Hopkins University; Sidney Kimmel Comprehensive Cancer Center; Children's Hospital Colorado; University of Florida; Alberta Children's Hospital; M.D. Anderson Cancer Center; Dana-Farber Cancer Institute; Children's Mercy Hospital & Clinics; All Children's Hospital; Arnold Palmer Hospital for Children/MD Anderson Cancer Center Orlando
Recruiting - verified February 2012
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Biological: Imprime PGG + cetuximab; Drug: Cetuximab
Sponsors: Biothera; Biothera
Recruiting - verified April 2012
Study of PM060184 in Patients With Advanced Solid Tumors

Condition: Solid Tumors
Intervention: Drug: PM060184
Sponsors: PharmaMar; PharmaMar
Recruiting - verified May 2012
Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer

Conditions: Ductal Breast Carcinoma in Situ; Lobular Breast Carcinoma in Situ; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer
Interventions: Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery; Other: laboratory biomarker analysis; Other: enzyme-linked immunosorbent assay; Genetic: gene expression analysis; Drug: systemic chemotherapy; Drug: tamoxifen citrate; Drug: aromatase inhibition therapy
Sponsors: Virginia Commonwealth University; Virginia Commonwealth University; National Cancer Institute (NCI)
Recruiting - verified April 2012
A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma

Condition: Renal Cell Carcinoma
Intervention: Drug: Tivozanib
Sponsors: AVEO Pharmaceuticals, Inc.; AVEO Pharmaceuticals, Inc.
Recruiting - verified September 2011
NP2 Enkephalin For Treatment of Intractable Cancer Pain

Conditions: Intractable Pain; Neoplasms
Interventions: Biological: NP2; Biological: Placebo
Sponsors: Diamyd Inc; Diamyd Inc; Paragon Biomedical; invivodata, Inc.
Recruiting - verified January 2012
Finasteride Challenge

Condition: Prostate Cancer
Intervention: Drug: Finasteride
Sponsors: The University of Texas Health Science Center at San Antonio; The University of Texas Health Science Center at San Antonio; National Institutes of Health (NIH)
Recruiting - verified August 2011
GSK1120212 Rollover Study

Condition: Cancer
Interventions: Drug: GSK1120212; Drug: Docetaxel + GSK1120212; Drug: Erlotinib + GSK1120212; Drug: Pemetrexed + GSK1120212; Drug: Carboplatin + GSK1120212; Drug: Nab-paclitaxel + GSK1120212; Drug: Gemcitabine + GSK1120212; Drug: Everolimus + GSK1120212
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
A Study of MDV3100 Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer

Condition: Prostatic Neoplasms
Interventions: Drug: MDV3100; Drug: Bicalutamide
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc; Medivation, Inc.
Recruiting - verified March 2012
A Study of DS-2248, in Subjects With Advanced Solid Tumors

Conditions: Solid Tumors; Non-small Cell Lung Carcinoma
Intervention: Drug: DS-2248
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.; Daiichi Sankyo Development Ltd
Recruiting - verified March 2012
Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma

Conditions: Grade IV Glioma; Grade IV Astrocytoma; Glioblastoma Multiforme
Intervention: Biological: TVI-Brain-1
Sponsors: TVAX Biomedical; TVAX Biomedical
Recruiting - verified April 2012
A Study of RO5185426 (Vemurafenib) in Patients With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation

Condition: Neoplasms
Intervention: Drug: RO5185426
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012
A Study to Evaluate Pazopanib in Comparison to Pemetrexed in Maintenance Setting in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) Population

Condition: Lung Cancer, Small Cell
Interventions: Drug: pazopanib; Drug: pemetrexed
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial

Condition: Metastatic Diffuse Gastric Cancer Including Carcinoma of the Gastro-esophageal Junction
Interventions: Drug: S-1 (Tegafur/Gimeracil/Oteracil) /cisplatin (investigational arm); Drug: Fluorouracil/cisplatin (control arm)
Sponsors: Taiho Pharma USA, Inc.; Taiho Pharma USA, Inc.
Recruiting - verified April 2012
BKM120 as Second-line Therapy for Advanced Endometrial Cancer

Condition: Advanced Endometrial Cancer
Intervention: Drug: BKM120
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
A Phase 1 Study of LY2787106 in Cancer and Anemia

Condition: Anemia
Intervention: Drug: LY2787106
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012
Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)

Conditions: Advanced Malignancies; B-Cell Lymphoma; Solid Tumor
Intervention: Drug: ASP3026
Sponsors: Astellas Pharma Inc; Astellas Pharma Inc
Recruiting - verified February 2012
MK-2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer

Conditions: Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer
Intervention: Drug: MK-2206
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute
Recruiting - verified February 2012
Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin

Condition: Lung Cancer - Non Small Cell
Interventions: Drug: Ipilimumab; Drug: Placebo; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified April 2012
A Dose Finding Study With Oral LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK)

Condition: Tumors Characterized by Genetic Abnormalities of ALK
Intervention: Drug: LDK378
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma

Condition: Smoldering Multiple Myeloma
Intervention: Drug: BHQ880
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
Prevention of Treatment Induced Neuropathy in Multiple Myeloma

Condition: Myeloma
Interventions: Other: Placebo; Drug: Minocycline
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified December 2011
Study of Ramucirumab or IMC-18F1 With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma

Conditions: Carcinoma of Urinary Tract; Urethral Carcinoma; Carcinoma of Ureter; Carcinoma of Renal Pelvis
Interventions: Drug: Docetaxel; Biological: Ramucirumab DP; Biological: IMC-18F1
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified March 2012
Akt Inhibitor MK-2206 in Patients With Advanced Breast Cancer Who Have Tumors With a PIK3CA Mutation and/or PTEN Loss

Condition: Breast Cancer
Intervention: Drug: MK2206
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Institutes of Health (NIH)
Recruiting - verified April 2012
Pilot Study of Hyperthermic Peritoneal Perfusion (HIPEC) for Adolescent and Young Adults With Desmoplastic Small Round Cell Tumor

Conditions: Advanced Cancers; Sarcoma
Interventions: Procedure: Hyperthermic Peritoneal Perfusion (HIPEC); Drug: Cisplatin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer

Conditions: Neoplasms; Ovarian Neoplasms; Fallopian Tube Neoplasms; Primary Peritoneal Neoplasm
Interventions: Biological: KHK2866; Drug: Gemcitabine and Carboplatin; Drug: paclitaxel; Drug: pegylated liposomal doxorubicin
Sponsors: Kyowa Hakko Kirin Pharma, Inc.; Kyowa Hakko Kirin Pharma, Inc.
Recruiting - verified February 2012
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

Condition: Breast Cancer
Interventions: Biological: trastuzumab; Drug: cyclophosphamide; Drug: docetaxel; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified February 2012
Gemcitabine Pharmacokinetics

Condition: Pancreatic Cancer
Intervention: Drug: Gemcitabine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)

Condition: Glioblastoma Multiforme
Interventions: Biological: ICT-107; Biological: Placebo DC
Sponsors: ImmunoCellular Therapeutics, Ltd.; ImmunoCellular Therapeutics, Ltd.
Recruiting - verified May 2012
Study of GO-203-2C Given Intravenously in Patients With Advanced Solid Tumors

Condition: Solid Tumors
Intervention: Drug: GO-203-2c
Sponsors: Genus Oncology, LLC; Genus Oncology, LLC
Recruiting - verified January 2012
Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma

Conditions: Brain and Central Nervous System Tumors; Lymphoma; Lymphoproliferative Disorder; Small Intestine Cancer; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: imetelstat sodium; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction

Conditions: Neoplasms; Lymphomas
Intervention: Drug: Belinostat
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified September 2011
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: exemestane; Drug: letrozole; Drug: systemic chemotherapy; Drug: tamoxifen citrate
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
A Dose Escalation Study of OMP-59R5 in Subjects With Solid Tumors

Condition: Solid Tumors
Intervention: Drug: OMP-59R5
Sponsors: OncoMed Pharmaceuticals, Inc.; OncoMed Pharmaceuticals, Inc.
Recruiting - verified December 2011
A Study of ChemoFx® Chemoresponse Assay in Solid Tumors - ChemoFx® Registry Study

Condition: Solid Organ Tumors
Intervention:
Sponsors: Precision Therapeutics; Precision Therapeutics
Recruiting - verified January 2012
Trial of Gemcitabine With or Without Bavituximab in Patients With Previously Untreated Stage IV Pancreatic Cancer

Condition: Metastatic Pancreatic Cancer
Interventions: Biological: bavituximab; Drug: Gemcitabine
Sponsors: Peregrine Pharmaceuticals; Peregrine Pharmaceuticals
Recruiting - verified May 2012
Study of REGN910 (SAR307746)

Condition: Solid Tumors
Interventions: Biological: REGN910(SAR307746); Biological: REGN910(SAR307746); Biological: REGN910(SAR307746); Biological: REGN910(SAR307746)
Sponsors: Regeneron Pharmaceuticals; Regeneron Pharmaceuticals; Sanofi-Aventis
Recruiting - verified May 2012
Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer

Condition: Breast Cancer
Intervention: Drug: Eribulin Mesylate
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified March 2012
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III or Stage IV Melanoma That Has Been Removed by Surgery

Condition: Melanoma (Skin)
Interventions: Biological: ipilimumab; Biological: recombinant interferon alfa-2b
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Proflavine: A Feasibility Study for In Vivo Imaging of Oral Neoplasia

Condition: Head and Neck Cancer
Interventions: Drug: Proflavine; Procedure: Imaging; Device: Widefield Multispectral Imaging Devices; Device: High-Resolution Microendoscope (HRME)
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Institutes of Health (NIH)
Recruiting - verified May 2012
Efficacy of NF-kB Inhibition for Reducing Symptoms During Maintenance Therapy in Multiple Myeloma Patients

Condition: Multiple Myeloma
Interventions: Drug: Curcumin; Other: Placebo
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Institutes of Health (NIH)
Not yet recruiting - verified April 2012
Brivanib in Treating Patients With Persistent or Recurrent Cervical Cancer

Condition: Cervical Cancer
Interventions: Drug: brivanib alaninate; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer

Condition: Advanced Cancers
Interventions: Drug: Hydroxychloroquine; Drug: Sirolimus; Drug: Vorinostat
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
Xerostomia Acupuncture Trial

Condition: Head And Neck Cancer
Interventions: Procedure: True Acupuncture; Procedure: Sham Acupuncture; Other: Standard Care; Other: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2012
Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma

Condition: Brain Cancer
Interventions: Drug: Vorinostat; Drug: Bevacizumab; Drug: Bevacizumab; Drug: Vorinostat
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Genentech
Recruiting - verified April 2012
Hypofractionation Trial

Condition: Breast Cancer
Interventions: Radiation: Hypofractionated Whole Breast Irradiation; Radiation: Conventionally Fractionated Whole Breast Irradiation
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified December 2011
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma

Condition: Metastatic Renal Cell Carcinoma
Interventions: Drug: Sunitinib; Biological: IMA901 plus GM-CSF; Drug: Cyclophosphamide
Sponsors: immatics Biotechnologies GmbH; immatics Biotechnologies GmbH
Recruiting - verified May 2012
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer

Conditions: Anemia; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small-Cell Lung; Bladder Cancer; Cancer of Head and Neck; Uterine Cervical Cancer
Interventions: Drug: ACE-011 - 15 mg; Drug: ACE-011 - 30 mg; Drug: ACE-011 - 45 mg
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified February 2012
A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Adults With Previously Untreated, Advanced Non-Small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer
Interventions: Drug: Carboplatin/Paclitaxel/MEDI-575; Drug: Carboplatin/Paclitaxel; Drug: Carboplatin/Paclitaxel/MEDI-575
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified May 2012
BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Drug: Carboplatin; Drug: Pemetrexed; Drug: Bevacizumab; Drug: Cetuximab; Drug: Cixutumumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Eli Lilly and Company; Genentech; ImClone LLC
Recruiting - verified May 2012
Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC)

Condition: Kidney Cancer
Intervention: Drug: Axitinib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Pfizer
Recruiting - verified April 2012
Manuka Honey in Preventing Esophagitis-Related Pain in Patients Receiving Chemotherapy and Radiation Therapy For Lung Cancer

Conditions: Dysphagia; Lung Cancer; Pain
Interventions: Drug: Manuka honey; Drug: chemotherapy; Other: questionnaire administration; Procedure: adjuvant therapy; Procedure: assessment of therapy complications; Procedure: quality-of-life assessment; Procedure: standard follow-up care; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Prohibitin Targeting Peptide 1

Condition: Prostate Cancer
Intervention: Drug: Prohibitin-TP01
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Not yet recruiting - verified May 2012
TKI258 for Metastatic Inflammatory Breast Cancer Patients

Condition: Breast Cancer
Intervention: Drug: Dovitinib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Novartis
Recruiting - verified January 2012
MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer

Conditions: Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer; Gastric Cancer
Intervention: Drug: Akt inhibitor MK2206
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study of Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer

Condition: Pain
Interventions: Drug: Sativex®; Drug: Placebo (GA-0034)
Sponsors: GW Pharmaceuticals Ltd.; GW Pharmaceuticals Ltd.; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified May 2011
Study of CA-18C3 in Subjects With Advanced Hematologic Malignancies

Condition: Hematologic Malignancies
Intervention: Drug: CA-18C3
Sponsors: XBiotech, Inc.; XBiotech, Inc.
Recruiting - verified April 2012
Multi-marker Stool Test for Detection of Colorectal Neoplasia: Marker Panel Selection and Technical Development Studies

Conditions: Colorectal Neoplasms; Digestive System Diseases; Colonic Diseases; Colorectal Cancer
Intervention:
Sponsors: Exact Sciences Corporation; Exact Sciences Corporation
Recruiting - verified August 2011
Delayed-Delayed Breast Reconstruction

Condition: Breast
Intervention: Procedure: Delayed Breast Reconstruction
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme

Condition: Relapsed Glioblastoma Multiforme
Intervention: Drug: VB-111
Sponsors: Vascular Biogenics Ltd. operating as VBL Therapeutics; Vascular Biogenics Ltd. operating as VBL Therapeutics
Recruiting - verified November 2011
Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy

Conditions: Leukemia; Lymphoma
Intervention: Drug: Ofatumumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; GlaxoSmithKline
Recruiting - verified February 2012
Frequency of EGFR Mutations in Latinos/Hispanics With Non-Small Cell Lung Cancer

Condition: Non-Small-Cell Lung Carcinoma
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified September 2011
A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011 AM1)

Condition: Herpes Zoster
Interventions: Biological: V212; Biological: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2012
Maximum Androgen Depletion

Condition: Prostate Cancer
Interventions: Drug: Abiraterone Acetate; Drug: Prednisone; Drug: Sunitinib; Drug: Dasatinib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Bristol-Myers Squibb; Ortho Biotech, Inc.; Pfizer
Recruiting - verified April 2012
Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer

Conditions: Hepatocellular Carcinoma; Liver Cancer
Intervention: Drug: bavituximab and sorafenib
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center
Recruiting - verified October 2010
A Study of ARRY-382 in Patients With Selected Advanced or Metastatic Cancers

Condition: Metastatic Cancer
Intervention: Drug: ARRY-382, cFMS inhibitor; oral
Sponsors: Array BioPharma; Array BioPharma
Recruiting - verified February 2012
Phase 1 and 2 Study of PX-866 and Cetuximab

Conditions: Incurable Metastatic Colorectal Carcinoma; Incurable Progressive, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: PX-866 and cetuximab; Drug: Cetuximab; Drug: PX-866 and cetuximab; Drug: Cetuximab
Sponsors: Oncothyreon Inc.; Oncothyreon Inc.
Recruiting - verified April 2012
A Study of AMG 337 in Subjects With Advanced Solid Tumors

Conditions: Advanced Malignancy; Advanced Solid Tumors; Cancer; Oncology; Oncology Patients; Tumors
Intervention: Drug: AMG 337
Sponsors: Amgen; Amgen
Recruiting - verified July 2011
BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study

Condition: Lung Cancer
Interventions: Drug: Erlotinib; Drug: AZD6244; Drug: MK-2206; Drug: Sorafenib; Drug: Erlotinib; Drug: MK-2206
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; AstraZeneca; Bayer; Merck; National Cancer Institute (NCI); OSI Pharmaceuticals
Recruiting - verified January 2012
Umbilical Cord Blood Transplant for Children With Myeloid Hematological Malignancies

Condition: Congenital Pediatric Disorders
Interventions: Drug: Busulfan; Drug: Cyclophosphamide; Drug: Fludarabine
Sponsors: Baylor College of Medicine; Baylor College of Medicine; Texas Children's Hospital
Recruiting - verified August 2011
Partial Breast Proton Beam Irradiation

Condition: Breast Cancer
Intervention: Radiation: Accelerated Partial Breast Irradiation (APBI)
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
Umbilical Cord Blood Transplant for Children With Lymphoid Hematological Malignancies

Conditions: Lymphoid Hematological Malignancies; Umbilical Cord Blood Transplant
Intervention: Drug: Cytoxan/TBI/Fludarabine
Sponsors: Baylor College of Medicine; Baylor College of Medicine; Texas Children's Hospital
Recruiting - verified August 2011
A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + MK-8669 Combination Therapies in Participants With Advanced Cancer (MK-0646-027 AM2)

Condition: Neoplasms Malignant
Interventions: Drug: dalotuzumab + MK-2206; Drug: dalotuzumab + MK-0752; Drug: Dalotuzumab + MK-8669 (ridaforolimus)
Sponsors: Merck; Merck
Recruiting - verified May 2012
Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer

Condition: Breast Cancer
Interventions: Procedure: palliative surgery; Procedure: therapeutic conventional surgery; Radiation: palliative radiation therapy; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Viral Therapy in Treating Young Patients With Relapsed or Refractory Solid Tumors

Condition: Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Biological: wild-type reovirus; Drug: cyclophosphamide; Genetic: reverse transcriptase-polymerase chain reaction; Other: laboratory biomarker analysis; Other: pharmacogenomic studies
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified September 2011
MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer

Condition: Kidney Cancer
Interventions: Drug: Akt inhibitor MK2206; Drug: everolimus
Sponsors: National Cancer Institute (NCI); M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified September 2011
Diet in Altering Disease Progression in Patients With Prostate Cancer on Active Surveillance

Condition: Prostate Cancer
Interventions: Behavioral: telephone-based intervention; Other: counseling intervention; Other: educational intervention; Procedure: therapeutic dietary intervention
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2012
Colonoscopy Versus Fecal Immunochemical Testing in Reducing Mortality From Colorectal Cancer (CONFIRM)

Condition: Colorectal Cancer
Interventions: Procedure: Colonoscopy; Procedure: FIT
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Not yet recruiting - verified April 2012
GDC-0449 in Treating Younger Patients With Recurrent or Refractory Medulloblastoma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: vismodegib; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Pediatric Brain Tumor Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012
A Study to Test Safety and Efficacy of IMGN901 in Combination With Carboplatin/Etoposide in Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer

Condition: Small Cell Lung Cancer and Other Solid Tumors
Interventions: Drug: IMGN901; Drug: IMGN901
Sponsors: ImmunoGen, Inc.; ImmunoGen, Inc.
Recruiting - verified July 2011
177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms

Condition: Neuroendocrine Tumors
Intervention: Drug: 177Lu-DOTATATE
Sponsors: Excel Diagnostics and Nuclear Oncology Center; Excel Diagnostics and Nuclear Oncology Center
Recruiting - verified March 2012
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients

Condition: Breast Cancer
Interventions: Biological: Ramucirumab DP; Biological: IMC-18F1; Drug: Capecitabine
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified May 2012
Multiple Ascending Dose of BMS-911543

Condition: Cancer
Intervention: Drug: BMS-911543
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified November 2011
Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab

Condition: Advanced HER2-positive Breast Cancer
Intervention: Drug: AUY922 + Trastuzumab
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
PH III Relapse or Refractory MM - Open Label With or Without Elotuzumab

Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Dexamethasone; Drug: Dexamethasone (Oral); Drug: Dexamethasone (IV); Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified May 2012
High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma

Condition: Myeloma
Interventions: Drug: Palifermin; Drug: Dexamethasone; Drug: Gemcitabine; Drug: Busulfan; Drug: Melphalan; Procedure: Stem Cell Transplant
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel

Condition: Non-small Cell Lung Cancer
Interventions: Drug: ISIS EIF4E Rx; Drug: ISIS EIF4E Rx; Drug: ISIS EIF4E Rx; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: Isis Pharmaceuticals; Isis Pharmaceuticals
Recruiting - verified March 2012
A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: tasquinimod
Sponsors: Active Biotech AB; Active Biotech AB
Recruiting - verified April 2012
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia

Conditions: Brain and Central Nervous System Tumors; Leukemia; Lymphoma; Lymphoproliferative Disorder; Small Intestine Cancer; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: Akt inhibitor MK2206; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2012
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma

Conditions: Brain and Central Nervous System Tumors; Kidney Cancer; Sarcoma
Interventions: Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: topotecan hydrochloride; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Everolimus and Octreotide With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery

Conditions: Islet Cell Tumor; Pancreatic Cancer
Interventions: Biological: bevacizumab; Drug: everolimus; Drug: octreotide acetate
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study of Eniluracil + 5-Fluorouracil (5-FU) + Leucovorin Versus Capecitabine in Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: Eniluracil; Drug: 5-Fluorouracil; Drug: Leucovorin; Drug: Capecitabine
Sponsors: Adherex Technologies, Inc.; Adherex Technologies, Inc.
Recruiting - verified August 2011
Avoiding the Hippocampus During Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

Conditions: Cognitive/Functional Effects; Metastatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: cognitive assessment; Procedure: quality-of-life assessment; Radiation: intensity-modulated radiation therapy; Radiation: whole-brain radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors

Condition: Cancer
Interventions: Drug: GSK2118436; Drug: GSK1120212; Drug: Other approved anti-cancer agent
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
A Phase II Study of Crenolanib (CP-868,596), a Selective and Potent Inhibitor of PDGFR, for the Treatment of Adult Gliomas

Condition: Glioma
Intervention: Drug: Crenolanib (CP-868,596)
Sponsors: Arog Pharmaceuticals LLC; Arog Pharmaceuticals LLC
Recruiting - verified January 2012
A Phase 1 Study in Advanced Cancer

Condition: Advanced Cancer
Intervention: Drug: LY2940680
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
Standard or Extended Pelvic Lymphadenectomy in Treating Patients Undergoing Surgery for Invasive Bladder Cancer

Condition: Bladder Cancer
Interventions: Procedure: therapeutic conventional surgery; Procedure: therapeutic lymphadenectomy
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012
Vitamin D and Breast Cancer Biomarkers in Female Patients

Condition: Breast Cancer
Interventions: Dietary Supplement: vitamin D; Other: placebo
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors

Condition: Breast Cancer
Interventions: Drug: BMS-754807; Drug: letrozole
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Mayo Clinic
Recruiting - verified December 2011
A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0917 Administered to Patients With Refractory Solid Tumors or Lymphoma

Condition: Solid Cancers
Intervention: Drug: GDC-0917
Sponsors: Genentech; Genentech
Recruiting - verified March 2012
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only

Condition: Colorectal Cancer
Interventions: Drug: Panitumumab; Drug: Oxaliplatin; Drug: Irinotecan; Drug: Leucovorin; Drug: 5-Fluorouracil
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; Amgen
Recruiting - verified July 2011
Renal Cell Carcinoma (RCC) Scramble

Condition: Renal Cell Carcinoma
Intervention: Procedure: Perfusion CT scan
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
GAMMA - Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas

Conditions: Adenocarcinoma of the Pancreas; Advanced Solid Tumors; Cancer; Cancer of Pancreas; Cancer of the Pancreas; Metastases; Metastatic Cancer; Metastatic Pancreatic Cancer; Pancreas Cancer; Pancreatic Cancer; Bone Metastases; Endocrine Cancer; Oncology; Oncology Patients; Solid Tumors; Advanced Malignancy
Interventions: Drug: AMG 479; Drug: Placebo; Drug: AMG 479; Drug: gemcitabine
Sponsors: Amgen; Amgen; Takeda Global Research & Development Center, Inc.
Recruiting - verified May 2012
A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)

Conditions: Renal Cell Carcinoma; Cancer
Interventions: Drug: pazopanib; Drug: placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery

Condition: Head and Neck Cancer
Interventions: Drug: cisplatin; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Symptom Burden in Head and Neck Cancer

Condition: Head And Neck Cancer
Interventions: Other: Placebo; Drug: Curcumin; Drug: Armodafinil; Drug: Minocycline; Drug: Bupropion
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Not yet recruiting - verified May 2012
Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer

Conditions: Prostate Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Genital Diseases, Male
Intervention: Drug: Abiraterone Acetate
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Available - verified April 2012
Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer

Conditions: Neoplasms, Breast; WT1-positive Primary Invasive Breast Cancer
Interventions: Biological: GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A; Biological: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: bevacizumab; Drug: irinotecan hydrochloride; Drug: temozolomide
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Vinorelbine Ditartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma

Condition: Sarcoma
Interventions: Biological: bevacizumab; Drug: cyclophosphamide; Drug: temsirolimus; Drug: vinorelbine tartrate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy

Condition: Kidney Cancer
Interventions: Drug: Pazopanib; Drug: Bevacizumab; Drug: Everolimus
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified December 2011
Trimodality Management of T1b Esophageal Cancers

Condition: Esophageal Cancer
Interventions: Drug: Docetaxel; Drug: 5-FU; Radiation: Radiotherapy; Procedure: Esophagectomy; Drug: Dexamethasone
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene

Conditions: Advanced Solid Tumors; With an Alteration of the PIK3CA Gene
Intervention: Drug: BYL719
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Sorafenib(Nexavar, BAY43-9006) / Capecitabine; Drug: Placebo / Capecitabine
Sponsors: Bayer; Bayer; Onyx Therapeutics, Inc.
Recruiting - verified April 2012
A Safety and Efficacy Study of Farletuzumab in Subjects With Adenocarcinoma of the Lung

Condition: Adenocarcinoma of the Lung
Interventions: Biological: farletuzumab; Other: Placebo; Drug: Platinum Containing Doublet
Sponsors: Morphotek; Morphotek
Recruiting - verified May 2012
Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma

Conditions: Melanoma; NY-ESO-1-positive; Progressive Metastatic Cutaneous Melanoma; Unresectable
Intervention: Biological: GSK Biologicals' 2241658A Antigen-Specific Cancer Immunotherapeutic (ASCI)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: MDV3100; Drug: Placebo
Sponsors: Medivation, Inc.; Medivation, Inc.; Astellas Pharma Inc
Recruiting - verified February 2012
Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab

Condition: Advanced Cancers
Interventions: Drug: Oxaliplatin; Drug: Capecitabine; Drug: Bevacizumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma

Condition: Metastatic Renal Cell Carcinoma
Interventions: Drug: Dovitinib; Drug: Sorafenib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males

Conditions: Anal Cancer; Nonneoplastic Condition; Penile Cancer; Precancerous Condition
Interventions: Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); AIDS Associated Malignancies Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012
Study of KB004 in Subjects With Hematologic Malignancies

Conditions: Acute Myeloid Leukemia (AML); Acute Lymphocytic Leukemia (ALL); Chronic Myelogenous Leukemia (CML); Myelodysplastic Syndrome (MDS); Myeloproliferative Neoplasms (MPN)
Intervention: Drug: KB004, Monoclonal Antibody
Sponsors: KaloBios Pharmaceuticals; KaloBios Pharmaceuticals
Recruiting - verified October 2011
Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor

Conditions: Pigmented Villonodular Synovitis; Diffuse-type Giant Cell Tumor; Tenosynovial Giant Cell Tumor
Intervention: Drug: nilotinib
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Brigham and Women's Hospital; Massachusetts General Hospital; Novartis
Recruiting - verified June 2011
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65

Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: Bortezomib; Drug: Dexamethasone; Procedure: Autologous Stem Cell Transplant
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Celgene Corporation; Millennium Pharmaceuticals, Inc.; Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Emory University; University of Michigan; Fox Chase Cancer Center; Memorial Sloan-Kettering Cancer Center; Fred Hutchinson Cancer Research Center; Barbara Ann Karmanos Cancer Institute; Duke University; University of California, San Francisco; University of Chicago; M.D. Anderson Cancer Center; UNC Lineberger Comprehensive Cancer Center
Recruiting - verified July 2011
Metformin and Endometrial Cancer

Condition: Endometrial Cancer
Intervention: Drug: Metformin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; American Cancer Society
Recruiting - verified May 2012
Administration of CMV-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme

Conditions: Glioblastoma Multiforme; GBM; Brain Cancer
Intervention: Biological: CMV-specific CTL
Sponsors: Baylor College of Medicine; Baylor College of Medicine; Texas Children's Hospital; Center for Cell and Gene Therapy, Baylor College of Medicine; The Methodist Hospital System
Recruiting - verified August 2011
Study of PX-866 and Docetaxel in Solid Tumors

Conditions: Non Small Cell Lung Cancer (NSCLC); Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Interventions: Drug: Docetaxel; Drug: PX-866 and Docetaxel
Sponsors: Oncothyreon Inc.; Oncothyreon Inc.
Recruiting - verified March 2012
Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma

Condition: Neuroblastoma
Interventions: Drug: isotretinoin; Drug: vorinostat; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); New Approaches to Neuroblastoma Therapy Consortium; National Cancer Institute (NCI)
Recruiting - verified August 2011
Yoga for Women With Breast Cancer Undergoing Radiotherapy

Condition: Breast Cancer
Interventions: Other: Yoga Program; Other: Stretching + Relaxation Program; Behavioral: Questionnaires
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified December 2011
CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater

Condition: Gastrointestinal Cancer
Interventions: Drug: Capecitabine; Drug: Oxaliplatin; Drug: Panitumumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Amgen
Recruiting - verified May 2012
A Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Advanced Hematological Malignancies

Conditions: AML; ALL; CML in Blast Crisis; High-Risk MDS; Multiple Myeloma
Intervention: Drug: TG02 citrate
Sponsors: Tragara Pharmaceuticals, Inc.; Tragara Pharmaceuticals, Inc.
Recruiting - verified December 2011
Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer

Conditions: Bladder Neoplasm; Intravesical Drug Administration; Neoplasm Recurrence, Local; Transitional Cell, Carcinoma; Carcinoma in Situ; Mycobacterium
Intervention: Biological: EN3348
Sponsors: Endo Pharmaceuticals; Endo Pharmaceuticals
Recruiting - verified February 2012
Rocking Motion: Physiologic Effect on the Surgical Stress Response

Condition: Gastrointestinal Cancer
Interventions: Procedure: Standard of Care; Procedure: Rocking Chair Motion; Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Institutes of Health (NIH)
Recruiting - verified February 2012
Safety, Tolerability, and Efficacy Study in Subjects With Advanced or Metastatic Breast Cancer

Condition: Advanced or Metastatic Breast Cancer
Intervention: Drug: KW-2450 in combination with lapatinib and letrozole
Sponsors: Kyowa Hakko Kirin Pharma, Inc.; Kyowa Hakko Kirin Pharma, Inc.
Recruiting - verified February 2012
Tolvaptan in Hyponatremic Cancer Patients

Condition: Advanced Cancers
Interventions: Drug: Tolvaptan; Drug: Placebo
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified April 2012
Study of Erlotinib in the Treatment of Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC) of the Skin

Condition: Skin Cancer
Intervention: Drug: Erlotinib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; OSI Pharmaceuticals
Recruiting - verified February 2012
Hormone Blockade in Combination With Targeted Agents

Conditions: Solid Tumors; Advanced Cancer
Interventions: Drug: Anastrozole; Drug: Bevacizumab; Drug: Everolimus; Drug: Sorafenib; Drug: Erlotinib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2

Conditions: Leukemia; Lymphoma
Interventions: Drug: Rasburicase; Drug: Allopurinol
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Sanofi-Aventis
Recruiting - verified April 2012
Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)

Condition: Hepatocellular Carcinoma
Interventions: Drug: Sorafenib (Nexavar, Bay43-9006); Drug: Sorafenib (Nexavar, Bay43-9006)
Sponsors: University of Florida; University of Florida
Recruiting - verified April 2012
Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma

Condition: Melanoma
Interventions: Drug: Genasense; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Genta Incorporated
Recruiting - verified April 2012
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer

Conditions: Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer
Interventions: Biological: trastuzumab; Drug: carboplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Clear Cell Ovarian Cancer

Condition: Ovarian Cancer
Interventions: Drug: carboplatin; Drug: paclitaxel; Drug: temsirolimus; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified November 2011
Colorectal Cancer Umbrella Protocol

Condition: Colorectal Cancer
Interventions: Behavioral: Cancer Symptom Questionnaire; Other: Biomarker Testing
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)

Condition: Hormone Refractory Prostate Cancer
Interventions: Drug: Docetaxel; Drug: TroVax + Docetaxel
Sponsors: Oxford BioMedica; Oxford BioMedica; MedSource
Recruiting - verified February 2012
RO4929097 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Drug: erlotinib hydrochloride; Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097
Sponsors: National Cancer Institute (NCI); M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified June 2011
RO4929097 in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Recently Completed Treatment With Front-Line Chemotherapy

Condition: Lung Cancer
Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097; Genetic: fluorescence in situ hybridization; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Other: pharmacogenomic studies; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified September 2011
Neoadjuvant Ipilimumab in Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Leuprolide Acetate; Drug: Ipilimumab; Procedure: Radical Prostatectomy
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Bristol-Myers Squibb
Recruiting - verified May 2012
Study Comparing Orteronel Plus Prednisone in Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Orteronel + prednisone; Drug: Placebo + prednisone
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2012
Study Comparing Orteronel Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Orteronel + prednisone; Drug: Placebo + prednisone
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2012
Azacitidine and CAPOX in Metastatic Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Drug: Azacitidine; Drug: Capecitabine; Drug: Oxaliplatin; Drug: Azacitidine MTD
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Celgene Corporation
Recruiting - verified March 2012
Social Contextual Influences on Physical Activity

Conditions: Cancer; Prevention
Interventions: Behavioral: PA Prescription Plan; Device: Pedometer; Behavioral: Newsletters
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified May 2012
Bevacizumab With Capecitabine and Oxaliplatin in Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater

Condition: Gastrointestinal Cancers
Interventions: Drug: Capecitabine; Drug: Oxaliplatin; Drug: Bevacizumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Genentech
Recruiting - verified March 2012
Symptom Burden in Patients With Cancer- and Treatment-Related Skin Problems

Condition: Skin Cancer
Interventions: Behavioral: Part 1: Interview + Questionnaires; Behavioral: Part 2: Multiple Questionnaires
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel

Condition: Cancer
Interventions: Drug: Trametinib (GSK1120212); Drug: Docetaxel; Drug: Erlotinib; Drug: Pemetrexed; Drug: Carboplatin; Drug: nab-Paclitaxel; Drug: Cisplatin
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
A Study of PNT2258 in Patients With Advanced Solid Tumors

Conditions: Cancer; Lymphoma; Prostate; Melanoma
Intervention: Drug: PNT2258
Sponsors: Pronai Therapeutics, Inc; Pronai Therapeutics, Inc
Recruiting - verified June 2011
TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cancer
Interventions: Drug: AMG 386; Drug: AMG 386 Placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2012
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Custirsen Sodium, Docetaxel, Prednisone; Drug: Docetaxel, Prednisone
Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical Industries; OncoGenex Technologies
Recruiting - verified May 2012
Dose Escalation, Combination Chemotherapy Safety Study of TL32711, in Subjects With Advanced or Metastatic Solid Tumors

Condition: Cancer
Interventions: Drug: TL32711; Drug: TL32711
Sponsors: TetraLogic Pharmaceuticals; TetraLogic Pharmaceuticals
Recruiting - verified November 2011
Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia (AML)

Conditions: Leukemia; Acute Myeloid Leukemia; Acute Nonlymphocytic Leukemia
Interventions: Drug: vosaroxin and cytarabine; Drug: placebo and cytarabine
Sponsors: Sunesis Pharmaceuticals; Sunesis Pharmaceuticals
Recruiting - verified April 2012
Avastin/Torisel With Carboplatin, Taxol, or Sorafenib

Condition: Advanced Cancer
Interventions: Drug: Temsirolimus; Drug: Bevacizumab; Drug: Paclitaxel; Drug: Sorafenib; Drug: Carboplatin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma

Condition: Kidney Cancer
Interventions: Drug: Everolimus; Drug: Sunitinib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Novartis
Recruiting - verified April 2012
Multimedia Patient Education

Condition: Lung Cancer
Interventions: Behavioral: Video; Behavioral: Questionnaires
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma

Condition: Neuroblastoma
Interventions: Biological: Neuroblastoma Vaccine; Drug: Cytoxan
Sponsors: Baylor College of Medicine; Baylor College of Medicine; Texas Children's Hospital; Center for Cell and Gene Therapy, Baylor College of Medicine
Recruiting - verified April 2012
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)

Condition: Advanced Cancers
Interventions: Drug: Lenalidomide; Drug: Bevacizumab; Drug: Sorafenib; Drug: Temsirolimus; Drug: Lenalidomide; Drug: Oxaliplatin; Drug: Leucovorin; Drug: 5-fluorouracil
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Celgene Corporation
Recruiting - verified May 2012
Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy

Condition: Liver Cancer
Interventions: Drug: Bevacizumab; Drug: Erlotinib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Genentech; OSI Pharmaceuticals
Recruiting - verified March 2012
Study Evaluating the Safety and Efficacy of Onartuzumab (Metmab) And/Or Bevacizumab in Combination With Paclitaxel in Patients With Metastatic, Triple Negative Breast Cancer

Condition: Breast Cancer
Interventions: Drug: bevacizumab; Drug: MetMAb; Drug: paclitaxel; Drug: placebo
Sponsors: Genentech; Genentech; Hoffmann-La Roche
Recruiting - verified March 2012
Study of Orally Administered TAK-960 in Patients With Advanced Nonhematologic Malignancies

Condition: Advanced Nonhematological Malignancies
Intervention: Drug: TAK-960
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified April 2012
Symptom Inventory for Gastrointestinal Stromal Tumors

Condition: Gastrointestinal Stromal Tumors
Interventions: Behavioral: Questionnaires; Behavioral: Interview; Behavioral: MDASI-GIST Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Novartis
Recruiting - verified March 2012
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma

Conditions: Multiple Myeloma; Diffuse Large B-Cell Lymphoma; Glioblastoma Multiforme; Hepatocellular Carcinoma; Non-Small Cell Lung Cancer; Gastrointestinal Neuroendocrine Tumors of Non-Pancreatic Origin; Hormone Receptor-Positive Breast Cancer
Intervention: Drug: CC-223
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2012
A Study in Second Line Metastatic Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Biological: Ramucirumab; Drug: Irinotecan; Biological: Placebo; Drug: Folinic Acid; Drug: 5-Fluorouracil
Sponsors: Eli Lilly and Company; Eli Lilly and Company; ImClone LLC
Recruiting - verified May 2012
Humanitarian Device Exemption (HDE) Treatment Protocol

Conditions: Carcinoma, Hepatocellular; Liver Cancer
Intervention: Device: TheraSphere Treatment
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Nordion (Canada) Inc.
Recruiting - verified May 2012
Minocycline in Oropharynx Cancer

Condition: Oropharynx Cancer
Interventions: Drug: Minocycline; Drug: Placebo
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified December 2011
A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis

Conditions: Estrogen Receptor Negative (ER-Negative) Breast Cancer; Progesterone Receptor Negative (PR-Negative) Breast Cancer; Human Epidermal Growth Factor Receptor 2 Negative (HER2-Negative) Breast Cancer; Brain Metastases
Intervention: Drug: INIPARIB + irinotecan
Sponsors: Sanofi-Aventis; Sanofi-Aventis; UNC Lineberger Comprehensive Cancer Center
Recruiting - verified October 2011
Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 in Castration-Resistant Prostate Cancer (CRPC)

Condition: Prostate Cancer
Intervention: Drug: ARN-509
Sponsors: Aragon Pharmaceuticals, Inc.; Aragon Pharmaceuticals, Inc.
Recruiting - verified March 2012
Donor Lymphocyte Infusion for Myeloma

Condition: Myeloma
Interventions: Biological: KLH Vaccine; Biological: KLH-id Vaccine; Drug: GM-CSF; Procedure: Apheresis; Procedure: Donor Lymphocyte Infusion (DLI)
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients

Conditions: Neuroblastoma; Rhabdomyosarcoma; Lymphoma; Wilm's Tumor; Ewing's Sarcoma
Intervention: Drug: Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
Sponsors: Jennerex Biotherapeutics; Jennerex Biotherapeutics; Solving Kids’ Cancer
Recruiting - verified March 2012
Nuvigil in Treatment of Cancer-Related Fatigue in Chronic Myeloid Leukemia Patients

Condition: Chronic Myeloid Leukemia
Interventions: Drug: Placebo; Drug: Armodafinil
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
A Study of Paclitaxel With or Without Ramucirumab in Metastatic Gastric Adenocarcinoma

Condition: Gastric Cancer
Interventions: Biological: Ramucirumab DP; Drug: Placebo; Drug: Paclitaxel
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified December 2011
An Extension Protocol for Subjects Who Were Previously Enrolled in Other ARQ 197 Protocols

Condition: Advanced Solid Tumors
Intervention: Drug: ARQ 197 as monotherapy or in combination with other drug(s)
Sponsors: ArQule; ArQule
Recruiting - verified January 2012
A Study of Chemotherapy and Ramucirumab vs. Chemotherapy Alone in Second Line Non-small Cell Lung Cancer Patients Who Received Prior First Line Platinum Based Chemotherapy

Condition: Non Small Cell Lung Cancer
Interventions: Drug: Docetaxel; Biological: Ramucirumab; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company; ImClone LLC
Recruiting - verified May 2012
Hypofractionated Proton Radiation Therapy

Conditions: Non-small Cell Lung Cancer; Small Cell Lung Cancer; Carcinoid; Thymic Cancer; Lung Cancer
Intervention: Radiation: Proton Therapy
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: ruxolitinib phosphate; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2012
A Study of RO5045337 in Patients With Solid Tumors

Condition: Neoplasms
Intervention: Drug: RO5045337
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012
Phase IB Intravesical Administration of SCH 721015

Condition: Bladder Cancer
Intervention: Drug: SCH 721015
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Merck
Recruiting - verified February 2012
Phase-3 Double-Blind, Placebo-Controlled Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence Myelofibrosis and RBC-Transfusion-Dependence

Condition: Primary Myelofibrosis
Interventions: Drug: Pomalidomide; Other: Placebo
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified May 2012
Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers

Condition: Carcinoma, Squamous Cell of the Head and Neck
Interventions: Biological: REOLYSIN; Drug: Carboplatin; Drug: Paclitaxel; Drug: Placebo
Sponsors: Oncolytics Biotech; Oncolytics Biotech
Recruiting - verified March 2012
A Study of Pemetrexed & Carboplatin/Cisplatin or Gemcitabine & Carboplatin/Cisplatin With or Without IMC-1121B in Patients Previously Untreated With Recurrent or Advanced Non-small Cell Lung Cancer (NSCLC)

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Biological: 1121B (ramucirumab); Drug: Pemetrexed; Drug: Carboplatin (AUC 6); Drug: Cisplatin; Drug: Gemcitabine; Drug: Carboplatin (AUC 5)
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified December 2011
Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED)

Condition: Ovarian Cancer
Interventions: Drug: EC145; Drug: Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®); Drug: placebo; Drug: EC20
Sponsors: Endocyte; Endocyte
Recruiting - verified March 2012
First in Man Study of SAR566658 Administered Every 3 Weeks in Patients With DS6-positive and Refractory Solid Tumors

Condition: Neoplasm Malignant
Intervention: Drug: SAR566658
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified March 2012
MLN8237 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia

Conditions: Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Kidney Cancer; Leukemia; Liver Cancer; Neuroblastoma; Sarcoma
Interventions: Drug: alisertib; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer

Condition: Neoplasms, Breast
Interventions: Drug: lapatinib; Drug: trastuzumab; Drug: Aromatase inhibitor; Drug: lapatinib
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
Open Vs Robotic-Assisted Radical Cystectomy: A Randomized Trial

Condition: Bladder Cancer Requiring Cystectomy
Interventions: Other: Quality of Life Questionnaires; Other: Get up and Go test; Other: Hand Grip test
Sponsors: The University of Texas Health Science Center at San Antonio; The University of Texas Health Science Center at San Antonio; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung

Condition: Non Squamous Lung Cancer
Interventions: Drug: treatment; Drug: treatment
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
Paclitaxel, Carboplatin and Cetuximab (PCC) Versus Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

Condition: Head and Neck Squamous Cell Carcinoma
Interventions: Drug: Paclitaxel; Drug: Carboplatin; Drug: Cetuximab; Drug: Cetuximab; Drug: Docetaxel; Drug: Cisplatin; Drug: Fluorouracil; Radiation: Radiotherapy (RT); Other: Chemotherapy
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
Bendamustine and Bevacizumab for Advanced Cancers

Condition: Advanced Cancer
Interventions: Drug: Bendamustine; Drug: Bevacizumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Cephalon; National Comprehensive Cancer Network
Recruiting - verified March 2012
Sperm Banking Among Adolescents Newly Diagnosed With Cancer: Development of a Profiling and Referral Tool

Condition: Cancer
Intervention:
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; National Institutes of Health (NIH); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified February 2012
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery

Condition: Colorectal Cancer
Interventions: Drug: celecoxib; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Other: placebo
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified February 2012
A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients

Condition: Advanced and Selected Solid Tumors
Intervention: Drug: BKM120 + GSK1120212
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
FLT-PET as an Imaging Biomarker With Temsirolimus, Topotecan, and Bortezomib

Condition: Advanced Cancer
Intervention: Drug: FLT-PET
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified February 2012
Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer

Conditions: Breast Cancer; Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Other: questionnaire administration; Procedure: evaluation of cancer risk factors; Procedure: quality-of-life assessment; Procedure: study of high risk factors
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
4'-Thio-araC (Thiarabine) in Advanced Hematologic Malignancies

Condition: Leukemia
Interventions: Drug: 3 Day Thiarabine; Drug: 5 Day Thiarabine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Access Pharmaceuticals, Inc.
Recruiting - verified February 2012
Safety and Pharmacokinetic Study of Cabazitaxel in Patients With Advanced Solid Tumors and Liver Impairment

Condition: Neoplasm Malignant
Intervention: Drug: Cabazitaxel (XRP6258)
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified May 2012
Radical Pleurectomy/Decortication (PD) and Intensity Modulated Radiotherapy (IMRT)

Conditions: Lung Cancer; Mesothelioma
Intervention: Radiation: IMRT
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified January 2012
Interactive Cancer Communication System (ICCS) Directed Physical Activity Enhancement for Colon Cancer Survivors

Condition: Colon Cancer
Interventions: Behavioral: Survivorship CHESS; Other: Control
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison; University of North Carolina, Chapel Hill; M.D. Anderson Cancer Center; Hartford Hospital
Recruiting - verified November 2011
Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer

Conditions: Cachexia; Nausea and Vomiting; Unspecified Childhood Solid Tumor, Protocol Specific; Weight Changes
Interventions: Drug: cyproheptadine hydrochloride; Other: placebo
Sponsors: National Cancer Institute (NCI); University of South Florida; National Cancer Institute (NCI)
Recruiting - verified December 2011
An Open-Label, 2-Cohort, Multicenter, Study of E7080 in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Condition: Unresectable Stage III or Stage IV Melanoma
Interventions: Drug: E7080; Drug: E7080
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified January 2012
A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Patients With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib

Condition: Hepatocellular Carcinoma
Interventions: Biological: Placebo; Biological: Ramucirumab DP (IMC-1121B)
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified February 2012
Neoadjuvant Therapy for Ovarian Cancer

Conditions: Epithelial Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer
Intervention: Drug: Carboplatin, paclitaxel, and bevacizumab
Sponsors: Columbia University; Columbia University; Genentech
Recruiting - verified October 2011
Survivorship in Lynch Syndrome Families

Condition: Colorectal Cancer
Interventions: Behavioral: Telephone Interview; Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified December 2011
A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment

Condition: Metastatic Renal Cell Carcinoma
Interventions: Drug: E7080; Drug: Everolimus; Drug: E7080 plus Everolimus
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified April 2012
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag

Condition: Thrombocytopaenia
Interventions: Drug: Eltrombopag olamine; Other: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma

Conditions: Stage IIIC Melanoma; Stage IV Melanoma
Intervention: Drug: Denileukin diftitox
Sponsors: Eisai Inc.; Eisai Inc.; PharmaBio Development Inc.
Recruiting - verified May 2012
Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC)

Conditions: Renal Cell Cancer; Kidney Cancer
Interventions: Drug: Sunitinib; Drug: Temsirolimus
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Pfizer
Recruiting - verified March 2012
LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment

Condition: Breast Neoplasms
Interventions: Drug: BIBW 2992; Drug: trastuzumab; Drug: vinorelbine; Drug: vinorelbine
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012
Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery

Condition: Kidney Cancer
Interventions: Drug: everolimus; Other: placebo
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer

Condition: Prostate Cancer
Interventions: Biological: cixutumumab; Drug: bicalutamide; Drug: goserelin acetate; Drug: leuprolide acetate
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified December 2011
A Dose Finding and Safety Study of Oral LDE225 in Children

Conditions: Medulloblastoma,; Rhabdomyosarcoma,; Neuroblastoma,; Hepatoblastoma,; High Grade Glioma,; Astrocytoma
Intervention: Drug: LDE225
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Safety and Efficacy of BKM120 in Combination With Trastuzumab in Patients With Relapsing HER2 Overexpressing Breast Cancer Who Have Previously Failed Trastuzumab

Conditions: Metastatic Breast Cancer; Trastuzumab; BKM120; HER2+
Intervention: Drug: BKM120
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Childhood Cancer Survivor Study

Condition: Cancer
Intervention:
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; National Cancer Institute (NCI); Fred Hutchinson Cancer Research Center; Nationwide Children's Hospital; M.D. Anderson Cancer Center; University of Southern California; Children's Hospital Medical Center, Cincinnati
Recruiting - verified April 2012
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers

Conditions: Acute Myelogenous Leukemia; Diffuse Large B-Cell Leukemia; Chronic Lymphocytic Leukemia; Follicular Lymphoma
Interventions: Drug: BMS-936564 (Anti-CXCR4); Drug: BMS-936564 (Anti-CXCR4)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified December 2011
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE)

Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine; Drug: pertuzumab; Drug: pertuzumab-placebo; Drug: trastuzumab [Herceptin]; Drug: docetaxel; Drug: paclitaxel
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche; Genentech
Recruiting - verified March 2012
A Phase 1 Study in Patients With Advanced Cancer

Conditions: Advanced Cancer; Non Small Cell Lung Cancer; Colorectal Cancer; Ovarian Cancer
Intervention: Drug: LY2606368
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified November 2011
Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies

Condition: Advanced Cancer
Interventions: Drug: Nab-paclitaxel; Drug: Bevacizumab; Drug: Gemcitabine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
Sym004 in Patients With Advanced Solid Tumors

Condition: Metastatic Colorectal Cancer
Intervention: Biological: Sym004
Sponsors: Symphogen A/S; Symphogen A/S
Recruiting - verified February 2012
Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)

Conditions: Brain Cancer; Glioblastoma Multiforme
Interventions: Drug: Vorinostat; Drug: Erlotinib; Drug: Temozolomide
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Merck
Recruiting - verified February 2012
An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+

Condition: Cervical Intraepithelial Neoplasia
Interventions: Biological: ADXS11-001 (Lm-LLO-E7); Drug: Placebo Control
Sponsors: Advaxis, Inc.; Advaxis, Inc.
Recruiting - verified January 2012
Pleural Catheters Versus Thoracoscopic Pleurodesis

Condition: Lung Cancer
Intervention: Behavioral: MDASI Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
Study of E7080 in Subjects With Advanced Endometrial Cancer and Disease Progression

Condition: Endometrial Cancer
Intervention: Drug: E7080
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified April 2012
Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)

Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: lenalidomide, bortezomib and dexamethasone; Drug: Lenalidomide
Sponsors: National Heart, Lung, and Blood Institute (NHLBI); National Heart, Lung, and Blood Institute (NHLBI); Blood and Marrow Transplant Clinical Trials Network; National Cancer Institute (NCI)
Recruiting - verified March 2012
Study of Administration of CMV-specific Cytotoxic T Lymphocytes Expressing CAR Targeting HER2 in Patients With GBM

Condition: Brain Cancer
Intervention: Biological: HER.CAR CMV-specific CTL
Sponsors: Baylor College of Medicine; Baylor College of Medicine; The Methodist Hospital System; Center for Cell and Gene Therapy, Baylor College of Medicine; Texas Children's Hospital
Recruiting - verified March 2012
Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery

Condition: Cervical Cancer
Interventions: Drug: cisplatin; Radiation: external beam radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer

Condition: Breast Cancer
Interventions: Drug: metformin hydrochloride; Other: placebo
Sponsors: NCIC Clinical Trials Group; NCIC Clinical Trials Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Simultaneous Integrated Boost (SIB) in Esophageal Cancer

Condition: Esophageal Cancer
Interventions: Drug: 5-Fluorouracil; Drug: Docetaxel; Radiation: Radiation Therapy
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer

Conditions: Colon Cancer; Rectal Cancer
Interventions: Biological: IMC-1121B; Biological: IMC-18F1; Drug: mFOLFOX-6
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified April 2012
Smoking Cessation Treatment for Head & Neck Cancer Patients

Conditions: Head and Neck Cancer; Smoking Cessation
Interventions: Behavioral: Acceptance and Commitment Therapy; Behavioral: Motivational and Behavioral Counseling; Drug: Varenicline
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
First-line Treatment of Weekly Paclitaxel With Carboplatin and Bevacizumab in Ovarian Cancer

Conditions: Epithelial Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer
Interventions: Drug: Carboplatin; Drug: Paclitaxel; Drug: Bevacizumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Genentech
Recruiting - verified January 2012
Study in Head and Neck Cancer

Condition: Head and Neck Neoplasms
Interventions: Drug: Cetuximab; Drug: Cisplatin; Drug: 5 - Fluorouracil
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified February 2012
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: vincristine sulfate; Other: clinical observation; Radiation: 3-dimensional conformal radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Neo-Adjuvant Study in Triple Negative Breast Cancer Patients

Condition: Breast Cancer
Interventions: Drug: Cetuximab; Drug: Ixabepilone
Sponsors: The Methodist Hospital System; The Methodist Hospital System; Bristol-Myers Squibb
Recruiting - verified June 2011
Elitek (Rasburicase) Immuno-Monitoring Study

Condition: Tumor Lysis Syndrome
Intervention:
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified February 2012
ABT-348 as Monotherapy or Combination With Carboplatin or Docetaxel to Treat Advanced Solid Tumors

Condition: Advanced Solid Tumors
Interventions: Drug: ABT-348; Drug: ABT-348 and carboplatin; Drug: ABT-348 and docetaxel; Drug: ABT-348; Drug: ABT-348
Sponsors: Abbott; Abbott
Recruiting - verified May 2012
ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignancies

Conditions: Acute Myelogenous Leukemia; Acute Lymphoblastic Leukemia; Chronic Myelogenous Leukemia; B-cell Chronic Lymphocytic Leukemia; Myelodysplasia
Interventions: Drug: ABT-348; Drug: ABT-348; Drug: ABT-348 and azacitidine
Sponsors: Abbott; Abbott
Recruiting - verified May 2012
Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid Malignancies

Condition: Leukemia
Intervention: Drug: Nelarabine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; GlaxoSmithKline
Recruiting - verified January 2012
MLN8237 in Patients With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer

Conditions: Ovarian Carcinoma; Fallopian Tube Cancer; Peritoneal Cancer; Breast Carcinoma
Interventions: Drug: MLN8237 + Paclitaxel; Drug: MLN8237+Paclitaxel vs. Paclitaxel alone
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified December 2011
A Phase 1 Study of MLN8237 in Patients With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen

Conditions: Advanced Solid Tumors; Adenocarcinoma of the Prostate
Intervention: Drug: MLN8237 plus docetaxel
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified April 2012
Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, or Chronic Sun-damaged Melanoma

Condition: Melanoma
Intervention: Drug: Dasatinib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Bristol-Myers Squibb
Recruiting - verified March 2012
MEK Inhibitor AZD6244 in Treating Young Patients With Recurrent or Refractory Low Grade Glioma

Condition: Brain and Central Nervous System Tumors
Intervention: Drug: AZD6244
Sponsors: Pediatric Brain Tumor Consortium; Pediatric Brain Tumor Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2012
Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Abiraterone Acetate; Drug: Prednisone; Drug: LHRHa
Sponsors: Cougar Biotechnology, Inc.; Cougar Biotechnology, Inc.
Recruiting - verified December 2010
Sirolimus and Vorinostat in Advanced Cancer

Condition: Advanced Cancer
Interventions: Drug: Sirolimus; Drug: Vorinostat
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
Lapatinib With Sirolimus or Metformin

Condition: Advanced Cancers
Interventions: Drug: Lapatinib; Drug: Sirolimus; Drug: Metformin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study

Conditions: Chronic Lymphocytic Leukemia; Lymphoma, Non-Hodgkin; Acute Myeloid Leukemia; Multiple Myeloma
Intervention: Drug: CAL-101
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified January 2012
A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Drug: hLL1-DOX (the doxorubicin conjugate of milatuzumab)
Sponsors: Immunomedics, Inc.; Immunomedics, Inc.
Recruiting - verified February 2012
Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC)

Condition: Squamous Cell Lung Cancer
Interventions: Drug: gemcitabine/carboplatin; Drug: gemcitabine/carboplatin plus Iniparib
Sponsors: Sanofi-Aventis; Sanofi-Aventis; BiPar Sciences
Recruiting - verified March 2012
Radiation Therapy in Treating Women With Locally Recurrent Breast Cancer Previously Treated With Repeat Breast-Preserving Surgery

Condition: Breast Cancer
Interventions: Other: circulating tumor cell analysis; Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: adjuvant therapy; Radiation: 3-dimensional conformal accelerated partial breast irradiation
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified July 2011
Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine, With or Without Bevacizumab, as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II, Stage III, Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or Fallopian Tube Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer
Interventions: Biological: bevacizumab; Drug: capecitabine; Drug: carboplatin; Drug: oxaliplatin; Drug: paclitaxel; Procedure: quality-of-life assessment
Sponsors: University College, London; University College, London; National Cancer Institute (NCI); Gynecologic Oncology Group
Recruiting - verified December 2011
Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy

Conditions: Cognitive/Functional Effects; Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Drug: systemic chemotherapy; Other: questionnaire administration; Procedure: assessment of therapy complications; Procedure: cognitive assessment; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified October 2011
A Study in Head and Neck Cancer

Condition: Head and Neck Cancer
Interventions: Drug: cetuximab; Drug: Cisplatin; Drug: Carboplatin; Drug: 5-fluorouracil
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy

Condition: Colorectal Cancer
Interventions: Biological: cetuximab; Biological: ramucirumab; Drug: irinotecan hydrochloride
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012
Subtotal Resection of Large Acoustic Neuromas With Possible Stereotactic Radiation Therapy

Condition: Neuroma, Acoustic
Interventions: Procedure: Microsurgery; Procedure: Stereotactic radiation therapy
Sponsors: Stanford University; Stanford University; University of Cincinnati; Baylor College of Medicine; Weill Medical College of Cornell University; University of Iowa; University of Texas; George Washington University
Recruiting - verified March 2012
Connect® MM- The Multiple Myeloma Disease Registry

Condition: Multiple Myeloma
Intervention:
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified June 2011
Lenalidomide and High-Dose Melphalan

Conditions: Myeloma; Stem Cell Transplantation
Interventions: Drug: Lenalidomide; Drug: Melphalan
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
Immunotherapy Study for Surgically Resected Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Biological: HyperAcute-Pancreas Immunotherapy; Drug: Gemcitabine; Radiation: 5FU Chemoradiation
Sponsors: NewLink Genetics Corporation; NewLink Genetics Corporation
Recruiting - verified May 2012
Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212

Condition: Cancer
Interventions: Drug: GSK2118436; Drug: GSK1120212
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified December 2011
Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM)

Conditions: Brain Cancer; Glioblastoma
Interventions: Drug: Standard Dose Bevacizumab; Drug: Low Dose Bevacizumab; Drug: Lomustine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)

Condition: Breast Cancer
Interventions: Drug: Placebo; Drug: Denosumab
Sponsors: Amgen; Amgen; Daiichi Sankyo Inc.
Recruiting - verified May 2012
Docetaxel And Cisplatin With or Without Erlotinib For Metastatic Or Recurrent Squamous Cell Carcinoma Of Head And Neck

Conditions: Head and Neck Cancer; Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: Cisplatin; Drug: Docetaxel; Drug: Erlotinib; Other: Placebo
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified December 2011
Phase II Study of Tesetaxel in Metastatic Melanoma

Conditions: Advanced Melanoma; Cancer
Intervention: Drug: Tesetaxel
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Genta Incorporated
Recruiting - verified April 2012
A Study in Head and Neck Cancer

Condition: Head and Neck Neoplasms
Interventions: Drug: Cetuximab; Drug: Carboplatin; Drug: 5 - Fluorouracil
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified March 2012
Comparative Trial of Cryotherapy Versus Caphosol Versus Saline Solution Mouth Washes for the Prevention of Oral Mucositis in Patients With Multiple Myeloma Undergoing Hematopoietic Stem Cell Transplantation

Conditions: Mucositis; Multiple Myeloma
Interventions: Drug: 0.9% Sodium Chloride irrigation solution; Other: Cryotherapy (ice chips); Device: Calcium phosphate (Caphosol) Ca2+/PO43- mouth rinse
Sponsors: The University of Texas Health Science Center at San Antonio; The University of Texas Health Science Center at San Antonio; South Texas Veterans Health Care System
Recruiting - verified March 2012
Trial of Bi-shRNA-furin and Granulocyte Macrophage Colony Stimulating Factor (GMCSF) Augmented Autologous Tumor Cell Vaccine for Advanced Cancer

Condition: Solid Tumors
Interventions: Biological: FANG; Biological: FANG
Sponsors: Gradalis, Inc.; Gradalis, Inc.
Recruiting - verified March 2012
Proton Beam Radiotherapy for Medulloblastoma and Pineoblastoma

Conditions: Brain Tumor; Medulloblastoma; Pineoblastoma
Intervention: Radiation: proton beam radiation
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified September 2011
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Drug: KW-2478 and bortezomib
Sponsors: Kyowa Hakko Kirin Pharma, Inc.; Kyowa Hakko Kirin Pharma, Inc.; Kyowa Hakko Kirin Company, Limited
Recruiting - verified March 2012
Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin

Condition: Skin Cancer
Intervention: Drug: Erlotinib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; OSI Pharmaceuticals
Recruiting - verified January 2012
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified March 2012
HAI Abraxane With Gemcitabine and Bevacizumab

Condition: Advanced Cancers
Interventions: Drug: HAI Abraxane; Drug: Gemcitabine; Drug: Bevacizumab; Drug: Filgrastim
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
Radiation Therapy in Treating Patients With Extensive Stage Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Radiation: prophylactic cranial irradiation; Radiation: selective external radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012
Docetaxel and Sirolimus in Patients With Advanced Malignancies

Condition: Advanced Cancer
Interventions: Drug: Docetaxel (Taxotere); Drug: Sirolimus (Rapamycin); Drug: Prednisone
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma

Condition: Sarcoma
Interventions: Biological: cixutumumab; Biological: dactinomycin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: irinotecan hydrochloride; Drug: temozolomide; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Conservative Surgery for Women With Cervical Cancer

Condition: Cervical Cancer
Intervention: Procedure: Conservative Surgery
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck

Conditions: Ovarian Cancer; Non Small Cell Lung Cancer; Prostate Cancer; Colorectal Cancer; Gastric Cancer; Esophageal Cancer; Cancer of Head and Neck
Interventions: Drug: LY2523355; Drug: pegfilgrastim
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
MLN8237 in Adults With Nonhematological Malignancies, Followed by MLN8237 in Lung, Breast, Head and Neck or Gastroesophageal Malignancies

Conditions: Advanced Nonhematological Malignancies; Non-Small Cell Lung Cancer; Small Cell Lung Cancer; Metastatic Breast Cancer; Head and Neck Squamous Cell Carcinoma; Gastroesophageal Adenocarcinoma
Intervention: Drug: MLN8237
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified April 2012
Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors

Condition: Ovarian Cancer
Interventions: Biological: bleomycin sulfate; Drug: carboplatin; Drug: cisplatin; Drug: etoposide phosphate; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Conditions: Breast Neoplasms; Breast Cancer; Breast Tumors
Interventions: Drug: Neratinib; Drug: ABT-888; Drug: Standard Therapy; Drug: AMG 386; Drug: AMG 479 (Ganitumab) plus Metformin
Sponsors: Foundation for the National Institutes of Health; Foundation for the National Institutes of Health
Recruiting - verified December 2011
5-Azacytidine and Oxaliplatin With Advanced Cancers Relapsed or Refractory to Any Platinum Therapy

Conditions: Advanced Cancer; Solid Tumor; Lymphoma
Interventions: Drug: 5-azacytidine; Drug: Oxaliplatin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI); Celgene Corporation
Recruiting - verified May 2012
Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma

Condition: Neuroblastoma
Interventions: Biological: aldesleukin; Biological: monoclonal antibody Ch14.18; Biological: sargramostim; Drug: isotretinoin; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2011
Aspirin in Reducing Events in the Elderly

Conditions: Functional Disability; Dementia; Heart Disease; Stroke; Cancer; Bleeding
Interventions: Drug: 100 mg enteric-coated aspirin; Drug: Placebo
Sponsors: Minneapolis Medical Research Foundation; Minneapolis Medical Research Foundation; National Health and Medical Research Council, Australia; Bayer; Monash University; Berman Center for Outcomes and Clinical Research
Recruiting - verified July 2011
M. D. Anderson Symptom Inventory - Ovarian Cancer

Condition: Ovarian Cancer
Interventions: Behavioral: Interview; Behavioral: Survey
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Genentech
Recruiting - verified April 2012
Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Panitumumab; Drug: Nab-paclitaxel; Drug: Carboplatin; Drug: 5-Fluorouracil; Drug: Epirubicin; Drug: Cyclophosphamide
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Celgene Corporation; Amgen
Recruiting - verified April 2012
Trial of Amrubicin as Treatment for Patients With HER2-Negative Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Intervention: Drug: Amrubicin
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; Celgene Corporation
Recruiting - verified July 2011
Assessment of Sexual Dysfunction, Depression and Anxiety in Underserved, Minority Gynecologic Cancers Patients

Condition: Gynecologic Cancer
Intervention: Behavioral: Surveys
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
Studying Biomarkers in Detecting Heart Damage in Patients Receiving Chemotherapy

Conditions: Cardiac Toxicity; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: systemic chemotherapy; Other: laboratory biomarker analysis; Other: questionnaire administration; Procedure: assessment of therapy complications
Sponsors: National Cancer Institute (NCI); M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified June 2011
Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma.

Condition: Carcinoma
Intervention: Drug: Everolimus
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified March 2012
BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Condition: Renal Cell Carcinoma
Interventions: Drug: Everolimus; Drug: BNC105P; Drug: Everolimus; Drug: BNC105P
Sponsors: Hoosier Oncology Group; Hoosier Oncology Group; Bionomics Limited
Recruiting - verified March 2012
A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

Condition: Melanoma
Intervention: Drug: nilotinib (AMN107)
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Drug: Panobinostat; Drug: Bortezomib
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
A Combination Therapy Study of MK2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010 AM5)

Condition: Locally Advanced or Metastatic Solid Tumors
Intervention: Drug: MK2206 plus AZD6244
Sponsors: Merck; Merck; AstraZeneca
Recruiting - verified May 2012
Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine

Conditions: Pancreatic Cancer; Ductal Adrenocarcinoma; Exocrine Pancreatic Cancer
Intervention: Drug: PCI-27483
Sponsors: Pharmacyclics; Pharmacyclics
Recruiting - verified January 2012
Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions

Condition: Refractory Head and Neck Cancer, Squamous Cell Carcinoma of the Skin, Carcinoma of the Breast, and Malignant Melanoma
Intervention: Drug: HF10
Sponsors: Takara Bio Inc.; Takara Bio Inc.
Recruiting - verified October 2011
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer

Condition: Liver Cancer
Interventions: Drug: doxorubicin hydrochloride; Drug: sorafenib tosylate
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified September 2011
Chemotherapy-Induced Peripheral Neuropathy Survey

Conditions: Breast Cancer; Colorectal Cancer; Myeloma; Chemotherapy-induced Peripheral Neuropathy
Interventions: Behavioral: Questionnaire; Behavioral: Sensory Tests; Behavioral: Interview
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies

Condition: Advanced Cancer
Interventions: Drug: Dasatinib; Drug: Bevacizumab; Drug: Paclitaxel
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
A Dose Escalation Study of an Antibody in Patients With Advanced Cancers

Condition: Advanced Cancers
Intervention: Drug: MABp1
Sponsors: XBiotech, Inc.; XBiotech, Inc.
Recruiting - verified March 2012
N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma

Condition: Neuroblastoma
Interventions: Drug: Vorinostat; Radiation: 131- I Metaiodobenzylguanidine; Procedure: Peripheral Blood Stem Cell Infusion; Drug: Filgrastim
Sponsors: New Approaches to Neuroblastoma Therapy Consortium; New Approaches to Neuroblastoma Therapy Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery

Condition: Pancreatic Cancer
Interventions: Drug: capecitabine; Drug: erlotinib hydrochloride; Drug: fluorouracil; Drug: gemcitabine hydrochloride; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors

Conditions: Brain Cancer; Choroid Plexus Tumors
Interventions: Drug: Carboplatin; Drug: Cisplatin; Drug: Cyclophosphamide; Drug: Dactinomycin; Drug: Doxorubicin; Drug: Etoposide; Drug: Irinotecan; Drug: Leucovorin; Drug: Methotrexate; Drug: Temozolomide; Drug: Vincristine
Sponsors: Tufts Medical Center; Tufts Medical Center
Recruiting - verified April 2012
First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor EMD 1214063 in Subjects With Advanced Solid Tumors

Condition: Patients With Solid Tumors, Either Refractory to Standard Therapy or for Which no Effective Standard Therapy is Available
Interventions: Drug: EMD 1214063; Drug: EMD 1214063
Sponsors: EMD Serono; EMD Serono
Recruiting - verified January 2012
External Beam Radiation Therapy and Cetuximab Followed by Irinotecan and Cetuximab for Children and Young Adults With Newly Diagnosed Diffuse Pontine Tumors and High-Grade Astrocytomas

Condition: Brain Cancer
Intervention: Other: cetuximab in conjunction with external beam radiation therapy, followed by cetuximab and irinotecan
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Children's Healthcare of Atlanta; Dana-Farber Cancer Institute; M.D. Anderson Cancer Center; Phoenix Children's Hospital; Alberta Children's Hospital; University of Colorado, Denver; Seattle Children's Hospital; Johns Hopkins University; Children's Mercy Hospital-Kansas City, MO; MD Anderson Cancer Center Orlando at Arnold Palmer Hospital for Children
Recruiting - verified March 2012
Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery

Conditions: Colorectal Cancer; Precancerous Condition
Interventions: Drug: rosuvastatin; Other: placebo
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified February 2012
Evaluating an Interactive Cancer Communication System (ICCS) in Lung Cancer

Condition: Lung Cancer, Stage IIIb or IV
Intervention: Other: CHESS website for lung cancer patient + internet access if needed
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison; Harry Gray Cancer Center Hartford Hospial; M.D. Anderson Cancer Center; University of Illinois
Recruiting - verified March 2012
Physician Perceptions About Parenteral Hydration in Latin America and Spain

Conditions: Dehydration; Advanced Cancers
Intervention: Behavioral: Survey
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified December 2011
Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide

Conditions: Blood Stem Cell Transplant Failure; Leukemia; Hematologic Malignancies
Interventions: Drug: Cyclophosphamide; Drug: Fludarabine; Drug: Melphalan; Drug: Mesna; Drug: Rituximab; Procedure: Stem Cell Transplantation; Drug: Thiotepa; Drug: Tacrolimus; Drug: Mycofenolate mofetil
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
Stage IV Surgery Versus Best Medical Therapy

Condition: Stage IV Resectable Melanoma
Interventions: Procedure: Surgery; Procedure: Surgery plus 2 adjuvant doses of BCG; Other: best medical therapy
Sponsors: John Wayne Cancer Institute; John Wayne Cancer Institute; Melanoma Research Alliance
Recruiting - verified May 2012
Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer

Condition: Breast Cancer
Intervention: Other: ChemoFX Assay
Sponsors: Precision Therapeutics; Precision Therapeutics; Department of Defense
Recruiting - verified December 2011
Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma

Condition: Sarcoma
Interventions: Biological: bevacizumab; Biological: filgrastim; Biological: pegfilgrastim; Drug: docetaxel; Drug: gemcitabine hydrochloride; Other: placebo
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Paclitaxel; Drug: Trastuzumab; Drug: Neratinib; Drug: Trastuzumab (post surgery); Drug: Doxorubicin; Drug: Cyclophosphamide
Sponsors: National Surgical Adjuvant Breast and Bowel Project (NSABP); National Surgical Adjuvant Breast and Bowel Project (NSABP); Wyeth Pharmaceuticals, Inc., a Pfizer Company
Recruiting - verified February 2012
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer

Conditions: HER2/Neu Over-expressing Locally Advanced Breast Cancer; Metastatic Breast Cancer
Interventions: Drug: everolimus, vinorelbine, trastuzumab; Drug: Placebo + vinorelbine + trastuzumab
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

Condition: Liver Cancer
Interventions: Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: doxorubicin-eluting beads; Drug: mitomycin C; Drug: sorafenib tosylate; Other: placebo
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012
Safety Study of PLX108-01 in Patients With Solid Tumors

Conditions: Solid Tumors; Mucoepidermal Carcinoma (MEC) of the Salivary Gland; Pigmented Villo-nodular Synovitis (PVNS); Gastrointestinal Stromal Tumors (GIST); Anaplastic Thyroid Carcinoma (ATC); Solid Tumors With Documented Malignant Pleural or Peritoneal Effusions; Malignant Peripheral Nerve Sheath Tumor (MPNST); Neurofibromatosis Type I (NF-1); Melanoma; Schwannomatosis
Intervention: Drug: PLX3397
Sponsors: Plexxikon; Plexxikon
Recruiting - verified May 2012
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy Followed by Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B Cell Lymphoma

Condition: Lymphoma, Large-Cell, Diffuse
Interventions: Drug: OFATUMUMAB + DHAP; Drug: RITUXIMAB + DHAP
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Subjects With KRAS Wild-Type Metastatic Colorectal Cancer

Condition: Metastatic Colorectal Cancer
Interventions: Drug: Cetuximab (Erbitux); Drug: Panitumumab (Vectibix)
Sponsors: Amgen; Amgen
Recruiting - verified May 2012
Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy

Condition: Breast Cancer
Interventions: Drug: Herceptin / Lapatinib; Drug: Letrozole
Sponsors: Baylor Breast Care Center; Baylor Breast Care Center; Translational Breast Cancer Reserach Consortium; GlaxoSmithKline
Recruiting - verified January 2012
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients

Condition: Multiple Myeloma
Interventions: Drug: Perifosine; Drug: Perifosine Placebo; Drug: Bortezomib; Drug: Dexamethasone
Sponsors: AEterna Zentaris; AEterna Zentaris; Dana-Farber Cancer Institute
Recruiting - verified February 2012
A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung

Condition: Carcinoma
Interventions: Biological: REOLYSIN; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: Oncolytics Biotech; Oncolytics Biotech; University of Texas
Recruiting - verified December 2011
Development of a Non-invasive Assessment of Skeletal Muscle Loss in Cancer Patients

Condition: Cachexia
Intervention:
Sponsors: The University of Texas, Galveston; The University of Texas, Galveston
Recruiting - verified July 2011
Data Collection of Normal Tissue Toxicity for Proton Therapy

Condition: Cancer
Intervention:
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified January 2012
Specialized Radiation Therapy in Treating Patients With Stage II, Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer and Poor Performance Status

Condition: Lung Cancer
Intervention: Radiation: hypofractionated radiation therapy
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center; National Cancer Institute (NCI)
Recruiting - verified March 2012
Doctor-Recommended Home-Based Exercise Program or Relaxation Training in Improving Physical Function and Controlling Symptoms in Patients With Stage IV or Recurrent Colon Cancer That Cannot Be Removed By Surgery

Condition: Colorectal Cancer
Interventions: Behavioral: exercise intervention; Behavioral: telephone-based intervention; Other: counseling intervention; Other: questionnaire administration; Other: survey administration; Procedure: management of therapy complications; Procedure: mind-body intervention procedure; Procedure: quality-of-life assessment; Procedure: stress management therapy
Sponsors: National Cancer Institute (NCI); M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified November 2011
A Clinical Study Using MEDI-551 in Adult Subjects With Relapsed or Refractory Advanced B-Cell Malignancies

Condition: B-cell Malignancies
Intervention: Drug: MEDI-551
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified May 2012
ExAblate Conformal Bone System Treatment of Metastatic Bone Tumors for the Palliation of Pain

Condition: Bone Metastases
Intervention: Device: ExAblate 2100
Sponsors: InSightec; InSightec
Recruiting - verified October 2011
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Liver Cancer

Condition: Liver Cancer
Interventions: Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: vincristine sulfate; Procedure: liver transplantation; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified November 2011
Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy

Condition: Cervical Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver

Conditions: Liver Cancer; Advanced Cancer
Interventions: Drug: Irinotecan; Drug: Bevacizumab; Drug: Oxaliplatin; Drug: Cetuximab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours

Conditions: Cancer; Advanced Solid Malignancies
Intervention: Drug: AZD4547
Sponsors: AstraZeneca; AstraZeneca
Recruiting - verified March 2012
Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma

Condition: Metastatic Melanoma
Interventions: Biological: REOLYSIN; Drug: Carboplatin; Drug: Paclitaxel
Sponsors: Oncolytics Biotech; Oncolytics Biotech; University of Texas
Recruiting - verified October 2011
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma

Conditions: Brain and Central Nervous System Tumors; Neurotoxicity
Interventions: Drug: temozolomide; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: ixabepilone; Drug: paclitaxel; Drug: temsirolimus
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified July 2011
Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer and Cholangiocarcinoma

Condition: Liver Cancer
Intervention: Radiation: Proton Beam Irradiation
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Dana-Farber Cancer Institute; Brigham and Women's Hospital; National Cancer Institute (NCI); M.D. Anderson Cancer Center
Recruiting - verified March 2012
A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer

Condition: Advanced Malignancies, Non-small Cell Lung Cancer
Interventions: Drug: MGCD265+erlotinib; Drug: MGCD265+docetaxel
Sponsors: MethylGene Inc.; MethylGene Inc.
Recruiting - verified November 2011
Dose-Escalation Study of GSK2126458

Conditions: Advanced Solid Tumor; Solid Tumours
Intervention: Drug: GSK2126458
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified September 2011
C-VISA BikDD: Liposome in Advanced Pancreatic Cancer

Condition: Pancreatic Cancer
Intervention: Genetic: BikDD Nanoparticle
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Not yet recruiting - verified May 2012
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Conditions: Adenocarcinoma; Her2+; Advanced Metastatic Breast Cancer; Metastatic ErbB2; Invasive Breast Cancer; Advanced Breast Cancer; Cancer; ErbB2+
Interventions: Drug: Lapatinib; Biological: Trastuzumab
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients

Conditions: Pancreatic Cancer; Venous Thromboembolism
Intervention: Drug: Dalteparin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Eisai Inc.
Recruiting - verified February 2012
Autologous CD19-specific T Cells Infusion

Conditions: Lymphoma; B-cell Lymphoma
Interventions: Procedure: Leukapheresis; Procedure: Stem Cell Transplant; Procedure: CD19-specific T Cell Infusion; Drug: IL-2; Drug: Carmustine; Drug: Etoposide; Drug: Cytarabine; Drug: Melphalan; Drug: Rituximab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
Ex-Vivo Depletion of Myeloma Cells From Peripheral Blood Progenitor Cell Grafts

Condition: Multiple Myeloma
Interventions: Procedure: Apheresis; Procedure: Stem Cell Transplantation; Drug: Melphalan
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Not yet recruiting - verified May 2012
BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer

Condition: Neoplasms
Intervention: Drug: BAY80-6946
Sponsors: Bayer; Bayer
Recruiting - verified April 2012
Correlation of Genomic Variation in Enzymes Responsible for Metabolism of Capecitabine With Drug Metabolism

Condition: Breast Cancer
Intervention: Drug: Capecitabine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Not yet recruiting - verified May 2012
Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist

Condition: Melanoma
Interventions: Drug: gp100; Drug: R848 gel; Drug: MAGE-3
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
Symptom Management in Patients With Recurrent or Persistent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer; Psychosocial Effects of Cancer and Its Treatment
Interventions: Other: communication intervention; Other: educational intervention; Other: internet-based intervention; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: assessment of therapy complications; Procedure: management of therapy complications; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Trial of Mitogen-activated Protein/Extracellular Signal-regulated Kinase Kinase (MEK) Inhibitor

Conditions: Acute Myeloid Leukemia; Hematological Malignancies
Interventions: Drug: Mek Inhibitor AS703026; Drug: Mek Inhibitor AS703026
Sponsors: EMD Serono; EMD Serono
Recruiting - verified October 2011
Preoperative Treatment With Cetuximab and/or IMC-A12

Condition: Head and Neck Squamous Cell Carcinoma
Interventions: Drug: Cetuximab; Drug: IMC-A12; Procedure: Surgical tumor resection
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; ImClone LLC
Recruiting - verified February 2012
Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer

Condition: Head and Neck Cancer
Interventions: Biological: cetuximab; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Biological: bevacizumab; Biological: cixutumumab; Drug: carboplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine or Ovarian Cancer

Conditions: Ovarian Cancer; Sarcoma
Interventions: Drug: carboplatin; Drug: ifosfamide; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Erlotinib Prior to Surgery in Patients With Head and Neck Cancer

Condition: Head And Neck Cancer
Intervention: Drug: Erlotinib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; OSI Pharmaceuticals
Recruiting - verified February 2012
A Study Of PF-04449913 In Select Hematologic Malignancies

Condition: Hematologic Malignancies
Intervention: Drug: PF-04449913
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Ondansetron Versus Aprepitant Plus Ondansetron for Emesis

Conditions: Hematologic Diseases; Acute Myelogenous Leukemia; Myelodysplastic Syndrome; Chronic Myelogenous Leukemia
Interventions: Drug: Ondansetron; Drug: Aprepitant
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified January 2012
Complete Decongestive Therapy (CDT) for Treatment of Head and Neck Lymphedema

Conditions: Lymphedema; Oropharyngeal Cancer; Head and Neck Cancer; Oral Cancer
Interventions: Other: Follow -Up Visits; Other: Full CDT; Other: Modified CDT Program
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Not yet recruiting - verified May 2012
Pioglitazone for Oral Premalignant Lesions

Conditions: Malignant Neoplasm Overlapping Lip Site; Mouth Neoplasms; Malignant Neoplasm of Other and Ill-defined Sites in the Lip, Oral Cavity and Pharynx; Leukoplakia; Other Lesions of Oral Mucosa; Pigmented Oral Mucosal Lesion; Unspecified Lesions of Oral Mucosa; Oral Lichenoid Lesions; Premalignant Lesion; Other and Unspecified Lesions of Oral Mucosa; Granuloma and Granuloma-like Lesions of Oral Mucosa; Diseases of the Oral Soft Tissue, Excluding Lesions Specific for Gingiva and Tongue; Oral Premalignant Lesion; Oral Premalignant Neoplasms; Oral Leukoplakia
Interventions: Drug: Pioglitazone; Drug: Placebo
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI); University of Minnesota - Clinical and Translational Science Institute; Memorial Sloan-Kettering Cancer Center; University of Wisconsin, Madison; University of Alabama at Birmingham; University of Iowa; University of Maryland; Roswell Park Cancer Institute; Columbia University; Weill Medical College of Cornell University; European Institute of Oncology
Recruiting - verified April 2012
Treatment of Blood Clots in Children With Cancer

Condition: Venous Thromboembolism
Intervention: Drug: Fragmin
Sponsors: Eisai Inc.; Eisai Inc.
Recruiting - verified April 2012
Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes

Condition: Nasopharyngeal Carcinoma
Interventions: Drug: Docetaxel; Drug: Carboplatin; Drug: Dexamethasone; Drug: EBV-specific cytotoxic T lymphocytes
Sponsors: Baylor College of Medicine; Baylor College of Medicine; Texas Children's Hospital; The Methodist Hospital System; Center for Cell and Gene Therapy, Baylor College of Medicine; M.D. Anderson Cancer Center
Recruiting - verified April 2012
Study of Patients With Advanced Non-Small Cell Lung Cancer

Condition: Advanced Non-Small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Carboplatin; Drug: Paclitaxel; Biological: Bevacizumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
Complementary and Alternative Medicine Usage Among Participants Enrolled in Phase I Oncology Clinical Trials

Condition: Advanced Malignancy
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Biological: bevacizumab; Biological: cetuximab; Drug: carboplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Phase I and Pharmacology Study of Camptothecin-20-O-Propionate Hydrate (CZ48) in Patients With Solid Tumors or Lymphoma

Conditions: Advanced Solid Tumors; Lymphomas
Intervention: Drug: 20(S)Camptothecin Propionate (CZ48)
Sponsors: New Mexico Cancer Care Alliance; New Mexico Cancer Care Alliance
Recruiting - verified April 2012
Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma

Condition: Head And Neck Cancer
Interventions: Drug: Erlotinib; Drug: RAD001
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Novartis; OSI Pharmaceuticals
Recruiting - verified April 2012
An SGN-35 Trial for Patients Who Have Previously Participated in an SGN-35 Study

Conditions: Disease, Hodgkin; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin
Intervention: Drug: SGN-35
Sponsors: Seattle Genetics, Inc.; Seattle Genetics, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified April 2012
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

Conditions: Bladder Cancer; Prostate Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: gemcitabine hydrochloride; Drug: placebo administration
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified August 2011
Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Analysis of Surgery in Patients Presenting With Stage IV Breast Cancer

Condition: Breast Cancer
Intervention:
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; University of Chicago; Dana-Farber Cancer Institute; Georgetown University; Johns Hopkins University; M.D. Anderson Cancer Center; University of Alabama at Birmingham; University of California, San Francisco; University of North Carolina; Duke University; Vanderbilt-Ingram Cancer Center; Indiana University Melvin and Bren Simon Cancer Center; Mayo Clinic; University of Pittsburgh; University of Michigan Health System
Recruiting - verified March 2012
Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

Conditions: Brain and Central Nervous System Tumors; Lymphoma; Neuroblastoma; Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: crizotinib; Other: pharmacogenomic studies; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2012
Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab

Condition: Advanced Cancers
Interventions: Drug: HAI Oxaliplatin; Drug: 5-FU; Drug: Bevacizumab; Drug: Cetuximab; Drug: Leucovorin; Drug: 5-FU; Drug: Bevacizumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
Sirolimus and Cetuximab in Advanced Malignancies

Condition: Advanced Cancer
Interventions: Drug: Sirolimus; Drug: Cetuximab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
RAD001 for Patients With Radioiodine Refractory Thyroid Cancer

Condition: Thyroid Cancer
Intervention: Drug: RAD001
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Massachusetts General Hospital; M.D. Anderson Cancer Center; Novartis
Recruiting - verified June 2011
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: buserelin; Drug: flutamide; Drug: goserelin acetate; Drug: leuprolide acetate; Drug: triptorelin; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
High-dose Chemotherapy for Poor-prognosis Relapsed Germ-Cell Tumors

Condition: Testicular Cancer
Interventions: Drug: Bevacizumab; Drug: Gemcitabine; Drug: Docetaxel; Drug: Melphalan; Drug: Carboplatin; Drug: Mesna; Drug: Ifosfamide; Drug: Etoposide; Procedure: Stem Cell Transplant
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
A Study of Trastuzumab Emtansine (T-DM1) in Combination With Docetaxel, and Potentially Pertuzumab, in Patients With Advanced Breast Cancer

Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine; Drug: docetaxel; Drug: pertuzumab
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012
Smoking Cessation for Low-Income Adults

Conditions: Smoking Cessation; Smoking
Interventions: Behavioral: Smoking cessation training, support, and telephone follow-up; Behavioral: Smoking cessation intervention; Behavioral: Weekly Telephone Coaching
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified April 2012
A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Drug: Vorinostat, Lenalidomide, Bortezomib, Dexamethasone
Sponsors: Emory University; Emory University; Merck; Celgene Corporation
Recruiting - verified April 2012
Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer

Condition: Breast Cancer
Interventions: Drug: cisplatin; Drug: everolimus; Drug: paclitaxel; Other: placebo
Sponsors: Vanderbilt-Ingram Cancer Center; Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting - verified December 2011
An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: PF-02341066
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: PF-02341066; Drug: Pemetrexed; Drug: Docetaxel
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
Study of Oral MLN9708 in Adult Patients With Relapsed and/or Refractory Multiple Myeloma

Condition: Relapsed and Refractory Multiple Myeloma
Intervention: Drug: Oral MLN9708
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified April 2012
Aggressive Local Therapy for Limited Bone-only Metastasis

Condition: Breast Cancer
Interventions: Drug: Standard Therapy; Procedure: Local Therapy
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified February 2012
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer

Condition: Solid Cancers
Interventions: Drug: carboplatin; Drug: docetaxel; Drug: trastuzumab
Sponsors: Genentech; Genentech
Recruiting - verified October 2011
Reflux Disease in Head and Neck Cancer Patients Undergoing Radiation Therapy

Conditions: Head and Neck Cancer; Oropharyngeal Cancer; Gastroesophageal Reflux Disease
Intervention: Drug: Dexlansoprazole
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; TAP Pharmaceutical Products Inc.
Not yet recruiting - verified May 2012
A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related Pain

Conditions: Pain, Burning; Pain, Crushing; Pain, Migratory; Pain, Radiating; Pain, Splitting
Interventions: Drug: JNJ-42160443; Drug: Placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2012
A Study to Evaluate New or Worsening Lens Opacifications in Subjects With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss Due to Androgen-Deprivation Therapy

Conditions: Cancer; Cataract; Low Bone Mineral Density; Osteopenia; Osteoporosis; Prostate Cancer
Interventions: Biological: Denosumab; Biological: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified March 2012
A Study to Evaluate the Effects of Combining Cabazitaxel With Cisplatin Given Every 3 Weeks in Patients With Advanced Solid Cancer

Condition: Solid Cancer
Intervention: Drug: cabazitaxel (XRP6258)
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified April 2012
Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: Dasatinib; Drug: Ixabepilone
Sponsors: Accelerated Community Oncology Research Network; Accelerated Community Oncology Research Network; Bristol-Myers Squibb
Recruiting - verified February 2012
Image-Guided Radiosurgery or Stereotactic Body Radiation Therapy in Treating Patients With Localized Spine Metastasis

Conditions: Metastatic Cancer; Pain
Interventions: Radiation: external beam radiation therapy; Radiation: image-guided radiation therapy; Radiation: radiosurgery; Radiation: stereotactic body radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors

Condition: Brain and Central Nervous System Tumors
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer

Condition: Kidney Neoplasms
Interventions: Drug: Axitinib (AG-013736); Drug: Sorafenib
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias

Conditions: Leukemia-relapsed or Refractory; Cancer
Interventions: Drug: GSK1120212; Drug: GSK1120212
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma

Conditions: Chordoma; Desmoid Tumor; Sarcoma
Interventions: Genetic: reverse transcriptase-polymerase chain reaction; Other: biologic sample preservation procedure; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Metastasectomy Study in Renal Cell Carcinoma (RCC)

Condition: Kidney Cancer
Intervention: Other: Evaluation
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified November 2011
A Study of Paclitaxel/Carboplatin With or Without IMC-3G3 in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Condition: Non-Small Cell Lung Cancer
Interventions: Biological: IMC-3G3; Drug: Paclitaxel; Drug: carboplatin
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified February 2012
Xeloda (Capecitabine) and External Beam Radiation

Condition: Breast Cancer
Interventions: Radiation: Radiation Therapy; Drug: Capecitabine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified January 2012
Image-Guided Adaptive Conformal Photon Versus Proton Therapy

Condition: Non-Small-Cell Lung Carcinoma
Interventions: Radiation: Photon Therapy; Radiation: Proton Therapy
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)

Condition: Glioblastoma Multiforme
Interventions: Device: NovoTTF-100A device; Drug: Temozolomide
Sponsors: NovoCure Ltd.; NovoCure Ltd.
Recruiting - verified March 2012
Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma

Condition: Head and Neck Squamous Cell Carcinoma
Intervention: Drug: Lymphoseek
Sponsors: Navidea Biopharmaceuticals; Navidea Biopharmaceuticals
Recruiting - verified March 2012
Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors

Conditions: Colorectal Cancer; Head and Neck Cancer; Neoplasm Metastasis
Interventions: Drug: BMS-754807; Drug: cetuximab (Erbitux®)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012
A Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Intervention: Drug: BZL101
Sponsors: Bionovo; Bionovo
Not yet recruiting - verified February 2012
A Study of BMS-833923 With Cisplatin and Capecitabine in Inoperable, Metastatic Gastric, Gastroesophageal, or Esophageal Adenocarcinomas

Conditions: Stomach Neoplasms; Esophageal Neoplasms
Interventions: Drug: BMS-833923; Drug: Cisplatin; Drug: Capecitabine
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Exelixis
Recruiting - verified June 2011
PAVES: Pegfilgrastim Anti-VEGF Evaluation Study

Conditions: Cancer; Colon Cancer; Colorectal Cancer; Fever; Locally Advanced; Metastatic Colorectal Cancer; Neutropenia; Rectal Cancer
Interventions: Drug: Pegfilgrastim; Drug: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified January 2012
A Prospective Study for the Assessment of Recurrence Risk in Stage II Colon Cancer Patients Using ColoPrint

Condition: Colon Cancer
Intervention:
Sponsors: Agendia; Agendia
Recruiting - verified March 2012
Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC

Condition: Hepatocellular Carcinoma
Interventions: Drug: Brivanib; Drug: Brivanib Placebo
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012
An Umbrella, Modular Study Based on Epidermal Growth Factor Receptor (EGFR) Mutation Status

Condition: Advanced Cancers
Intervention: Drug: Erlotinib Hydrochloride (Tarceva)
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

Condition: Neuroblastoma
Interventions: Genetic: fluorescence in situ hybridization; Genetic: gene expression analysis; Genetic: nucleic acid amplification; Genetic: polymerase chain reaction; Genetic: reverse transcriptase-polymerase chain reaction; Other: cytology specimen collection procedure; Other: flow cytometry; Procedure: biopsy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Collecting and Storing Tissue From Young Patients With Cancer

Condition: Cancer
Interventions: Genetic: DNA analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: biologic sample preservation procedure; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study of Kidney Tumors in Young Patients

Conditions: Kidney Cancer; Nonneoplastic Condition
Interventions: Genetic: loss of heterozygosity analysis; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Other: immunohistochemistry staining method; Procedure: computed tomography; Procedure: magnetic resonance imaging
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer

Conditions: Leukemia; Neoplasm of Uncertain Malignant Potential; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Other: cytology specimen collection procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Tumor Marker YKL-40 in Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Intervention: Other: diagnostic laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Collecting Tumor Samples From Patients With Gynecological Tumors

Condition: Cancer
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified December 2011
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium

Conditions: Breast Cancer; Hypercalcemia of Malignancy; Colon Cancer; Endocrine Cancer; Head and Neck Cancer; Kidney Cancer; Lung Cancer; Lymphoma; Metastatic Cancer; Multiple Myeloma; Parathyroid Neoplasms; Renal Cancer; Thyroid Cancer; Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma; Non-Small Cell Lung Cancer
Intervention: Drug: denosumab
Sponsors: Amgen; Amgen
Recruiting - verified May 2012
Collecting and Storing Biological Samples From Patients With Ewing Sarcoma

Condition: Sarcoma
Interventions: Other: biologic sample preservation procedure; Other: medical chart review
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study of Erlotinib in Combination With Bortezomib

Condition: Advanced Cancer
Interventions: Drug: Erlotinib Hydrochloride; Drug: Bortezomib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
Study of Erlotinib in Combination With Dasatinib

Condition: Advanced Cancer
Interventions: Drug: Erlotinib Hydrochloride; Drug: Dasatinib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
Erlotinib in Combination With Cetuximab

Condition: Advanced Cancers
Interventions: Drug: Erlotinib; Drug: Cetuximab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: Panitumumab; Drug: Carboplatin; Drug: Gemcitabine
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; Amgen; Eli Lilly and Company
Recruiting - verified October 2011
Collecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma

Condition: Sarcoma
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Caregiver Assessments of the Quality of Home Hospice Care

Condition: Advanced Cancer
Intervention: Behavioral: Phone Interview/Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified November 2011
Studying Biomarkers in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells

Conditions: Cervical Cancer; Precancerous Condition
Interventions: Genetic: DNA analysis; Genetic: gene expression analysis; Other: diagnostic laboratory biomarker analysis; Other: immunohistochemistry staining method; Procedure: cone biopsy; Procedure: endocervical curettage; Procedure: histopathologic examination; Procedure: loop electrosurgical excision procedure
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified December 2011
Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial

Conditions: Leukemia; Lymphoma
Intervention: Other: biologic sample preservation procedure
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Dose-escalation Study of Oral CX-4945

Conditions: Advanced Solid Tumors; Breast Cancer; Inflammatory Breast Cancer; Castleman's Disease; Multiple Myeloma
Intervention: Drug: CX-4945 oral formulation
Sponsors: Cylene Pharmaceuticals; Cylene Pharmaceuticals
Recruiting - verified June 2011
Acupuncture for Chemo-Induced Peripheral Neuropathy

Conditions: Lymphoma; Myeloma; Peripheral Neuropathy
Intervention: Other: Acupuncture
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Millennium Pharmaceuticals, Inc.
Recruiting - verified December 2011
Her2 and TGFBeta in Treatment of Her2 Positive Malignancy

Condition: Lung Malignancy
Intervention: Genetic: Genetically modified T cells
Sponsors: Baylor College of Medicine; Baylor College of Medicine; The Methodist Hospital System; Center for Cell and Gene Therapy, Baylor College of Medicine
Recruiting - verified April 2012
Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Conditions: Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
Interventions: Biological: bevacizumab; Drug: everolimus; Other: placebo
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2011
Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma

Conditions: Brain Cancer; Pediatric Cancers
Interventions: Drug: Bevacizumab; Drug: Lapatinib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; CERN Foundation - Collaborative Ependymoma Research Network
Recruiting - verified March 2012
Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma

Condition: Advanced Cancer, Various, NOS
Interventions: Drug: BMS-833923; Drug: Lenalidomide; Drug: Dexamethasone; Drug: Bortezomib
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Exelixis
Recruiting - verified February 2012
Fludarabine, Bendamustine and Rituximab Conditioning for Patients With Lymphoid Malignancies

Conditions: Leukemia; Lymphoma
Interventions: Drug: Bendamustine; Drug: Rituximab; Drug: Fludarabine; Procedure: Stem Cell Transplant (SCT)
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Cephalon
Recruiting - verified April 2012
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets

Condition: Bone Metastases
Intervention: Device: Bone Scan: F18-Fluoride PET/CT or TC-MDP
Sponsors: American College of Radiology - Image Metrix; American College of Radiology - Image Metrix; Academy of Molecular Imaging
Recruiting - verified June 2011
N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma

Condition: Neuroblastoma
Interventions: Drug: Bevacizumab; Drug: cyclophosphamide; Drug: zoledronic acid
Sponsors: New Approaches to Neuroblastoma Therapy Consortium; New Approaches to Neuroblastoma Therapy Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012
Autologous T Lymphocytes Engrafted With a Chimeric Antigen Receptor Targeting the Kappa Light Chain

Conditions: Lymphoma; Myeloma; Leukemia
Intervention: Biological: Genetically modified T cells
Sponsors: Baylor College of Medicine; Baylor College of Medicine; Texas Children's Hospital; The Methodist Hospital System; Center for Cell and Gene Therapy, Baylor College of Medicine
Recruiting - verified April 2012
Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas

Conditions: Glial Cell Tumors; Malignant Gliomas; Glioblastoma Multiforme; Anaplastic Astrocytoma; Gliomatosis Cerebri; Gliosarcoma; Brainstem Glioma
Interventions: Drug: Valproic acid; Drug: Bevacizumab; Radiation: Radiation therapy
Sponsors: Baylor College of Medicine; Baylor College of Medicine
Recruiting - verified February 2012
Testosterone for Treating Cachexia in Patients With Advanced or Recurrent Cervical Cancer

Conditions: Cachexia; Cervical Cancer
Interventions: Drug: Standard of Care Chemotherapy and/or Radiation plus Placebo (Saline) Testosterone; Drug: Arm II: Standard of Care Chemotherapy and/or Radiation plus Testosterone Enanthate
Sponsors: The University of Texas, Galveston; The University of Texas, Galveston; National Cancer Institute (NCI)
Recruiting - verified March 2012
Clinical Response to Chemotherapy With Fluoro-L-Thymidine With Positron Emission Tomography (FLT-PET)

Condition: Advanced Cancers
Interventions: Radiation: PET Scan; Drug: FLT
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
Phosphatidylinositol 3 Kinase and Mammalian Target of Rapamycin (PI3K-mTOR) in Advanced Cancer Patients

Condition: Advanced Cancers
Intervention: Drug: Temsirolimus
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
Prostate Conformal Cryotherapy

Condition: Prostate Cancer
Intervention: Procedure: Cryoablation
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Endocare, Inc.; Gen-Probe, Incorporated; FirmaMed; Envisioneering Medical Technologies
Recruiting - verified April 2012
A Trial In Patients With Advanced Cancer And Leukemia

Conditions: Neoplasms by Histologic Type; Leukemia, Lymphoid; Leukemia, T-Cell; Solid Tumors
Intervention: Drug: PF-03084014
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Fatigue, Sleep and Cytokines in Primary Brain Tumor (PBT) Patients

Condition: Brain Cancer
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Everolimus; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Conditions: Breast Cancer; Lung Cancer; Metastatic Cancer; Multiple Myeloma and Plasma Cell Neoplasm; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Procedure: assessment of therapy complications
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Efficacy/Safety of Imprime PGG® Injection With Bevacizumab and Paclitaxel/Carboplatin in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)

Condition: Non-Small Cell Lung Cancer
Interventions: Biological: Imprime PGG® Injection; Biological: Bevacizumab; Drug: Paclitaxel; Drug: Carboplatin
Sponsors: Biothera; Biothera
Recruiting - verified March 2012
PMRR-NO: Pulmonary Metabolic Radiation Response Versus Exhaled Nitric Oxide

Conditions: Gastrointestinal Disease; Esophageal Cancer; Lung Cancer
Interventions: Procedure: Breathing Test; Behavioral: Respiratory Symptoms Questionnaire; Procedure: Pet Scan
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
Vorinostat, Isotretinoin, and Combination Chemotherapy in Treating Young Patients Who Have Undergone Surgery for Embryonal Tumors of the Central Nervous System

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: isotretinoin; Drug: thiotepa; Drug: vincristine sulfate; Drug: vorinostat; Radiation: Conformal radiation
Sponsors: Pediatric Brain Tumor Consortium; Pediatric Brain Tumor Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2012
4D PET/CT Imaging in Lung and Colorectal Cancer With Liver Metastasis

Conditions: Colorectal Cancer; Lung Cancer; Liver Cancer
Intervention: Procedure: PET/CT Scan
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; GE Healthcare
Recruiting - verified May 2012
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed By Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

Condition: Breast Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study of Immunotherapy to Treat Advanced Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Placebo
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified December 2011
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

Conditions: Non-Small Cell Lung Cancer; Anemia; Cancer; Lung Cancer
Interventions: Drug: darbepoetin alfa 500 mcg Q3W; Drug: placebo
Sponsors: Amgen; Amgen
Recruiting - verified May 2012
Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer

Condition: Breast Cancer
Interventions: Biological: bevacizumab; Biological: pegfilgrastim; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: paclitaxel albumin-stabilized nanoparticle formulation
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies

Conditions: Stem Cell Transplantation; Leukemia; Lymphoma
Interventions: Drug: Thiotepa; Drug: Clofarabine; Drug: Busulfan; Procedure: Allogeneic Stem Cell Transplantation; Drug: Thymoglobulin (ATG); Drug: G-CSF (Filgrastim)
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified February 2012
Stereotactic Body Radiation Therapy and Vertebroplasty in Treating Patients With Localized Spinal Metastasis

Conditions: Metastatic Cancer; Pain; Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Radiation: stereotactic body radiation therapy
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center
Recruiting - verified March 2012
Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Cisplatin, and Cetuximab Given Together With Radiation Therapy in Treating Patients With Locally Advanced Stage III or Stage IV Head and Neck Cancer

Condition: Head and Neck Cancer
Interventions: Biological: cetuximab; Drug: cisplatin; Drug: paclitaxel albumin-stabilized nanoparticle formulation; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center
Recruiting - verified March 2012
Initiative for Molecular Profiling in Advanced Cancer Therapy (IMPACT) Trial, An Umbrella Protocol

Condition: Advanced Cancers
Intervention: Other: Molecular Profiling Analyses
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified February 2012
Pilot Study of AuroLase(tm) Therapy in Refractory and/or Recurrent Tumors of the Head and Neck

Condition: Head and Neck Cancer
Intervention: Device: AuroLase Therapy
Sponsors: Nanospectra Biosciences, Inc.; Nanospectra Biosciences, Inc.
Recruiting - verified October 2011
Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer
Interventions: Radiation: CyberKnife Stereotactic Radiotherapy; Procedure: Surgery
Sponsors: Accuray Incorporated; Accuray Incorporated; M.D. Anderson Cancer Center
Recruiting - verified February 2012
A Study for Patients With Pancreatic Cancer

Condition: Pancreatic Neoplasms
Interventions: Drug: LY2603618; Drug: Gemcitabine
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
Breast Cancers: Risk Factors Among Mexican Women in Mexico, Mexican-American and African-American Women in the U.S.

Condition: Breast Cancer
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2012
Study of the Combination of Vorinostat and Radiation Therapy for the Treatment of Patients With Brain Metastases

Condition: Brain Metastases
Interventions: Drug: Vorinostat; Radiation: Radiation Therapy
Sponsors: Thomas Jefferson University; Thomas Jefferson University; Merck
Recruiting - verified January 2012
Multi-Virus-Specific Cytotoxic T Lymphocytes (CTLs)

Condition: Acute Lymphoblastic Leukemia
Intervention: Biological: Genetically modified T cells
Sponsors: Baylor College of Medicine; Baylor College of Medicine; Texas Children's Hospital; The Methodist Hospital System; Center for Cell and Gene Therapy, Baylor College of Medicine
Recruiting - verified April 2012
Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer

Condition: Carcinoma, Renal Cell
Interventions: Drug: axitinib; Drug: axitinib; Drug: axitinib
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer

Condition: Head and Neck Cancer
Interventions: Drug: cetuximab; Drug: cisplatin; Radiation: intensity-modulated radiation therapy
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center
Recruiting - verified March 2012
FDG-PET-CT and Biomarkers in Esophageal Cancer

Conditions: Gastrointestinal Disease; Esophageal Cancer
Interventions: Procedure: PET/CT (FDG PET/CT); Other: Biomarker Testings
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified April 2012
Utility of Endobronchial Ultrasound Guided Needle Biopsy in Early Stage Non- Small Cell Lung Cancer (NSCLC)

Condition: Lung Cancer
Intervention: Procedure: EBUS-TBNA
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
Sentinel Lymph Node (SLN) Biopsy for Sebaceous Gland Carcinoma of Eyelid

Condition: Eye Cancer
Interventions: Procedure: Lymphatic Mapping; Procedure: SLN Mapping/Biopsy
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
Everolimus(RAD001) For Advanced Renal Cell Carcinoma(RCC)Before Kidney Removal

Condition: Kidney Cancer
Intervention: Drug: everolimus
Sponsors: Baylor College of Medicine; Gilad Amiel; University of Texas Southwestern Medical Center
Recruiting - verified February 2012
Bladder Cancer Imaging Study-OCT Imaging to Stage Bladder Tumors

Condition: Bladder Cancer
Intervention:
Sponsors: Baylor College of Medicine; Baylor College of Medicine
Recruiting - verified March 2012
TKI258 in Castrate Resistant Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: TK1258
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Novartis
Recruiting - verified May 2012
Hepatic Arterial Infusion of Nab-Paclitaxel in Patients With Metastatic Melanoma in the Liver

Conditions: Melanoma; Liver Metastasis
Intervention: Drug: Nab-Paclitaxel (Abraxane)
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
An Open-Label Study of Trastuzumab Emtansine (T-DM1) vs Capecitabine+Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer (EMILIA)

Condition: Breast Cancer
Interventions: Drug: trastuzumab emtansine; Drug: lapatinib; Drug: capecitabine [Xeloda]
Sponsors: Genentech; Genentech
Recruiting - verified April 2012
Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)

Conditions: Lung Cancer; Non-Small Cell Lung Cancer
Interventions: Drug: Dasatinib; Drug: Erlotinib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Bristol-Myers Squibb; OSI Pharmaceuticals
Recruiting - verified January 2012
Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma

Conditions: Brain Tumors; Spinal Cord Tumors
Interventions: Drug: Temozolomide; Drug: Lapatinib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
Spousal Support in Head and Neck Cancer

Condition: Head And Neck Cancer
Intervention: Behavioral: Questionnaires & Study Visit
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified November 2011
African American Church-based Cohort

Condition: Cancer
Interventions: Behavioral: Questionnaire; Other: Body Measurements; Behavioral: Self-help Materials
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
A Study of QBI-139 in Subjects With Advanced Solid Tumors

Condition: Solid Tumors
Intervention: Drug: QBI-139
Sponsors: Quintessence Biosciences, Inc.; Quintessence Biosciences, Inc.
Recruiting - verified January 2010
A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma

Conditions: Multiple Myeloma; Plasma Cell Leukemia
Interventions: Drug: ARRY-520, KSP(Eg5) inhibitor; intravenous; Drug: Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous; Drug: Dexamethasone, steroid; oral
Sponsors: Array BioPharma; Array BioPharma
Recruiting - verified February 2012
A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors

Conditions: Cancer; Oncology; Tumors; Advanced Malignancy; Advanced Solid Tumors; Oncology Patients
Intervention: Drug: AMG 208
Sponsors: Amgen; Amgen
Recruiting - verified May 2012
Radical Trachelectomy for Cervical Cancer

Condition: Cervical Cancer
Intervention: Behavioral: Questionnaires
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified December 2011
Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer

Conditions: Endometrial Cancer; Fatigue; Neurotoxicity
Interventions: Drug: carboplatin; Drug: paclitaxel; Radiation: brachytherapy; Radiation: intensity-modulated radiation therapy; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Delta-24-RGD for Recurrent Malignant Gliomas

Conditions: Brain Cancer; Central Nervous System Diseases
Interventions: Drug: DELTA-24-RGD-4C; Procedure: Tumor Removal
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer

Condition: Cervical Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: paclitaxel; Drug: topotecan hydrochloride
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified December 2011
Pelvic Fractures and Radiation Therapy for Cervical Cancer

Conditions: Cervical Cancer; Endometrial Cancer; Vaginal Cancer
Intervention: Procedure: CT or MRI + Blood Test
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified December 2011
Cancer Support Programs

Condition: Prostate Cancer
Interventions: Behavioral: Group Meetings; Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified January 2012
Pelvic Exenteration for Gynecologic Malignancy

Conditions: Cervical Cancer; Endometrial Cancer; Vaginal Cancer; Vulvar Cancer; Gynecologic Cancer
Intervention: Behavioral: Questionnaires
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
Capecitabine, Gemcitabine, and Radiation Therapy in Treating Patients With Cholangiocarcinoma of the Gallbladder or Bile Duct

Conditions: Extrahepatic Bile Duct Cancer; Gallbladder Cancer
Interventions: Drug: capecitabine; Drug: gemcitabine hydrochloride; Procedure: adjuvant therapy; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Levonorgestrel Intrauterine Device (IUD) to Treat Complex Atypical Hyperplasia (CAH) and Grade 1 Endometrioid Endometrial Carcinoma (G1EEC)

Conditions: Hyperplasia; Endometrial Cancer
Intervention: Device: Levonorgestrel IUD
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Bayer
Recruiting - verified November 2011
Personalized Treatment Selection for Dasatinib in Metastatic Breast Cancer

Condition: Breast Cancer
Intervention: Drug: Dasatinib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Bristol-Myers Squibb
Recruiting - verified May 2012
Longitudinal Study of Symptoms in Colorectal Cancer

Condition: Colorectal Cancer
Intervention: Behavioral: Questionnaires
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery.

Condition: Breast Cancer
Intervention: Drug: Bevacizumab, nab-paclitaxel, carboplatin, doxorubicin hydrochloride, cyclophosphamide, PEG-Filgrastim
Sponsors: University of Tennessee Cancer Institute; University of Tennessee Cancer Institute; National Comprehensive Cancer Network; Celgene Corporation; Genentech
Recruiting - verified February 2012
Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy

Condition: Prostate Cancer
Interventions: Drug: Androgen Deprivation Therapy; Drug: bicalutamide; Drug: bevacizumab
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Genentech; Beth Israel Deaconess Medical Center; Brigham and Women's Hospital; Cancer Institute of New Jersey
Recruiting - verified February 2012
Radiation Therapy and Cardiac Enzymes

Condition: Tumor
Intervention:
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
Neuropsychological and Behavioral Testing in Young Patients With Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor (PNET)

Conditions: Brain and Central Nervous System Tumors; Chemotherapeutic Agent Toxicity; Cognitive/Functional Effects; Neurotoxicity; Psychosocial Effects of Cancer and Its Treatment; Radiation Toxicity; Therapy-related Toxicity
Interventions: Other: questionnaire administration; Procedure: cognitive assessment; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Multicenter Clinical Study of the Sonablate®500 for the Treatment of Locally Recurrent Prostate Cancer With HIFU

Condition: Recurrent Prostate Cancer
Intervention: Device: High Intensity Focused Ultrasound
Sponsors: USHIFU, LLC; USHIFU, LLC
Recruiting - verified April 2012
Study of Temsirolimus, Topotecan, and Bortezomib

Condition: Advanced Cancer
Interventions: Drug: Torisel (Temsirolimus); Drug: Hycamtin (Topotecan); Drug: Velcade (Bortezomib)
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified February 2012
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy

Condition: Breast Cancer
Interventions: Biological: trastuzumab; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI)
Recruiting - verified April 2012
A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Pemetrexed; Drug: Paclitaxel; Drug: Carboplatin; Biological: Bevacizumab; Biological: Bevacizumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
Adherence to Swallowing Exercises in Oropharyngeal Cancer

Condition: Head and Neck Cancer
Interventions: Behavioral: Interview; Behavioral: Phone Call; Other: Brochure; Other: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
Intrapleural Catheter Daily Versus Three Times a Week Drainage

Conditions: Advanced Cancer; Pleural Effusion
Interventions: Procedure: Intrapleural catheter (IPC) drained; Procedure: IPC Placement; Radiation: Chest X-Ray
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal Junction

Conditions: Adenocarcinoma of the Gastroesophageal Junction; Esophageal Cancer
Interventions: Biological: panitumumab; Drug: cisplatin; Drug: docetaxel; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified June 2011
Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors

Conditions: Cancer; Non-Small Cell Lung Cancer; Endometrial Carcinoma; Ovarian Carcinoma
Interventions: Drug: XL147 (SAR245408),; Drug: paclitaxel; Drug: carboplatin
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified March 2012
Prophylactic Cranial Irradiation (PCI) for Small Cell Carcinoma of the Urothelium

Condition: Bladder Cancer
Interventions: Radiation: PCI; Other: Brain X-ray
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
Prostate Active Surveillance Study

Condition: Prostatic Neoplasms
Intervention:
Sponsors: University of Washington; University of Washington; Canary Foundation; Early Detection Research Network
Recruiting - verified June 2011
Stereotactic Body Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer

Condition: Lung Cancer
Intervention: Radiation: stereotactic body radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Safety and Exploratory Efficacy of Kanglaite Injection in Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Drug: Kanglaite Injection plus gemcitabine; Drug: Gemcitabine
Sponsors: KangLaiTe USA; KangLaiTe USA
Recruiting - verified January 2012
Multiple Ascending Dose (MDX1105-01)

Condition: Cancer, Multiple Indications
Interventions: Biological: Anti-PDL-1 antibody; Biological: Anti-PDL-1 antibody; Biological: Anti-PDL-1 antibody; Biological: Anti-PDL-1 antibody; Biological: Anti-PDL-1 antibody
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified May 2012
Cryoablation Therapy in Treating Patients With Invasive Ductal Breast Cancer

Condition: Breast Cancer
Interventions: Procedure: cryosurgery; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study Of Letrozole With Or Without PD 0332991 For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer

Condition: Breast Cancer
Interventions: Drug: PD 0332991; Drug: letrozole; Drug: letrozole
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patients With Lymphoma or Multiple Myeloma

Condition: Hematologic Malignancies, Multiple Myeloma, Lymphoma
Intervention: Drug: MLN4924
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified April 2012
A Phase I Dose-Escalation Study of IMGN388 in Patients With Solid Tumors

Condition: Solid Tumor
Intervention: Drug: IMGN388
Sponsors: ImmunoGen, Inc.; ImmunoGen, Inc.
Recruiting - verified July 2011
Magnetic Resonance Temperature Imaging & Imaging-Guided Laser Induced Thermal Therapy for Treatment of Metastatic Brain Tumors

Condition: Brain Tumor
Intervention: Procedure: Visualase® Thermal Therapy System
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; BioTex, Inc.
Recruiting - verified May 2012
Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy

Conditions: Brain and Central Nervous System Tumors; Childhood Germ Cell Tumor; Extragonadal Germ Cell Tumor; Liver Cancer; Neuroblastoma; Ototoxicity; Ovarian Cancer; Sarcoma
Interventions: Drug: sodium thiosulfate; Procedure: examination
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
8-Chloro-Adenosine in Chronic Lymphocytic Leukemia

Conditions: Leukemia; Chronic Lymphocytic Leukemia
Intervention: Drug: 8-Chloro-Adenosine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI); FDA Office of Orphan Products Development
Recruiting - verified March 2012
Induction Therapy-Docetaxel, Cisplatin and Fluorouracil in Untreated Advanced Squamous Cell or Undifferentiated Carcinoma of the Paranasal Sinuses

Conditions: Paranasal Sinuses; Squamous Cell Carcinoma
Interventions: Drug: Docetaxel; Drug: 5-Fluorouracil; Drug: Cisplatin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Sanofi-Aventis
Recruiting - verified March 2012
International Pediatric Adrenocortical Tumor Registry

Condition: Adrenocortical Tumor
Intervention:
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified April 2012
Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic

Condition: Metastatic Breast Cancer
Interventions: Drug: Dasatinib + Letrozole; Drug: Letrozole
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; US Oncology Research
Recruiting - verified February 2012
Detecting Anal and Genital Human Papillomavirus Infection and Squamous Intraepithelial Lesions in HIV-Positive Patients Enrolled in AIDS Cancer Clinical Trials

Conditions: Aids-related Malignancies; Lymphoma; Precancerous Condition; Sarcoma
Interventions: Genetic: polymerase chain reaction; Other: cytology specimen collection procedure; Other: histological technique; Procedure: colposcopic biopsy
Sponsors: AIDS Malignancy Clinical Trials Consortium; AIDS Malignancy Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified November 2011
Safety Study of CALAA-01 to Treat Solid Tumor Cancers

Conditions: Cancer; Solid Tumor
Intervention: Drug: CALAA-01
Sponsors: Calando Pharmaceuticals; Calando Pharmaceuticals
Recruiting - verified February 2012
Oxaliplatin, Capecitabine, Cetuximab, and Radiation Therapy Followed By Surgery in Treating Patients With Stage II or Stage III Rectal Cancer

Condition: Colorectal Cancer
Interventions: Biological: cetuximab; Drug: capecitabine; Drug: oxaliplatin; Genetic: gene expression analysis; Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Procedure: neoadjuvant therapy; Procedure: therapeutic surgical procedure; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Chemotherapy and Radiation in Treating Patients With Stage 3 Non-Small Cell Lung Cancer

Condition: Non Small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Cisplatin; Drug: Etoposide; Drug: Cisplatin; Drug: Vinorelbine; Drug: Paclitaxel; Drug: Carboplatin; Radiation: Thoracic Radiation Therapy (TRT); Radiation: Thoracic Radiation Therapy (TRT)
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
Correlation of MR Thermal Imaging to Actual Size of Ablation During Laser Ablation Therapy

Conditions: Advanced Cancer; Bone Metastases
Interventions: Procedure: Laser Ablation; Procedure: Magnetic Resonance Thermal Imaging
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; BioTex, Inc.
Recruiting - verified January 2012
Genetic Mutations and Environmental Exposure in Young Patients With Retinoblastoma and in Their Parents and Young Healthy Unrelated Volunteers

Condition: Retinoblastoma
Interventions: Genetic: DNA ploidy analysis; Genetic: DNA stability analysis; Genetic: Southern blotting; Genetic: genetic linkage analysis; Genetic: loss of heterozygosity analysis; Genetic: mutation analysis; Genetic: polymorphism analysis; Genetic: reverse transcriptase-polymerase chain reaction; Other: environmental carcinogenesis study; Other: questionnaire administration; Other: study of socioeconomic and demographic variables; Procedure: evaluation of cancer risk factors; Procedure: mutation carrier screening
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Inflammatory Cytokines in Symptom Production in Multiple Myeloma

Condition: Multiple Myeloma
Interventions: Behavioral: Questionnaire; Behavioral: Neurocognitive Testing; Behavioral: Neurosensory Testing
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; AstraZeneca
Recruiting - verified January 2012
Phase I Trial of TGFB2-Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine for Advanced Cancer

Condition: Advanced Metastatic Carcinoma
Intervention: Biological: TGFβ2 Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine
Sponsors: Mary Crowley Medical Research Center; Mary Crowley Medical Research Center
Recruiting - verified August 2011
Safety and Efficacy of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease

Condition: Symptomatic Refractory Resistant Carcinoid Disease
Interventions: Drug: Pasireotide; Drug: Octreotide
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified March 2012
Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy

Conditions: Lung Neoplasm; Carcinoma Non-small Cell Lung Cancer Stage IIIA; Carcinoma Non-small Cell Lung Cancer Stage IIIB; Carcinoma Non-small Cell Lung Cancer Stage IV
Interventions: Biological: Lucanix™; Other: Placebo Comparator
Sponsors: NovaRx Corporation; NovaRx Corporation
Recruiting - verified April 2012
Study of MLN4924 in Adult Patients With Nonhematologic Malignancies

Condition: Advanced Nonhematologic Malignancies
Intervention: Drug: MLN4924
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified April 2012
Quantitative Analysis of Outcomes in Breast Reconstruction

Condition: Breast Cancer
Interventions: Behavioral: Questionnaire; Procedure: Digital Imaging
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
Evaluation of Robot-Assisted Surgery in Gynecologic Oncology

Condition: Gynecologic Cancer
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer

Conditions: Hedgehog Pathway; Smoothened; Basal Cell Carcinoma (BCC); Basal Cell Nevoid Syndrome (BCNS)
Intervention: Drug: BMS-833923 (XL139)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Exelixis
Recruiting - verified August 2011
ChemoFx® PRO - A Post-Market Data Collection Study

Conditions: Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer; Uterine Neoplasms; Endometrial Cancer; Vaginal Cancer; Vulvar Cancer; Cervical Cancer; Lung Cancer; Carcinoid Tumor of Lung; Sarcoma of Lung; Mesothelioma; Colorectal Cancer
Intervention:
Sponsors: Precision Therapeutics; Precision Therapeutics
Recruiting - verified June 2011
Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme

Condition: Malignant Gliomas
Interventions: Drug: Irinotecan; Drug: Lenalidomide
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Celgene Corporation
Recruiting - verified January 2012
Sexual Behavior in Head and Neck Cancer Patients

Conditions: Oropharyngeal Cancer; Head and Neck Cancer; Squamous Cell Carcinoma
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified February 2012
Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer

Condition: Esophageal Cancer
Interventions: Biological: cetuximab; Drug: cisplatin; Drug: paclitaxel; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Panitumumab Pediatric Study

Condition: Solid Tumors
Intervention: Drug: Panitumumab Treatment
Sponsors: Amgen; Amgen
Recruiting - verified July 2011
Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: etoposide phosphate; Drug: methotrexate; Drug: thiotepa; Drug: vincristine sulfate; Genetic: mutation analysis; Other: immunohistochemistry staining method; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: 3-dimensional conformal radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) Treatment of Metastatic Bone Tumors for the Palliation of Pain

Conditions: Bone Metastases; Multiple Myeloma
Interventions: Device: ExAblate 2000; Device: Sham
Sponsors: InSightec; InSightec
Recruiting - verified October 2011
Pharmacokinetics and Safety Study of Azacitidine in Cancer Patients With and Without Impaired Renal Function

Conditions: MDS; AML; Solid Tumors; Multiple Myeloma; Non-Hodgkin's Lymphoma; Hodgkin's Disease
Interventions: Drug: azacitidine; Drug: azacitidine; Drug: azacitidine; Drug: azacitidine; Drug: azacitidine; Drug: azacitidine; Drug: azacitidine
Sponsors: Celgene Corporation; Celgene Corporation
Recruiting - verified March 2012
Relationship Between Quality of Life, Treatment Modalities, and Patient Treatment/Outcome Expectations

Condition: Rectal Cancer
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden

Conditions: Multiple Myeloma; Primary Amyloidosis
Interventions: Drug: Melphalan; Procedure: Stem Cell Infusion; Behavioral: Questionnaires; Drug: Granulocyte-colony stimulating factor (G-CSF); Procedure: Apheresis
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma

Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: bortezomib; Drug: dexamethasone; Drug: lenalidomide
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified June 2011
CyberKnife Radiosurgical Treatment of Inoperable Early Stage Non-Small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer
Intervention: Radiation: CyberKnife Stereotactic Radiosurgery
Sponsors: Accuray Incorporated; Accuray Incorporated; University of Pittsburgh
Recruiting - verified February 2012
Three Different Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide

Condition: Lung Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI); Radiation Therapy Oncology Group
Recruiting - verified May 2012
Screening for Familial Colorectal Cancer (CRC) Patients

Condition: Colorectal Cancer
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
Fludarabine, Busulfan, and Alemtuzumab Followed By Donor Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disease

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Precancerous Condition
Interventions: Biological: alemtuzumab; Drug: busulfan; Drug: fludarabine phosphate; Drug: tacrolimus; Procedure: allogeneic hematopoietic stem cell transplantation
Sponsors: National Cancer Institute (NCI); Baylor College of Medicine
Recruiting - verified June 2009
Lifestyle Intervention for Heart Failure

Condition: Heart Failure
Interventions: Other: Usual Care; Behavioral: Exercise Training; Behavioral: Dietary Counseling
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified February 2012
Sorafenib Long Term Extension Program (STEP)

Condition: Neoplasms
Intervention: Drug: Sorafenib (Nexavar, BAY43-9006)
Sponsors: Bayer; Bayer; ICON Clinical Research
Recruiting - verified May 2012
A Study of RO5045337 [RG7112] in Patients With Hematologic Neoplasms.

Condition: Hematologic Neoplasms
Intervention: Drug: RO5045337
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified May 2012
A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer

Conditions: Breast Cancer,; Advanced Solid Tumors,; Cowden Syndrome
Intervention: Drug: BEZ235
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified November 2011
T Lymphocytes in Treating Patients Undergoing a Donor Bone Marrow Transplant

Condition: Cancer
Interventions: Biological: allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes; Genetic: polymerase chain reaction; Other: immunological diagnostic method; Procedure: adjuvant therapy
Sponsors: National Cancer Institute (NCI); Baylor College of Medicine
Recruiting - verified June 2009
Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)

Condition: Hepatocellular Carcinoma
Interventions: Drug: ThermoDox; Drug: 5% Dextrose Solution
Sponsors: Celsion; Celsion
Recruiting - verified June 2011
Laparoscopic Approach to Cervical Cancer

Condition: Cervical Cancer
Interventions: Procedure: Total Abdominal Radical Hysterectomy; Procedure: Total Laparoscopic or Robotic Radical Hysterectomy
Sponsors: Queensland Centre for Gynaecological Cancer; Queensland Centre for Gynaecological Cancer; M.D. Anderson Cancer Center
Recruiting - verified June 2011
Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Drug: Bevacizumab; Drug: Erlotinib; Drug: Capecitabine; Radiation: Radiation Therapy
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Genentech
Recruiting - verified May 2012
Dasatinib in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma

Conditions: Brain and Central Nervous System Tumors; Liver Cancer; Lymphoma; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: dasatinib; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Effect of Pulmonary Rehabilitation on Surgical Outcomes in the Cancer Setting

Condition: Lung Cancer
Interventions: Other: Questionnaire; Behavioral: Pulmonary Rehabilitation
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
Magnetic Resonance Imaging in Patients With Breast Cancer

Condition: Breast Cancer
Intervention: Procedure: MRI
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
Social-Psychological Aspects of Orbital Exenteration

Condition: Eye Cancer
Interventions: Behavioral: Audio-Taped Interview; Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma

Condition: Lymphoma
Interventions: Biological: rituximab; Drug: bortezomib; Drug: carboplatin; Drug: dexamethasone; Drug: etoposide; Drug: ifosfamide; Genetic: polymerase chain reaction; Genetic: western blotting
Sponsors: AIDS Malignancy Clinical Trials Consortium; AIDS Malignancy Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified December 2011
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Condition: Head and Neck Cancer
Interventions: Biological: bevacizumab; Drug: carboplatin; Drug: cisplatin; Drug: docetaxel; Drug: fluorouracil
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP)

Condition: Adenomatous Polyposis Coli
Interventions: Drug: Celecoxib; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
A Multicenter Trial On The Utility and Impact Of Computed Tomography and Serum CA-125 In the Management of Newly Diagnosed Ovarian Cancer

Condition: Ovarian Cancer
Intervention: Other: CA 125 and CT scan
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Johns Hopkins University; M.D. Anderson Cancer Center
Recruiting - verified January 2012
Post Transplant For Patients Undergoing Matched Sibling Stem Cell Transplantation

Conditions: Leukemia; Cancer; Lymphoma
Interventions: Drug: Ara-C; Drug: Cytoxan; Drug: Mesna; Radiation: TBI Fraction; Procedure: Stem Cell Infusion; Drug: Methotrexate; Drug: Tacrolimus
Sponsors: Baylor College of Medicine; Baylor College of Medicine; Texas Children's Hospital
Recruiting - verified April 2012
CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia

Conditions: Lymphoma; Leukemia
Interventions: Drug: CD19CAR-zeta or CD19CAR-28-zeta; Drug: CD19CAR-zeta or CD19CAR-28-zeta; Drug: CD19CAR-zeta or CD19CAR-28-zeta
Sponsors: Baylor College of Medicine; Baylor College of Medicine; Texas Children's Hospital; The Methodist Hospital System
Recruiting - verified April 2012
Brain Mets - Capecitabine and WBRT

Condition: Breast Cancer
Interventions: Drug: sunitinib; Drug: capecitabine; Radiation: WBRT
Sponsors: Baylor Breast Care Center; Baylor Breast Care Center
Recruiting - verified January 2012
Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Arimidex with Faslodex; Drug: Arimidex without Faslodex
Sponsors: Baylor Breast Care Center; Baylor Breast Care Center; AstraZeneca
Recruiting - verified January 2012
Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising PSA After Surgery for Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: flutamide; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Radiation Therapy Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified May 2012
Computed Tomography Urography (CTU) vs Intravenous Urography (IVU) on Patients at Risk of Urothelial Tumors

Condition: Bladder Cancer
Interventions: Other: Computed Tomography Urography (CTU); Other: Intravenous Urography (IVU)
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; GE Healthcare
Recruiting - verified April 2012
Octreotide and Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

Condition: Neuroendocrine Carcinoma
Interventions: Biological: bevacizumab; Biological: recombinant interferon alfa-2b; Drug: octreotide acetate
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified January 2012
Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis

Conditions: Breast Cancer; Bone Metastases
Interventions: Drug: Dasatinib; Drug: Zoledronic Acid
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Bristol-Myers Squibb
Recruiting - verified March 2012
Quality of Life Study for Prostate Cancer Patients

Condition: Prostate Cancer
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
A Phase I Study to Assess the Safety and Distribution of VB-111 in Patients With Advanced Metastatic Cancer

Condition: Advanced and/or Metastatic Solid Organ Cancer
Intervention: Drug: VB-111
Sponsors: Vascular Biogenics Ltd. operating as VBL Therapeutics; Vascular Biogenics Ltd. operating as VBL Therapeutics
Recruiting - verified March 2012
Endobronchial Ultrasound Versus Mediastinoscopy in Patients With Non-Small Cell Lung Cancer (NSCLC)

Condition: Lung Cancer
Interventions: Procedure: Endobronchial Ultrasound; Procedure: Mediastinoscopy
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
Lapatinib in Treating Women With Ductal Carcinoma In Situ of the Breast

Condition: Breast Cancer
Interventions: Drug: lapatinib ditosylate; Other: placebo
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI); Breast Cancer Research Foundation
Recruiting - verified November 2011
Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma

Condition: Retinoblastoma
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: thiotepa; Drug: vincristine sulfate; Procedure: autologous bone marrow transplantation; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Magnetic Resonance Elastography and 2-Point Dixon MR Imaging Techniques in Diffuse Liver Disease

Condition: Liver Cancer
Interventions: Procedure: Magnetic Resonance Elastogram; Procedure: 2-Point Dixon Magnetic Resonance Imaging
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
Fluorescence & Reflectance Imaging to Detect Oral Neoplasia

Condition: Oral Cancer
Interventions: Procedure: Portable Spectroscopy System; Procedure: Multispectral Digital Microscope; Procedure: Fast Excitation-Emission Matrix System
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Institute of Dental and Craniofacial Research (NIDCR)
Recruiting - verified April 2012
Bevacizumab in Multiple Phase I Combinations

Condition: Advanced Cancer
Interventions: Drug: Bevacizumab; Drug: Sorafenib; Drug: Erlotinib; Drug: Trastuzumab; Drug: Lapatinib; Drug: Sunitinib; Drug: Cetuximab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
Early Detection of Ovarian Cancer

Condition: Ovarian Cancer
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
Early Detection of Cardiotoxicity During Sunitinib or Sorafenib Chemotherapy Using Cardiac Biomarkers

Condition: Advanced Cancers
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors and Multiple Myeloma

Conditions: Ovarian Cancer; Renal Cancer; Non-small Cell Lung Cancer; Small Cell Lung Cancer; Solid Tumors; Multiple Myeloma
Intervention: Drug: carfilzomib
Sponsors: Onyx Pharmaceuticals; Onyx Therapeutics, Inc.
Recruiting - verified July 2011
Valproic Acid and Bevacizumab in Patients With Advanced Cancer

Condition: Advanced Cancer
Interventions: Drug: Valproic Acid; Drug: Bevacizumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified February 2012
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors

Condition: Brain Tumors
Intervention: Drug: temozolomide, thiotepa, carboplatin, 13-cis-retinoic acid
Sponsors: New York University School of Medicine; New York University School of Medicine; Children's Hospitals and Clinics of Minnesota; Schneider Children's Hospital
Recruiting - verified January 2012
Pancreatic Cancer Genetic Epidemiology (PACGENE) Study

Condition: Pancreatic Cancer
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified April 2012
Brachytherapy for Prostatic Carcinoma Patients

Condition: Prostate Cancer
Interventions: Procedure: Brachytherapy; Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
Vaccine Therapy in Treating Patients With Breast Cancer

Condition: Breast Cancer
Interventions: Biological: GP2 peptide + GM-CSF vaccine; Biological: GM-CSF (sargramostim); Biological: AE37 + GM-CSF vaccine; Biological: GM-CSF (sargramostim)
Sponsors: San Antonio Military Medical Center; San Antonio Military Medical Center; Antigen Express, Inc.; Norwell, Inc.
Recruiting - verified March 2012
Molecular Epidemiology of Therapy-related Acute Myeloid Leukemia/Myelodysplastic Syndrome (AML/MDS)

Conditions: Leukemia; Myelodysplastic Syndrome
Intervention: Behavioral: Interview
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified April 2012
Barriers to Care for Patients With Cervical Cancer or Precancerous Lesions

Condition: Cervical Cancer
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
Psychophysical Studies of Cancer Therapy-Induced Pain

Conditions: Advanced Cancer; Pain
Intervention: Other: Sensory Tests
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
Quality of Life Associated With a Low-Risk Screening Program for Ovarian Cancer

Condition: Ovarian Cancer
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
Primary Breast Cancer Occurring Concomitant With Pregnancy

Conditions: Breast Cancer; Pregnancy
Interventions: Drug: 5-Fluorouracil; Drug: Cyclophosphamide; Drug: Doxorubicin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
Pilot Study to Develop 3 Tesla MRI for Evaluation of Renal Tumors

Condition: Kidney Neoplasms
Intervention: Procedure: 3 Tesla MRI Scan
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
Women Who Are At Risk Or May Have Lynch Syndrome

Conditions: Hereditary Nonpolyposis Colorectal Cancer; Lynch Syndrome
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
Effects of Tibetan Yoga on Fatigue and Sleep in Cancer

Condition: Breast Cancer
Interventions: Behavioral: Tibetan Yoga; Behavioral: Stretching Program; Other: No Intervention; Behavioral: Questionnaire; Behavioral: Booster Program
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified December 2011
Spectroscopy for Diagnostic Assessment of Oral Mucosal Lesions

Condition: Oral Cancer
Intervention: Procedure: Fluorescence Spectroscopy
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
Collection of Outcomes Data for Pregnant Patients With Cancer

Conditions: Solid Tumors; Pregnancy
Intervention: Other: Data Collection
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
Sample Collection From Melanoma Patients

Condition: Melanoma
Interventions: Procedure: Blood Sample; Procedure: Tumor Sample
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
Measuring Sleep Disturbance Among Cancer Patients

Condition: Advanced Cancer
Interventions: Behavioral: Questionnaire; Device: Actigraph
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
M.D. Anderson Symptom Inventory (MDASI) Validation Study in Cancer Patients

Condition: Advanced Cancer
Intervention: Behavioral: Survey
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
Safety and Efficacy of Marqibo in Metastatic Malignant Uveal Melanoma

Condition: Metastatic Malignant Uveal Melanoma
Intervention: Drug: Marqibo® (vincristine sulfate liposomes injection)
Sponsors: Talon Therapeutics, Inc; Talon Therapeutics, Inc
Recruiting - verified September 2011
Genetics of Wilms' Tumor and/or the Associated Conditions of Aniridia, Hemihypertrophy, and Genitourinary Anomalies

Conditions: Wilms' Tumor; Aniridia
Interventions: Behavioral: Questionnaire; Other: Blood specimen
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2012
Quality of Life Questionnaire for Pediatric Patients Undergoing Peritoneal Perfusion

Condition: Peritoneal Neoplasms
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified January 2012
FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Drug: 5-FU; Drug: Cetuximab; Drug: Dasatinib; Drug: Leucovorin; Drug: Oxaliplatin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Bristol-Myers Squibb
Recruiting - verified December 2011
Psychosocial Aspects of Multiple Endocrine Neoplasia (MEN) Syndromes

Condition: Multiple Endocrine Neoplasia
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified November 2011
Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Procedure: therapeutic thoracoscopy; Procedure: videothoracoscopy
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI); Radiation Therapy Oncology Group; American College of Surgeons; Southwest Oncology Group
Recruiting - verified April 2012
Cardiomyopathy Tissue Bank in a Cancer Population

Condition: Heart Disease
Intervention: Procedure: Blood Sample
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
Study of Insulin Resistance and Endometrial Cancer in Harris County, Texas

Condition: Endometrial Cancer
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor

Condition: Solid Tumors
Interventions: Drug: Dasatinib; Drug: Erlotinib; Drug: Lapatinib; Drug: Lenalidomide; Drug: Sorafenib; Drug: Sunitinib; Drug: Valproic Acid
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified December 2011
Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer

Condition: Endometrial Cancer
Interventions: Drug: cisplatin; Radiation: brachytherapy; Radiation: external beam radiation therapy
Sponsors: National Cancer Institute (NCI); Gynecologic Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Oxaliplatin and Paclitaxel Plus Bevacizumab in Advanced Peritoneal Carcinomatosis

Condition: Peritoneal Cancer
Interventions: Drug: Bevacizumab; Drug: Oxaliplatin; Drug: Paclitaxel
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
Active Surveillance in Prostate Cancer

Condition: Prostate Cancer
Intervention: Behavioral: Survey
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified February 2012
SRS Study in Patients With Non-Small Cell Lung Cancer

Condition: Lung Cancer
Intervention: Procedure: Stereotactic Body Radiation Therapy (SBRT)
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
Olanzapine in Patients With Advanced Cancer and Weight Loss

Conditions: Advanced Cancer; Weight Loss
Intervention: Drug: Olanzapine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
Study of Quality of Life for Prostate Proton Therapy

Condition: Prostate Cancer
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified December 2011
Data Collection for Patients With Low Grade Ovarian Carcinoma

Conditions: Ovarian Cancer; Peritoneum Tumors
Intervention: Behavioral: Data Collection
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified December 2011
Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors

Conditions: Solid Tumor; Urethral Cancer
Interventions: Drug: Bortezomib; Drug: Gemcitabine; Drug: Doxorubicin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2012
Health and Cancer Issues in the South Asian Community

Condition: Health
Interventions: Behavioral: Focus Groups; Behavioral: Questionnaire; Behavioral: Interview
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified February 2012
Health Habits and Cancer Risk Comparison Among Migrant Sri Lankans and Sri Lankans

Condition: Acculturation
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
Inflammatory Breast Cancer (IBC) Registry

Condition: Breast Cancer
Interventions: Other: Interview; Procedure: Blood and Tissue Collection
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified February 2012
Spectral Diagnosis of Cutaneous Malignancy

Condition: Skin Cancer
Intervention: Device: Spectral Diagnosis Probe
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; University of Texas
Recruiting - verified March 2012
Delayed-Immediate Breast Reconstruction

Condition: Breast Cancer
Intervention: Procedure: Delayed-Immediate Breast Reconstruction
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Susan G. Komen Breast Cancer Foundation
Recruiting - verified April 2012
Safety Study of Infusion of SGT-53 to Treat Solid Tumors

Condition: Neoplasm
Intervention: Genetic: SGT-53
Sponsors: SynerGene Therapeutics, Inc.; SynerGene Therapeutics, Inc.
Recruiting - verified August 2011
3T Perfluorocarbon-Filled Endorectal Magnetic Resonance Spectroscopic Imaging of Prostate

Condition: Prostate Cancer
Intervention: Procedure: 3T Magnetic Resonance Spectroscopic Imaging
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Department of Defense
Recruiting - verified December 2011
Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin

Conditions: Ototoxicity; Unspecified Childhood Solid Tumor, Protocol Specific
Intervention: Procedure: management of therapy complications
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Treatment of B-Chronic Lymphocytic Leukemia (B-CLL) With Autologous CD40 Ligand and IL-2-Expressing Tumor Cells

Condition: Chronic Lymphocytic Leukemia (CLL)
Intervention: Genetic: IL2
Sponsors: Baylor College of Medicine; Baylor College of Medicine; The Methodist Hospital System; Center for Cell and Gene Therapy, Baylor College of Medicine
Recruiting - verified August 2011
Six-Minute Walk Test in Patients at High Risk for Complications From Lung Resection

Condition: Lung Cancer
Intervention: Other: Six-Minute Walk Test
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer

Condition: Bladder Cancer
Interventions: Drug: gemcitabine hydrochloride; Other: placebo
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors

Condition: Neuroendocrine Tumors
Intervention: Drug: High Dose Indium-111 pentetreotide (Neuroendomedix)
Sponsors: Radio Isotope Therapy of America; Radio Isotope Therapy of America; Excel Diagnostic Imaging Clinics; RadioMedix; St. Luke's Episcopal Hospital, Texas
Recruiting - verified July 2011
Oral Margin Spectroscopy Detection Using Optical Spectroscopy

Condition: Oral Tumors
Interventions: Device: FastEEM4 System; Device: Multispectral Digital Microscope
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Institute of Dental and Craniofacial Research (NIDCR); National Institutes of Health (NIH)
Recruiting - verified March 2012
Bortezomib and Reduced Intensity Allogenic Stem Cell Transplantation for Lymphoid Malignancies

Condition: Lymphoma
Interventions: Drug: Carmustine; Drug: Cytarabine; Drug: Etoposide; Drug: Melphalan; Drug: Rituximab; Drug: Bortezomib; Other: Allogeneic Stem Cell Infusion
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2012
Optical Imaging of Skin Cancers for Margin Delineation of Non-melanoma Skin Cancers

Condition: Skin Cancer
Intervention: Procedure: Optical Imaging
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Institute of Dental and Craniofacial Research (NIDCR)
Recruiting - verified March 2012
Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: docetaxel; Drug: goserelin acetate; Drug: leuprolide acetate; Procedure: conventional surgery
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; NCIC Clinical Trials Group
Recruiting - verified September 2011
Proton Beam Radiation Therapy for Intraocular and Periocular Retinoblastoma

Condition: Retinoblastoma
Interventions: Radiation: Proton Beam Radiation Therapy; Procedure: Ophthalmic EUA
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
3T Endorectal Magnetic Resonance Spectroscopic Imaging (MRSI) of Prostate

Condition: Prostate Cancer
Interventions: Procedure: AIR-MRSI; Procedure: PFC-MRSI
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.

Conditions: Metastatic Breast Cancer; Advanced Breast Cancer; Gastrointestinal Stromal Tumor; Hepatocellular Carcinoma; Metastasizing Breast Cancer (F); Metastatic Castration-Resistant Prostrate Cancer; Metastatic Renal Cell Cancer; Non Small Cell Lung Cancer; Pancreatic Islet Cell Carcinoma
Intervention: Drug: sunitinib
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Bevacizumab and Bortezomib in Patients With Advanced Malignancy

Conditions: Advanced Malignancy; Lymphoma; Myeloma; Solid Tumors
Interventions: Drug: Bevacizumab; Drug: Bortezomib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
Gliogene: Brain Tumor Linkage Study

Conditions: Brain Tumor; Glioma
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified April 2012
Erlotinib Prevention of Oral Cancer (EPOC)

Condition: Oral Cancer
Interventions: Drug: Erlotinib; Drug: Placebo
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified April 2012
Role of p53 Gene in Metabolism Regulation in Patients With Li-Fraumeni Syndrome

Conditions: Li-Fraumeni Syndrome; Cardiovascular Capacity
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 2011
Chemoradiation-Induced Nausea and Emesis: Quality of Life

Conditions: Gastric Cancer; Pancreatic Cancer; Cervical Cancer; Vulvar Cancer; Endometrial Cancer; Anal Cancer
Interventions: Behavioral: Interview; Other: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Merck
Recruiting - verified December 2011
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: filgrastim; Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: isotretinoin; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Fenretinide in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors

Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: fenretinide; Other: pharmacological study
Sponsors: California Cancer Consortium; California Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012
Spousal Relationships and Pain in Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Behavioral: Questionnaire; Behavioral: Interview
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Department of Defense
Recruiting - verified May 2012
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms Tumor

Conditions: Kidney Cancer; Metastatic Cancer
Interventions: Biological: dactinomycin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: vincristine sulfate; Procedure: therapeutic conventional surgery; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified January 2012
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Biological: filgrastim; Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: etoposide phosphate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisone; Drug: therapeutic hydrocortisone; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Education With or Without Exercise and Counseling in Preventing Lymphedema in Women With Stage I, Stage II, or Stage III Breast Cancer Who Are Undergoing Axillary Lymph Node Dissection

Conditions: Breast Cancer; Lymphedema; Perioperative/Postoperative Complications
Interventions: Behavioral: exercise intervention; Other: educational intervention; Procedure: assessment of therapy complications; Procedure: complementary or alternative medicine procedure; Procedure: management of therapy complications; Procedure: quality-of-life assessment; Procedure: therapeutic conventional surgery
Sponsors: National Cancer Institute (NCI); Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified May 2012
Prognostic Molecular and Environmental Factors in High-Risk Colon Cancer Patients

Condition: Colon Cancer
Intervention: Behavioral: Questionnaire
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy

Conditions: Breast Cancer; Neoplasm Metastasis
Interventions: Other: Standard supportive care (packed RBC transfusion); Drug: epoetin alfa + packed RBC transfusion
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified May 2012
EAP (Expanded Access Protocol) Of Lapatinib Combined With Capecitabine In Metastatic Breast Cancer

Condition: Neoplasms, Breast
Intervention: Drug: lapatinib + capecitabine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified April 2012
Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma

Condition: Brain and Central Nervous System Tumors
Interventions: Drug: carboplatin; Drug: cisplatin; Drug: cyclophosphamide; Drug: etoposide; Drug: leucovorin calcium; Drug: methotrexate; Drug: thiotepa; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2011
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery

Condition: Lung Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: docetaxel; Drug: gemcitabine hydrochloride; Drug: pemetrexed disodium; Drug: vinorelbine tartrate
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; North Central Cancer Treatment Group
Recruiting - verified February 2012
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer

Condition: Breast Cancer
Intervention: Drug: Zometa® (zoledronic acid)
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer

Condition: Prostate Cancer
Interventions: Drug: antiandrogen therapy; Drug: docetaxel
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)

Condition: Breast Cancer
Interventions: Drug: anastrozole; Drug: chemotherapy; Drug: exemestane; Drug: letrozole; Drug: tamoxifen citrate
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI); Southwest Oncology Group; Cancer and Leukemia Group B; American College of Surgeons; North Central Cancer Treatment Group; NCIC Clinical Trials Group; National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified July 2011
Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor

Condition: Adrenocortical Carcinoma
Interventions: Biological: filgrastim; Biological: pegfilgrastim; Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: mitotane; Procedure: conventional surgery
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified July 2011
Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors

Conditions: Neurofibromatosis Type 1; Sarcoma
Interventions: Biological: filgrastim; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: Sarcoma Alliance for Research through Collaboration; Sarcoma Alliance for Research through Collaboration; National Cancer Institute (NCI)
Recruiting - verified March 2012
Multicenter Selective Lymphadenectomy Trial II (MSLT-II)

Condition: Melanoma
Interventions: Procedure: Completion Lymphadenectomy; Procedure: Monitoring with nodal ultrasound
Sponsors: John Wayne Cancer Institute; John Wayne Cancer Institute; National Institutes of Health (NIH)
Recruiting - verified January 2012
Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization

Condition: Melanoma
Interventions: Biological: Dendritic Cell Immunization; Drug: Cyclophosphamide; Drug: Fludarabine; Biological: T Cells; Biological: Interleukin-2
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Chiron Corporation
Recruiting - verified March 2012
Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients

Condition: Breast Cancer
Interventions: Drug: Taxotere; Drug: Adriamycin/Cytoxan; Drug: docetaxol; Drug: doxorubicin
Sponsors: Baylor Breast Care Center; Baylor Breast Care Center; Baylor College of Medicine
Recruiting - verified November 2011
Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma

Condition: Prostate Cancer
Interventions: Drug: Docetaxel; Drug: Prednisone
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs; Sanofi-Aventis
Recruiting - verified September 2011
Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma

Condition: Sarcoma
Interventions: Biological: PEG-interferon alfa-2b; Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: methotrexate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI); University College London Hospitals
Recruiting - verified June 2011
Radiation Therapy in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer

Condition: Breast Cancer
Interventions: Radiation: 3-dimensional conformal accelerated partial breast irradiation; Radiation: brachytherapy; Radiation: whole breast irradiation
Sponsors: National Cancer Institute (NCI); National Surgical Adjuvant Breast and Bowel Project (NSABP); National Cancer Institute (NCI); Radiation Therapy Oncology Group; Southwest Oncology Group
Recruiting - verified May 2012
Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: filgrastim; Drug: cisplatin; Drug: cyclophosphamide; Drug: vincristine sulfate; Procedure: autologous hematopoietic stem cell transplantation; Radiation: radiation therapy
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified January 2012
Cisplatin, Metronomic Low-Dose Interferon Alfa, Gemcitabine, and Fever-Range Whole-Body Hyperthermia in Treating Patients With Inoperable or Metastatic Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Biological: recombinant interferon alfa; Drug: cisplatin; Drug: gemcitabine hydrochloride; Procedure: hyperthermia treatment
Sponsors: National Cancer Institute (NCI); The University of Texas Health Science Center, Houston
Recruiting - verified December 2008
Stem Cell Transplant for Hematologic Diseases

Condition: Hematologic Malignancies
Interventions: Biological: Campath 1H; Drug: Fludarabine; Procedure: Stem Cell Transplant; Radiation: TBI
Sponsors: Baylor College of Medicine; Baylor College of Medicine; Texas Children's Hospital; The Methodist Hospital System
Recruiting - verified April 2012
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer

Conditions: Glioblastoma Multiforme; Glioblastoma; GBM; Grade IV Astrocytoma; Glioma; Brain Cancer; Brain Tumor
Intervention: Drug: Dendritic cell immunotherapy
Sponsors: Northwest Biotherapeutics; Northwest Biotherapeutics
Recruiting - verified May 2012
Clinical Trial to Screen Participants Who Are at High Genetic Risk for Ovarian Cancer

Condition: Ovarian Cancer
Interventions: Other: screening questionnaire administration; Procedure: study of high risk factors
Sponsors: National Cancer Institute (NCI); Massachusetts General Hospital; National Cancer Institute (NCI)
Recruiting - verified April 2008
Isotretinoin With or Without Monoclonal Antibody, Interleukin-2, and Sargramostim Following Stem Cell Transplantation in Treating Patients With Neuroblastoma

Condition: Neuroblastoma
Interventions: Biological: aldesleukin; Biological: monoclonal antibody Ch14.18; Biological: sargramostim; Drug: isotretinoin
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma

Condition: Sarcoma
Interventions: Biological: dactinomycin; Drug: busulfan; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: melphalan; Drug: vincristine sulfate; Procedure: autologous hematopoietic stem cell transplantation; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); University Hospitals, Leicester; National Cancer Institute (NCI); Children's Cancer and Leukaemia Group; Societe Francaise Oncologie Pediatrique; European Organization for Research and Treatment of Cancer - EORTC; Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany; Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria; Swiss Group for Clinical Cancer Research; EBMT Solid Tumors Working Party; Children's Oncology Group
Recruiting - verified December 2011
N99-02: Melphalan and Buthionine Sulfoximine Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Children With Resistant or Recurrent Neuroblastoma

Condition: Neuroblastoma
Interventions: Drug: buthionine sulfoximine; Drug: melphalan; Procedure: Peripheral blood stem cell infusion; Other: Filgrastim
Sponsors: New Approaches to Neuroblastoma Therapy Consortium; New Approaches to Neuroblastoma Therapy Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012